C36B1.5,Y59A8B.6,R02D3.1		O43172,O94906,Q9UDR5	OMIM:613983,RETINITIS PIGMENTOSA 60; RP60;OMIM:615922,RETINITIS PIGMENTOSA 70; RP70;OMIM:238700,HYPERLYSINEMIA, TYPE I;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP;OMIM:268700,SACCHAROPINURIA	DOID:0050572,('cone-rod dystrophy',),3,0.0002;DOID:0010584,('retinitis pigmentosa',),3,0.0000	
F23C8.5,F59G1.7,F27D4.1		P13804,P38117	OMIM:231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD		
F37B12.2,ZK1127.10,E01A2.1		P48507,P32929,P48506	OMIM:230450,GAMMA-GLUTAMYLCYSTEINE SYNTHETASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO;OMIM:608446,MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO;OMIM:219500,CYSTATHIONINURIA		
Y110A7A.4,Y47D3A.29,R01H10.1		Q14181,P09884,P04818		DOID:0050769,('N syndrome',),2,0.0172	
R03A10.4,T10B9.7,C14F11.1		P24557,Q6YP21,P00505	OMIM:231095,GHOSAL HEMATODIAPHYSEAL DYSPLASIA; GHDD		
F25B4.1,R12C12.1,C05D11.11		P48728,P23378,P34896	OMIM:182940,NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO; NTD;OMIM:605899,GLYCINE ENCEPHALOPATHY; GCE;OMIM:209850,AUTISM	DOID:0009268,('glycine encephalopathy',),3,0.0374;DOID:0012849,('autistic disorder',),3,0.0000	
F44B9.4,R02F2.1,F42D1.2		P17735,Q14094,O60563	OMIM:276600,TYROSINEMIA, TYPE II; TYRSN2		
F58G11.1,K10B2.1,F45D3.5		O95202,Q9UKB1,Q9UBV2			
F46A9.4,W06D4.4,F48E8.7		Q9NVM4,Q13309			
D1005.1,T20G5.2,B0365.1		O75390,P53396			
W03D2.4,ZK742.3,M04B2.1,T04C10.1	0.0473,MI:cel-lin-4,MI:cel-lin-4;0.0486,MI:cel-miR-237,MI:cel-miR-237;0.0500,MI:cel-miR-82,MI:cel-miR-82;0.0384,MI:cel-miR-47,MI:cel-miR-47;0.0479,MI:cel-miR-80,MI:cel-miR-80;0.0447,MI:cel-miR-270,MI:cel-miR-270;0.0389,MI:cel-miR-244,MI:cel-miR-244	Q13627,Q9Y462,P12004	OMIM:300495,AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2;OMIM:300803,MENTAL RETARDATION, X-LINKED 97; MRX97;OMIM:614104,MENTAL RETARDATION, AUTOSOMAL DOMINANT 7; MRD7;OMIM:615919,ATAXIA-TELANGIECTASIA-LIKE DISORDER 2; ATLD2	DOID:0012849,('autistic disorder',),2,0.0000	
Y71H2AM.5,Y37D8A.14,T02H6.11,F54D8.2	0.05,MI:cel-miR-50,MI:cel-miR-50	P14927,P12074,P20674,P14854	OMIM:615158,MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 3; MC3DN3;OMIM:220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY;OMIM:616039,CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE D; CMTRID		
Y71H2B.3,Y75B8A.30,ZC302.1,F41E6.4	0.0489,MI:cel-miR-242,MI:cel-miR-242;0.0473,MI:cel-miR-784,MI:cel-miR-784;0.0500,MI:cel-miR-249,MI:cel-miR-249	Q6IN85,P49959,P60510,P78318	OMIM:604391,ATAXIA-TELANGIECTASIA-LIKE DISORDER 1; ATLD1;OMIM:167000,OVARIAN CANCER;OMIM:176807,PROSTATE CANCER;OMIM:114480,BREAST CANCER;OMIM:300472,CORPUS CALLOSUM, AGENESIS OF, WITH MENTAL RETARDATION, OCULAR COLOBOMA, AND MICROGNATHIA	DOID:0001612,('breast cancer',),2,0.0005;DOID:0010283,('prostate cancer',),2,0.0127	
T05H10.6,F23B12.5,C04C3.3,ZK836.2	0.03230,GO:0055114,oxidation-reduction process;0.01150,GO:0006091,generation of precursor metabolites and energy;0.01150,GO:0015980,energy derivation by oxidation of organic compounds;0.00729,GO:0045333,cellular respiration;0.00313,GO:0009060,aerobic respiration;0.04790,GO:0006082,organic acid metabolic process;0.04790,GO:0043436,oxoacid metabolic process;0.04790,GO:0019752,carboxylic acid metabolic process;0.00104,GO:0072350,tricarboxylic acid metabolic process;0.00104,GO:0006101,citrate metabolic process;0.00104,GO:0006099,tricarboxylic acid cycle;0.04900,GO:1990234,transferase complex;0.00937,GO:1990204,oxidoreductase complex;0.00104,GO:0045239,tricarboxylic acid cycle enzyme complex;0.00104,GO:0045240,dihydrolipoyl dehydrogenase complex;0.00104,GO:0045252,oxoglutarate dehydrogenase complex;0.05000,GO:0016491,oxidoreductase activity;0.00313,GO:0016903,oxidoreductase activity, acting on the aldehyde or oxo group of donors;0.00104,GO:0016624,oxidoreductase activity, acting on the aldehyde or oxo group of donors, disulfide as acceptor;0.00104,GO:0004591,oxoglutarate dehydrogenase (succinyl-transferring) activity	P11177,Q96HY7,P08559,P10515	OMIM:256000,LEIGH SYNDROME; LS;OMIM:615025,CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Q; CMT2Q;OMIM:245348,PYRUVATE DEHYDROGENASE E2 DEFICIENCY; PDHDD;OMIM:614111,PYRUVATE DEHYDROGENASE E1-BETA DEFICIENCY; PDHBD;OMIM:312170,PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY; PDHAD;OMIM:204750,2-AMINOADIPIC 2-OXOADIPIC ACIDURIA; AMOXAD		
H02I12.1,H12C20.2,Y59A8B.7,ZK337.1	0.05,MI:cel-miR-356,MI:cel-miR-356	Q6YHK3,Q15691,P54278	OMIM:614337,COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 4; HNPCC4;OMIM:176807,PROSTATE CANCER;OMIM:400042,SPERMATOGENIC FAILURE, Y-LINKED, 1; SPGFY1;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:276300,MISMATCH REPAIR CANCER SYNDROME; MMRCS	DOID:0009256,('colorectal cancer',),3,0.0006;DOID:0001520,('colon carcinoma',),3,0.0006	CORUM:1176
R05D3.4,F37E3.1,F26A3.2,Y73B6BL.33	0.0500,MI:cel-miR-799,MI:cel-miR-799;0.0291,MI:cel-miR-268,MI:cel-miR-268	P31943,Q5VTR2,Q09161,P52298			
ZC84.3,ZK792.6,K03E6.6,F08F1.8		O75122,P01112	OMIM:163200,SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM;OMIM:109800,BLADDER CANCER;OMIM:162900,NEVUS, EPIDERMAL;OMIM:218040,COSTELLO SYNDROME; CSTLO;OMIM:255300,MYOPATHY, CONGENITAL;OMIM:188470,THYROID CANCER, NONMEDULLARY, 2; NMTC2	DOID:0050469,('Costello syndrome',),3,0.0390	
C10C5.5,C34B2.5,C10C5.3,F53F4.10	0.05000,GO:1901135,carbohydrate derivative metabolic process;0.01560,GO:1901657,glycosyl compound metabolic process;0.04370,GO:0019637,organophosphate metabolic process;0.01460,GO:0019693,ribose phosphate metabolic process;0.03120,GO:0055086,nucleobase-containing small molecule metabolic process;0.02500,GO:0006753,nucleoside phosphate metabolic process;0.00625,GO:0009141,nucleoside triphosphate metabolic process;0.00625,GO:0009144,purine nucleoside triphosphate metabolic process;0.00521,GO:0009199,ribonucleoside triphosphate metabolic process;0.00521,GO:0009205,purine ribonucleoside triphosphate metabolic process;0.00729,GO:0009123,nucleoside monophosphate metabolic process;0.00521,GO:0009126,purine nucleoside monophosphate metabolic process;0.00729,GO:0009161,ribonucleoside monophosphate metabolic process;0.00521,GO:0009167,purine ribonucleoside monophosphate metabolic process;0.02500,GO:0009117,nucleotide metabolic process;0.01350,GO:0009259,ribonucleotide metabolic process;0.01150,GO:0006091,generation of precursor metabolites and energy;0.03230,GO:0055114,oxidation-reduction process;0.01150,GO:0015980,energy derivation by oxidation of organic compounds;0.00729,GO:0045333,cellular respiration;0.00417,GO:0022900,electron transport chain;0.00417,GO:0022904,respiratory electron transport chain;0.02080,GO:0072521,purine-containing compound metabolic process;0.01250,GO:0006163,purine nucleotide metabolic process;0.01040,GO:0009150,purine ribonucleotide metabolic process;0.01560,GO:0009116,nucleoside metabolic process;0.01350,GO:0009119,ribonucleoside metabolic process;0.01250,GO:0042278,purine nucleoside metabolic process;0.01040,GO:0046128,purine ribonucleoside metabolic process;0.00521,GO:0046034,ATP metabolic process;0.00417,GO:0006119,oxidative phosphorylation;0.00417,GO:0042773,ATP synthesis coupled electron transport;0.00417,GO:0042775,mitochondrial ATP synthesis coupled electron transport;0.00313,GO:0006120,mitochondrial electron transport, NADH to ubiquinone;0.01880,GO:0031975,envelope;0.01460,GO:0098796,membrane protein complex;0.03020,GO:0044429,mitochondrial part;0.00937,GO:1990204,oxidoreductase complex;0.00313,GO:0030964,NADH dehydrogenase complex;0.00729,GO:0098798,mitochondrial protein complex;0.00417,GO:0070469,respiratory chain;0.00417,GO:0098803,respiratory chain complex;0.00313,GO:0045271,respiratory chain complex I;0.01880,GO:0031967,organelle envelope;0.01150,GO:0019866,organelle inner membrane;0.01670,GO:0005740,mitochondrial envelope;0.01250,GO:0031966,mitochondrial membrane;0.01040,GO:0044455,mitochondrial membrane part;0.01150,GO:0005743,mitochondrial inner membrane;0.00417,GO:0005746,mitochondrial respiratory chain;0.00729,GO:0098800,inner mitochondrial membrane protein complex;0.00313,GO:0005747,mitochondrial respiratory chain complex I;0.05000,GO:0016491,oxidoreductase activity;0.00521,GO:0016651,oxidoreductase activity, acting on NAD(P)H;0.00208,GO:0016655,oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor;0.00313,GO:0003954,NADH dehydrogenase activity;0.00208,GO:0050136,NADH dehydrogenase (quinone) activity;0.00208,GO:0008137,NADH dehydrogenase (ubiquinone) activity;0.04070,MI:cel-miR-1,MI:cel-miR-1;0.05000,MI:cel-miR-260,MI:cel-miR-260;0.04130,MI:cel-miR-256,MI:cel-miR-256;0.04600,MI:cel-miR-80,MI:cel-miR-80;0.04200,MI:cel-miR-245,MI:cel-miR-245;0.04500,MI:cel-miR-60,MI:cel-miR-60;0.03730,MI:cel-miR-244,MI:cel-miR-244	Q03154,P19404,Q99614	OMIM:252010,MITOCHONDRIAL COMPLEX I DEFICIENCY;OMIM:609924,AMINOACYLASE 1 DEFICIENCY; ACY1D		
M03F8.2,ZK1290.12,Y16B4A.1,K02E2.2	0.05,MI:cel-miR-58,MI:cel-miR-58	Q9UH73			
Y47H9C.5,T28A11.13,F46E10.9,F49H12.5	0.0373,MI:cel-miR-86,MI:cel-miR-86;0.0322,MI:cel-miR-268,MI:cel-miR-268;0.0433,MI:cel-miR-47,MI:cel-miR-47;0.0500,MI:cel-miR-249,MI:cel-miR-249	Q9H3N1,Q8IXB1			
F29B9.2,Y48B6A.11		O75164			
F01F1.4,F33E11.3		Q6ZMI0,Q96T51			
C27H6.1,K11D12.2		P52655			
DY3.2,M01B2.4		P20700	OMIM:182940,NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO; NTD;OMIM:169500,LEUKODYSTROPHY, DEMYELINATING, ADULT-ONSET, AUTOSOMAL DOMINANT; ADLD		
T17E9.2,ZK1058.5		O60551,Q8TCB7			
C45G7.1,K09C8.5					
F11A10.8,H27M09.1		Q9UJV9,O95639			
Y54E10A.5,Y71F9AL.14		Q9BTE1,O00399			
E02H1.6,F25G6.2		Q92797			
C36E8.3,K08E5.3		Q8IUK5			
M03A8.1,F53C11.3,Y54G11A.5,T05C12.3	0.0389,GO:0009607,response to biotic stimulus;0.0389,GO:0051704,multi-organism process;0.0500,GO:0009605,response to external stimulus;0.0389,GO:0043207,response to external biotic stimulus;0.0389,GO:0051707,response to other organism;0.0389,GO:0009617,response to bacterium;0.0375,GO:0098542,defense response to other organism;0.0375,GO:0042742,defense response to bacterium;0.0319,GO:0050829,defense response to Gram-negative bacterium;0.0500,MI:cel-miR-79,MI:cel-miR-79	Q16698,P04040	OMIM:614097,ACATALASEMIA;OMIM:125853,DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM	DOID:0009352,('type 2 diabetes mellitus',),2,0.0172;DOID:0002582,('acatalasia',),2,0.0172	
M03A8.1,F54F3.4,F53C11.3,T05C12.3	0.0389,GO:0009607,response to biotic stimulus;0.0500,GO:0009605,response to external stimulus;0.0389,GO:0043207,response to external biotic stimulus;0.0389,GO:0051704,multi-organism process;0.0389,GO:0051707,response to other organism;0.0389,GO:0009617,response to bacterium;0.0375,GO:0098542,defense response to other organism;0.0375,GO:0042742,defense response to bacterium;0.0319,GO:0050829,defense response to Gram-negative bacterium;0.0497,MI:cel-miR-35,MI:cel-miR-35;0.0497,MI:cel-miR-36,MI:cel-miR-36;0.0500,MI:cel-miR-41,MI:cel-miR-41	Q16698			
C18C4.10,F20D6.5,E02C12.6,C42D8.8	0.049700,MI:cel-miR-36,MI:cel-miR-36;0.050000,MI:cel-miR-41,MI:cel-miR-41;0.000802,MI:cel-miR-78,MI:cel-miR-78;0.049700,MI:cel-miR-35,MI:cel-miR-35;0.044600,MI:cel-miR-794,MI:cel-miR-794	P51693,Q07866			
C18C4.10,E02C12.6,C42D8.8,B0286.3	0.0375,MI:cel-miR-794,MI:cel-miR-794;0.0500,MI:cel-miR-78,MI:cel-miR-78	P51693,Q07866,P22234			
C18C4.10,H37A05.2,E02C12.6,C42D8.8	0.0396,MI:cel-miR-794,MI:cel-miR-794;0.0351,MI:cel-miR-796,MI:cel-miR-796;0.0500,MI:cel-miR-66,MI:cel-miR-66	P51693,Q07866			
F11C7.3,F46A9.5,D1054.3,T28B4.1	0.0500,GO:0032446,protein modification by small protein conjugation;0.0500,GO:0016567,protein ubiquitination;0.0486,GO:0010498,proteasomal protein catabolic process;0.0486,GO:0043161,proteasome-mediated ubiquitin-dependent protein catabolic process;0.0278,GO:0031146,SCF-dependent proteasomal ubiquitin-dependent protein catabolic process;0.0319,GO:0000151,ubiquitin ligase complex;0.0292,GO:0031461,cullin-RING ubiquitin ligase complex;0.0278,GO:0019005,SCF ubiquitin ligase complex;0.0427,MI:cel-miR-90,MI:cel-miR-90;0.0500,MI:cel-miR-1,MI:cel-miR-1;0.0431,MI:cel-miR-243,MI:cel-miR-243	P63208,Q9UF56,Q9Y2Z0			
H02I12.1,H12C20.2,F40G9.10,ZK337.1	0.0462,MI:cel-miR-264,MI:cel-miR-264;0.0500,MI:cel-miR-356,MI:cel-miR-356	Q6YHK3,P54278	OMIM:614337,COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 4; HNPCC4;OMIM:176807,PROSTATE CANCER;OMIM:400042,SPERMATOGENIC FAILURE, Y-LINKED, 1; SPGFY1;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:276300,MISMATCH REPAIR CANCER SYNDROME; MMRCS	DOID:0009256,('colorectal cancer',),3,0.0006;DOID:0001520,('colon carcinoma',),3,0.0006	
F41H10.6,T27A3.2,C34F11.9,C51F7.1	0.0409,MI:cel-miR-252,MI:cel-miR-252;0.0470,MI:cel-miR-392,MI:cel-miR-392;0.0500,MI:cel-miR-249,MI:cel-miR-249;0.0450,MI:cel-miR-42,MI:cel-miR-42	O14641,P45974,Q9UBN7	OMIM:182940,NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO; NTD;OMIM:300863,CHONDRODYSPLASIA WITH PLATYSPONDYLY, DISTINCTIVE BRACHYDACTYLY, HYDROCEPHALY, AND MICROPHTHALMIA		
C07G1.5,Y66H1B.2,Y39A3CR.3,F47A4.2	0.0464,MI:cel-miR-49,MI:cel-miR-49;0.0348,MI:cel-miR-86,MI:cel-miR-86;0.0463,MI:cel-miR-797,MI:cel-miR-797;0.0467,MI:cel-miR-792,MI:cel-miR-792;0.0500,MI:cel-miR-250,MI:cel-miR-250;0.0445,MI:cel-miR-83,MI:cel-miR-83;0.0493,MI:cel-miR-43,MI:cel-miR-43;0.0473,MI:cel-miR-2,MI:cel-miR-2;0.0326,MI:cel-miR-785,MI:cel-miR-785	Q86TV6,O14964,P21333,Q93074	OMIM:300321,FG SYNDROME 2; FGS2;OMIM:108720,ATELOSTEOGENESIS, TYPE I; AO1;OMIM:300495,AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2;OMIM:249620,OHDO SYNDROME;OMIM:157700,MITRAL VALVE PROLAPSE 1; MVP1;OMIM:305620,FRONTOMETAPHYSEAL DYSPLASIA; FMD;OMIM:304120,OTOPALATODIGITAL SYNDROME, TYPE II; OPD2;OMIM:604715,ORTHOSTATIC INTOLERANCE;OMIM:309520,LUJAN-FRYNS SYNDROME;OMIM:305450,OPITZ-KAVEGGIA SYNDROME; OKS;OMIM:314400,CARDIAC VALVULAR DYSPLASIA, X-LINKED; CVD1;OMIM:300049,PERIVENTRICULAR NODULAR HETEROTOPIA 1; PVNH1;OMIM:300895,OHDO SYNDROME, X-LINKED; OHDOX;OMIM:300048,INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED;OMIM:309350,MELNICK-NEEDLES SYNDROME; MNS;OMIM:311300,OTOPALATODIGITAL SYNDROME, TYPE I; OPD1;OMIM:604229,PETERS ANOMALY;OMIM:300244,TERMINAL OSSEOUS DYSPLASIA; TOD	DOID:0012849,('autistic disorder',),3,0.0000;DOID:0000988,('mitral valve prolapse',),3,0.0355	
C07G1.5,Y66H1B.2,Y48E1C.3,Y39A3CR.3	0.0445,MI:cel-miR-83,MI:cel-miR-83;0.0326,MI:cel-miR-785,MI:cel-miR-785;0.0473,MI:cel-miR-2,MI:cel-miR-2;0.0493,MI:cel-miR-43,MI:cel-miR-43;0.0441,MI:cel-miR-784,MI:cel-miR-784;0.0464,MI:cel-miR-49,MI:cel-miR-49;0.0463,MI:cel-miR-797,MI:cel-miR-797;0.0500,MI:cel-miR-250,MI:cel-miR-250;0.0348,MI:cel-miR-86,MI:cel-miR-86	Q86TV6,O14964,P21333,Q3MII6	OMIM:300321,FG SYNDROME 2; FGS2;OMIM:108720,ATELOSTEOGENESIS, TYPE I; AO1;OMIM:300495,AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2;OMIM:157700,MITRAL VALVE PROLAPSE 1; MVP1;OMIM:305620,FRONTOMETAPHYSEAL DYSPLASIA; FMD;OMIM:304120,OTOPALATODIGITAL SYNDROME, TYPE II; OPD2;OMIM:604715,ORTHOSTATIC INTOLERANCE;OMIM:305450,OPITZ-KAVEGGIA SYNDROME; OKS;OMIM:314400,CARDIAC VALVULAR DYSPLASIA, X-LINKED; CVD1;OMIM:300049,PERIVENTRICULAR NODULAR HETEROTOPIA 1; PVNH1;OMIM:300048,INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED;OMIM:309350,MELNICK-NEEDLES SYNDROME; MNS;OMIM:300244,TERMINAL OSSEOUS DYSPLASIA; TOD;OMIM:604229,PETERS ANOMALY;OMIM:311300,OTOPALATODIGITAL SYNDROME, TYPE I; OPD1	DOID:0012849,('autistic disorder',),3,0.0000;DOID:0000988,('mitral valve prolapse',),3,0.0355	
R10E9.1,K04G7.10,D1007.7,Y37E11AR.2	0.050,MI:cel-miR-257,MI:cel-miR-257;0.038,MI:cel-miR-251,MI:cel-miR-251	P08621,O95104,Q8IUQ4,Q96DH6			CORUM:846
R09E12.3,Y37E3.1,ZK856.13,C09H10.6	0.05,MI:cel-miR-58,MI:cel-miR-58	Q8N0Z6,P31948,Q9Y5Q9			
F59A2.3,T11G6.8		Q9NW64,Q07021			
T26G10.1,C32E8.10		Q9H0S4,Q13492	OMIM:209850,AUTISM;OMIM:601626,LEUKEMIA, ACUTE MYELOID; AML	DOID:0012849,('autistic disorder',),2,0.0000	
R11G10.1,Y48G10A.3		Q9UGV2			
F08A8.4,F28A10.6		Q9UKU7	OMIM:611283,ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY		
M01D7.4,Y48B6A.13,F09E5.15,E04A4.7,C31E10.7	0.012300,GO:0051186,cofactor metabolic process;0.012300,GO:0006732,coenzyme metabolic process;0.036800,GO:0019637,organophosphate metabolic process;0.024600,GO:0090407,organophosphate biosynthetic process;0.011400,GO:0006790,sulfur compound metabolic process;0.001750,GO:0035383,thioester metabolic process;0.041200,GO:0006629,lipid metabolic process;0.027200,GO:0044255,cellular lipid metabolic process;0.002630,GO:0006720,isoprenoid metabolic process;0.009650,GO:0006644,phospholipid metabolic process;0.000877,GO:0046490,isopentenyl diphosphate metabolic process;0.010500,GO:0008610,lipid biosynthetic process;0.000877,GO:0008299,isoprenoid biosynthetic process;0.007890,GO:0008654,phospholipid biosynthetic process;0.000877,GO:0009240,isopentenyl diphosphate biosynthetic process;0.001750,GO:0006637,acyl-CoA metabolic process;0.001750,GO:0006084,acetyl-CoA metabolic process;0.000877,GO:0019287,isopentenyl diphosphate biosynthetic process, mevalonate pathway;0.037700,GO:0005829,cytosol;0.007020,GO:0016829,lyase activity;0.003510,GO:0016830,carbon-carbon lyase activity;0.001750,GO:0016831,carboxy-lyase activity;0.000877,GO:0004163,diphosphomevalonate decarboxylase activity;0.040300,MI:cel-miR-65,MI:cel-miR-65;0.044000,MI:cel-miR-63,MI:cel-miR-63;0.039100,MI:cel-miR-251,MI:cel-miR-251;0.050000,MI:cel-miR-786,MI:cel-miR-786;0.044200,MI:cel-miR-66,MI:cel-miR-66;0.041300,MI:cel-miR-64,MI:cel-miR-64;0.037600,MI:cel-miR-252,MI:cel-miR-252;0.045700,MI:cel-miR-229,MI:cel-miR-229	P00167,P32119,P99999,P53602,Q01415	OMIM:202110,ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY;OMIM:612004,THROMBOCYTOPENIA 4; THC4;OMIM:250790,METHEMOGLOBINEMIA TYPE IV		
T07A9.8,C01B10.8		Q8N6R0,O43159			
T04A11.4,Y54G11A.9		Q86U28			
C06A1.1,K06H7.3		Q9H8Y5			
Y41C4A.10,Y82E9BR.15		Q15369,Q15370			
F45G2.10,Y18D10A.9		O76071,Q9Y3D0	OMIM:209850,AUTISM		
F59E10.1,Y39A1A.12,C43E11.10,C26C6.1	0.0355,MI:cel-miR-252,MI:cel-miR-252;0.0500,MI:cel-miR-124,MI:cel-miR-124	Q13416,Q13415,Q86U86,Q99741	OMIM:224690,MEIER-GORLIN SYNDROME 1; MGORS1;OMIM:613805,MEIER-GORLIN SYNDROME 5; MGORS5;OMIM:114500,COLORECTAL CANCER; CRC	DOID:0009256,('colorectal cancer',),2,0.0001;DOID:0001520,('colon carcinoma',),2,0.0001	
Y87G2A.9,CD4.4,C09G12.9,Y87G2A.10	0.0476,MI:cel-miR-38,MI:cel-miR-38;0.0390,MI:cel-miR-258,MI:cel-miR-258;0.0500,MI:cel-miR-262,MI:cel-miR-262	P60604,Q9UK41,Q9H9H4,Q99816	OMIM:114480,BREAST CANCER	DOID:0001612,('breast cancer',),2,0.0002	
K06A1.1,T17A3.1,C50F7.10,F59F3.5	0.05,MI:cel-miR-246,MI:cel-miR-246	Q9H227,P17948	OMIM:115200,CARDIOMYOPATHY, DILATED, 1A; CMD1A;OMIM:109730,AORTIC VALVE DISEASE 1; AOVD1		CORUM:1176
K04F10.4,R05D3.4,F37E3.1,F26A3.2	0.0500,MI:cel-miR-799,MI:cel-miR-799;0.0291,MI:cel-miR-268,MI:cel-miR-268	Q5VTR2,Q09161,P52298			
T13H5.4,W07E6.4,F08B4.7,F11A10.2	0.0474,GO:0008380,RNA splicing;0.0421,GO:0000375,RNA splicing, via transesterification reactions;0.0395,GO:0000377,RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;0.0395,GO:0000398,mRNA splicing, via spliceosome;0.0421,GO:0005681,spliceosomal complex	P09234,Q12874,Q15459			CORUM:2657;CORUM:1030;CORUM:2660;CORUM:1036;CORUM:1037;CORUM:1029;CORUM:107;CORUM:1009;CORUM:5495
Y39G10AL.3,Y49F6B.1,K02F2.3,F21H11.2	0.05,MI:cel-miR-230,MI:cel-miR-230	P51946,P50613,Q15393,O94915			
R07G3.5,Y60A3A.1,R07B7.11,C27A12.5	0.0334,MI:cel-lsy-6,MI:cel-lsy-6;0.0411,MI:cel-miR-784,MI:cel-miR-784;0.0500,MI:cel-miR-124,MI:cel-miR-124	A6NJ46,Q8IYT8,Q96HS1,P06280	OMIM:601367,STROKE, ISCHEMIC;OMIM:301500,FABRY DISEASE		
F33D4.2,F57B9.2,T20B12.2,C26E6.3	0.0385,MI:cel-miR-71,MI:cel-miR-71;0.0500,MI:cel-miR-273,MI:cel-miR-273;0.0443,MI:cel-miR-70,MI:cel-miR-70	A5YKK6,P20226,Q14643,Q92600	OMIM:117360,SPINOCEREBELLAR ATAXIA 29; SCA29;OMIM:168600,PARKINSON DISEASE, LATE-ONSET; PD;OMIM:607136,SPINOCEREBELLAR ATAXIA 17; SCA17;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:606658,SPINOCEREBELLAR ATAXIA 15; SCA15	DOID:0005419,('schizophrenia',),4,0.0000	
ZK1128.8,Y59A8B.22,F59G1.3,T20D3.7,C05D9.1,W06D4.5	0.0493,MI:cel-miR-43,MI:cel-miR-43;0.0500,MI:cel-miR-250,MI:cel-miR-250;0.0479,MI:cel-miR-254,MI:cel-miR-254;0.0364,MI:cel-miR-358,MI:cel-miR-358	Q4G0F5,O60749,Q9UMY4,Q96QK1,Q9UBQ0,Q9UNH7	OMIM:614203,PARKINSON DISEASE 17; PARK17		
ZK686.3,T22D1.4,T09A5.11,Y63D3A.6,Y57G11C.15,C18E9.2,F41H10.8	0.05,MI:cel-miR-797,MI:cel-miR-797	P39656,Q99442,P04843,Q9UGP8,Q9H9S3,Q13454	OMIM:174050,POLYCYSTIC LIVER DISEASE; PCLD;OMIM:209850,AUTISM;OMIM:614507,CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ir; CDG1R;OMIM:611093,MENTAL RETARDATION, AUTOSOMAL RECESSIVE 7; MRT7	DOID:0050770,('polycystic liver disease',),4,0.0079;DOID:0012849,('autistic disorder',),7,0.0000	
K09A9.5,T10E9.7,T26A5.3,C33A12.1	0.050,MI:cel-miR-273,MI:cel-miR-273;0.043,MI:cel-miR-797,MI:cel-miR-797	O75489,Q16718,O75306	OMIM:252010,MITOCHONDRIAL COMPLEX I DEFICIENCY;OMIM:256000,LEIGH SYNDROME; LS		
Y57G11C.10,T05G5.8,T25G12.4,W03C9.3,F53F10.4,R05D11.3,F53G12.1,F59B2.7,D1037.4,C39F7.4,C15C7.2	0.0500,MI:cel-miR-250,MI:cel-miR-250;0.0301,MI:cel-miR-795,MI:cel-miR-795;0.0449,MI:cel-miR-2,MI:cel-miR-2	P50395,P62820,P51149,P61019,Q92930,Q5VIR6,P61970,P62491,P20340	OMIM:209850,AUTISM;OMIM:600882,CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B; CMT2B;OMIM:615851,PONTOCEREBELLAR HYPOPLASIA, TYPE 2E; PCH2E	DOID:0060271,('pontocerebellar hypoplasia type 2E',),10,0.0000;DOID:0012849,('autistic disorder',),7,0.0000	CORUM:2901;CORUM:2903;CORUM:2905;CORUM:2904;CORUM:2920
F46C5.9,K08F9.2,D2013.2,ZK1307.6	0.050000,MI:cel-miR-791,MI:cel-miR-791;0.046700,MI:cel-miR-66,MI:cel-miR-66;0.034000,MI:cel-miR-785,MI:cel-miR-785;0.036200,MI:cel-miR-86,MI:cel-miR-86;0.044000,MI:cel-let-7,MI:cel-let-7;0.000899,MI:cel-miR-228,MI:cel-miR-228;0.036900,MI:cel-miR-794,MI:cel-miR-794;0.046000,MI:cel-miR-784,MI:cel-miR-784	Q96P53,Q9UM11,O75083,Q9Y4P3			
C14B9.4,K02B12.1,F07A11.6,C10C6.1	0.05,MI:cel-miR-792,MI:cel-miR-792	Q96T58,P09086,P53350,Q6P0Q8			
F54C4.2,F55A3.3,B0464.2,T20B12.8,F25B3.6,C55A6.9,C32F10.5,B0035.11	0.0500,MI:cel-miR-792,MI:cel-miR-792;0.0408,MI:cel-miR-56*,MI:cel-miR-56*	Q8WVC0,Q8N7H5,Q92541,Q08945,P63272,Q6PD62,Q9Y5B9	OMIM:209850,AUTISM;OMIM:614867,PEROXISOME BIOGENESIS DISORDER 5B; PBD5B;OMIM:614866,PEROXISOME BIOGENESIS DISORDER 5A (ZELLWEGER); PBD5A	DOID:0012849,('autistic disorder',),7,0.0000	CORUM:1200
Y71H2B.10,Y105E8A.9,K11D2.3,F41H10.11,F55A12.7,F29G9.3	0.044800,MI:cel-miR-2,MI:cel-miR-2;0.000923,MI:cel-miR-43,MI:cel-miR-43;0.050000,MI:cel-miR-250,MI:cel-miR-250;0.042900,MI:cel-miR-797,MI:cel-miR-797;0.045100,MI:cel-miR-67,MI:cel-miR-67	O43747,Q10567,P56377,Q9BXS5,Q86VX9	OMIM:304340,PETTIGREW SYNDROME; PGS		CORUM:1167;CORUM:938
R01H2.5,C53B4.7,F01G4.2,C15H11.4,W01C9.4	0.0500,MI:cel-miR-253*,MI:cel-miR-253*;0.0487,MI:cel-miR-35,MI:cel-miR-35;0.0472,MI:cel-miR-90,MI:cel-miR-90;0.0487,MI:cel-miR-36,MI:cel-miR-36;0.0470,MI:cel-miR-252,MI:cel-miR-252;0.0498,MI:cel-miR-47,MI:cel-miR-47;0.0482,MI:cel-miR-46,MI:cel-miR-46;0.0488,MI:cel-miR-251,MI:cel-miR-251;0.0500,MI:cel-miR-40,MI:cel-miR-40	Q99714,O60547,Q13630,Q96NR8	OMIM:268000,RETINITIS PIGMENTOSA; RP;OMIM:612712,LEBER CONGENITAL AMAUROSIS 13; LCA13;OMIM:300438,17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;OMIM:204000,LEBER CONGENITAL AMAUROSIS 1; LCA1;OMIM:300220,MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:300495,AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2	DOID:0012849,('autistic disorder',),3,0.0000;DOID:0050572,('cone-rod dystrophy',),2,0.0001;DOID:0010584,('retinitis pigmentosa',),2,0.0000	
F17C11.8,W02A11.2,Y65B4A.3,C27F2.5	0.05,MI:cel-miR-74,MI:cel-miR-74	Q96H20,Q86VN1,Q9BRG1,Q96FZ7			
K02D10.5,Y73B6BL.30		O95721,Q6QNY1	OMIM:219050,CRYPTORCHIDISM, UNILATERAL OR BILATERAL;OMIM:609528,CEREBRAL DYSGENESIS, NEUROPATHY, ICHTHYOSIS, AND PALMOPLANTAR KERATODERMA SYNDROME		
F47D12.4,T05A7.4		P26583			
Y57E12AL.5,F26D10.9		O75586			
C42C1.5,Y47D9A.1		Q9Y5P6,Q96IJ6	OMIM:615350,MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 14; MDDGA14;OMIM:615351,MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 14; MDDGB14;OMIM:615510,ALACRIMA, ACHALASIA, AND MENTAL RETARDATION SYNDROME; AAMR;OMIM:615352,MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 14; MDDGC14	DOID:0011724,('limb-girdle muscular dystrophy',),2,0.0243	
MTCE.31,MTCE.23		P00414,P00403			
F17E5.2,Y104H12BR.1					
F55C5.8,W03H9.4		Q8WUQ7,Q9UHB9			
F13B9.1,C42D8.5		O15027,Q9BYF1			
T01D1.2,T21G5.3		Q92879			
C46F11.2,C45B11.3		P00390			
F52B5.3,K10C8.1,C16A3.7		O95453,Q9H6S0,Q12986			
Y71H2AM.5,Y37D8A.14,T02H6.11,F54D8.2,C23G10.3,Y119D3B.17	0.05,MI:cel-miR-50,MI:cel-miR-50	P57723,P23396,P20674,P12074,P14927,P14854	OMIM:615158,MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 3; MC3DN3;OMIM:220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY;OMIM:616039,CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE D; CMTRID	DOID:0003762,('cytochrome-c oxidase deficiency disease',),6,0.0223	
Y110A7A.8,M03C11.7,C36B1.5,Y59A8B.6,ZK863.6	0.0406,MI:cel-miR-56*,MI:cel-miR-56*;0.0389,MI:cel-miR-358,MI:cel-miR-358;0.0500,MI:cel-miR-792,MI:cel-miR-792	Q8WWY3,O43172,O43395,O94906	OMIM:601414,RETINITIS PIGMENTOSA 18; RP18;OMIM:613983,RETINITIS PIGMENTOSA 60; RP60;OMIM:600138,RETINITIS PIGMENTOSA 11; RP11;OMIM:615922,RETINITIS PIGMENTOSA 70; RP70;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP	DOID:0050572,('cone-rod dystrophy',),5,0.0031;DOID:0010584,('retinitis pigmentosa',),5,0.0001	
Y110A7A.8,Y46G5A.4,K03H1.2,K07C5.6,K04G7.10	0.05,GO:0000375,RNA splicing, via transesterification reactions;0.05,GO:0005681,spliceosomal complex	Q8WWY3,Q92620,P08621,O75643,O95391	OMIM:204000,LEBER CONGENITAL AMAUROSIS 1; LCA1;OMIM:600138,RETINITIS PIGMENTOSA 11; RP11;OMIM:120300,COLOBOMA OF MACULA;OMIM:610359,RETINITIS PIGMENTOSA 33; RP33;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP	DOID:0050572,('cone-rod dystrophy',),5,0.0062;DOID:0010584,('retinitis pigmentosa',),5,0.0002	
Y47G6A.11,T28A8.7,K08A8.3,F08B4.5,ZK1127.11,Y43F4B.6	0.05,MI:cel-miR-241,MI:cel-miR-241	O95239,O60216,O15457,P52701,P56282,P40692	OMIM:158320,MUIR-TORRE SYNDROME; MRTES;OMIM:300923,MENTAL RETARDATION, X-LINKED 100; MRX100;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:613659,GASTRIC CANCER;OMIM:211980,LUNG CANCER;OMIM:614350,COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5; HNPCC5;OMIM:609310,COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 2; HNPCC2;OMIM:614701,CORNELIA DE LANGE SYNDROME 4; CDLS4;OMIM:162200,NEUROFIBROMATOSIS, TYPE I; NF1;OMIM:209850,AUTISM;OMIM:176807,PROSTATE CANCER;OMIM:276300,MISMATCH REPAIR CANCER SYNDROME; MMRCS;OMIM:167000,OVARIAN CANCER;OMIM:608089,ENDOMETRIAL CANCER;OMIM:114480,BREAST CANCER	DOID:0001520,('colon carcinoma',),6,0.0163;DOID:0008712,('neurofibromatosis',),6,0.0015;DOID:0001324,('lung cancer',),2,0.0015;DOID:0002871,('endometrial carcinoma',),6,0.0245;DOID:0001612,('breast cancer',),6,0.0392;DOID:0050465,('Muir-Torre syndrome',),6,0.0020;DOID:0009256,('colorectal cancer',),6,0.0149;DOID:0012849,('autistic disorder',),4,0.0000	
T25E12.5,T14F9.3,ZK593.1,F25H5.3,ZC395.7	0.0500,MI:cel-miR-232,MI:cel-miR-232;0.0479,MI:cel-miR-1,MI:cel-miR-1	Q9BY32,P07686,P14618	OMIM:613850,INOSINE TRIPHOSPHATASE DEFICIENCY;OMIM:210900,BLOOM SYNDROME; BLM;OMIM:268800,SANDHOFF DISEASE	DOID:0003323,('Sandhoff disease',),4,0.0003	
Y87G2A.5,F13A7.10,ZK121.1,Y45G12C.2,C29E4.7,C02D5.3	0.05,MI:cel-miR-245,MI:cel-miR-245	Q9NS18,P78417,P26640			
R01H2.6,F25H2.8,M7.1,F39B2.2,Y54G2A.31,F40G9.3	0.05,MI:cel-miR-38,MI:cel-miR-38	Q7Z7E8,P68036,Q13404,P62837,P61088,P61086			
Y47G6A.11,T28A8.7,F53H1.1,ZK1127.11,Y43F4B.6	0.044,GO:0016071,mRNA metabolic process;0.036,GO:0008380,RNA splicing;0.032,GO:0000375,RNA splicing, via transesterification reactions;0.030,GO:0000377,RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;0.038,GO:0006397,mRNA processing;0.030,GO:0000398,mRNA splicing, via spliceosome;0.042,GO:0010501,RNA secondary structure unwinding;0.050,GO:0004386,helicase activity;0.046,GO:0070035,purine NTP-dependent helicase activity;0.046,GO:0003724,RNA helicase activity;0.046,GO:0008186,RNA-dependent ATPase activity;0.046,GO:0008026,ATP-dependent helicase activity;0.046,GO:0004004,ATP-dependent RNA helicase activity;0.050,MI:cel-miR-64,MI:cel-miR-64	P52701,O95239,O15457,Q7L014,P40692	OMIM:158320,MUIR-TORRE SYNDROME; MRTES;OMIM:300923,MENTAL RETARDATION, X-LINKED 100; MRX100;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:211980,LUNG CANCER;OMIM:614350,COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5; HNPCC5;OMIM:609310,COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 2; HNPCC2;OMIM:162200,NEUROFIBROMATOSIS, TYPE I; NF1;OMIM:613659,GASTRIC CANCER;OMIM:176807,PROSTATE CANCER;OMIM:276300,MISMATCH REPAIR CANCER SYNDROME; MMRCS;OMIM:167000,OVARIAN CANCER;OMIM:608089,ENDOMETRIAL CANCER;OMIM:114480,BREAST CANCER	DOID:0008712,('neurofibromatosis',),5,0.0059;DOID:0001612,('breast cancer',),5,0.0138;DOID:0050465,('Muir-Torre syndrome',),5,0.0069;DOID:0009256,('colorectal cancer',),5,0.0059;DOID:0001520,('colon carcinoma',),5,0.0069;DOID:0001324,('lung cancer',),2,0.0038	
F32E10.4,F28B3.8,ZK742.1,Y48G1A.5,Y49E10.6,C53D5.6,T10F2.3	0.0497,MI:cel-miR-63,MI:cel-miR-63;0.0467,MI:cel-miR-64,MI:cel-miR-64;0.0455,MI:cel-miR-65,MI:cel-miR-65;0.0500,MI:cel-miR-66,MI:cel-miR-66	O14980,P55060,O00410,O00629,Q14974			
ZK430.1,R13A5.12,M01F1.2,K12H4.3,Y46E12BL.2,K09H9.6,ZK945.3,F13E6.1,Y48G8AL.5,R05H10.2,Y54H5A.1,F56D2.6,T07A9.9,Y66H1A.4,T01C3.7,K01G5.5,R144.7,T25G3.3,Y39A1A.14,Y45F10D.7,Y71G12B.8,W07E6.1,ZC376.5,Y54E10A.10,Y75B8A.7,Y73E7A.2,Y48B6A.1,Y39B6A.33,F55F8.5,H06I04.3,F32E10.1,F55A12.8,F13H8.2,ZK795.3,K01C8.9,F10E7.5,Y39B6A.2,ZK512.2,W01B11.3,K07C5.4,JC8.2,F55F8.2,F27C1.6,C24H12.4,C16A3.3,C15H11.9,C07E3.2,Y53C12B.1,F28D1.1,C48B6.2,C18A3.3,C47E12.7,C43E11.9,C37H5.5,C53H9.2,C44E4.4,F44G4.1,B0511.6,B0035.12,B0024.11	2.33e-02,GO:0043467,regulation of generation of precursor metabolites and energy;2.33e-02,GO:0043457,regulation of cellular respiration;2.33e-02,GO:1901857,positive regulation of cellular respiration;2.05e-09,GO:1901360,organic cyclic compound metabolic process;1.42e-06,GO:0071840,cellular component organization or biogenesis;1.84e-12,GO:0044085,cellular component biogenesis;4.88e-15,GO:0022613,ribonucleoprotein complex biogenesis;3.43e-16,GO:0042254,ribosome biogenesis;2.42e-06,GO:0042273,ribosomal large subunit biogenesis;4.17e-02,GO:0042274,ribosomal small subunit biogenesis;1.01e-09,GO:0006725,cellular aromatic compound metabolic process;4.92e-03,GO:0071826,ribonucleoprotein complex subunit organization;4.45e-04,GO:0043170,macromolecule metabolic process;1.05e-06,GO:0010467,gene expression;1.62e-09,GO:0046483,heterocycle metabolic process;5.00e-02,GO:0022607,cellular component assembly;5.74e-04,GO:0070925,organelle assembly;2.23e-02,GO:0065003,macromolecular complex assembly;2.06e-02,GO:0034622,cellular macromolecular complex assembly;3.59e-03,GO:0022618,ribonucleoprotein complex assembly;2.74e-04,GO:0042255,ribosome assembly;2.04e-05,GO:0000027,ribosomal large subunit assembly;1.18e-07,GO:0006807,nitrogen compound metabolic process;3.42e-08,GO:0034641,cellular nitrogen compound metabolic process;9.34e-10,GO:0006139,nucleobase-containing compound metabolic process;4.01e-11,GO:0090304,nucleic acid metabolic process;1.56e-04,GO:0044260,cellular macromolecule metabolic process;4.59e-12,GO:0016070,RNA metabolic process;4.77e-12,GO:0034660,ncRNA metabolic process;5.36e-14,GO:0016072,rRNA metabolic process;2.33e-02,GO:0016074,snoRNA metabolic process;2.33e-02,GO:0033979,box H/ACA snoRNA metabolic process;2.33e-02,GO:0016073,snRNA metabolic process;3.56e-04,GO:0010501,RNA secondary structure unwinding;2.69e-10,GO:0006396,RNA processing;2.33e-12,GO:0034470,ncRNA processing;2.33e-02,GO:0043144,snoRNA processing;2.33e-02,GO:0031126,snoRNA 3'-end processing;2.33e-02,GO:0034964,box H/ACA snoRNA processing;2.33e-02,GO:0000495,box H/ACA snoRNA 3'-end processing;5.36e-14,GO:0006364,rRNA processing;3.72e-02,GO:0030490,maturation of SSU-rRNA;2.12e-02,GO:0000462,maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);5.15e-06,GO:0000470,maturation of LSU-rRNA;3.55e-04,GO:0000463,maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);8.66e-05,GO:0009451,RNA modification;2.33e-02,GO:0040031,snRNA modification;4.63e-02,GO:0016556,mRNA modification;1.05e-03,GO:0001522,pseudouridine synthesis;2.33e-02,GO:0031120,snRNA pseudouridine synthesis;2.33e-02,GO:1990481,mRNA pseudouridine synthesis;2.04e-05,GO:0000154,rRNA modification;4.63e-02,GO:0031118,rRNA pseudouridine synthesis;2.33e-02,GO:0031167,rRNA methylation;2.33e-02,GO:0070475,rRNA base methylation;3.19e-05,GO:0043226,organelle;3.64e-12,GO:0043228,non-membrane-bounded organelle;9.65e-08,GO:0044422,organelle part;5.49e-06,GO:0043227,membrane-bounded organelle;1.98e-05,GO:0043229,intracellular organelle;3.64e-12,GO:0043232,intracellular non-membrane-bounded organelle;3.29e-06,GO:0043231,intracellular membrane-bounded organelle;2.52e-12,GO:0005634,nucleus;5.21e-06,GO:0032991,macromolecular complex;6.84e-11,GO:1990904,ribonucleoprotein complex;6.84e-11,GO:0030529,intracellular ribonucleoprotein complex;6.62e-14,GO:0030684,preribosome;1.05e-03,GO:0030687,preribosome, large subunit precursor;1.83e-11,GO:0032040,small-subunit processome;8.21e-10,GO:0030686,90S preribosome;3.44e-03,GO:0005732,small nucleolar ribonucleoprotein complex;5.28e-03,GO:0043234,protein complex;8.41e-14,GO:0031974,membrane-enclosed lumen;4.02e-14,GO:0043233,organelle lumen;5.23e-09,GO:0044446,intracellular organelle part;4.02e-14,GO:0070013,intracellular organelle lumen;2.02e-13,GO:0044428,nuclear part;8.03e-16,GO:0031981,nuclear lumen;2.33e-02,GO:0005697,telomerase holoenzyme complex;2.33e-02,GO:0072588,box H/ACA RNP complex;1.70e-18,GO:0005730,nucleolus;1.72e-13,GO:0044452,nucleolar part;2.33e-02,GO:0031428,box C/D snoRNP complex;5.04e-05,GO:0034388,Pwp2p-containing subcomplex of 90S preribosome;5.15e-06,GO:0034457,Mpp10 complex;2.33e-02,GO:0031429,box H/ACA snoRNP complex;2.33e-02,GO:0070545,PeBoW complex;1.40e-03,GO:0005488,binding;2.70e-06,GO:1901363,heterocyclic compound binding;2.70e-06,GO:0097159,organic cyclic compound binding;1.10e-07,GO:0003676,nucleic acid binding;1.55e-08,GO:0003723,RNA binding;4.07e-07,GO:0030515,snoRNA binding;2.42e-06,GO:0019843,rRNA binding;3.55e-04,GO:0042134,rRNA primary transcript binding;1.79e-02,GO:0044877,macromolecular complex binding;4.63e-02,GO:0003682,chromatin binding;1.93e-03,GO:0016817,hydrolase activity, acting on acid anhydrides;1.93e-03,GO:0016818,hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides;1.93e-03,GO:0016462,pyrophosphatase activity;1.93e-03,GO:0017111,nucleoside-triphosphatase activity;7.22e-04,GO:0004386,helicase activity;5.16e-04,GO:0070035,purine NTP-dependent helicase activity;5.16e-04,GO:0003724,RNA helicase activity;2.69e-03,GO:0016887,ATPase activity;2.14e-03,GO:0042623,ATPase activity, coupled;5.16e-04,GO:0008186,RNA-dependent ATPase activity;5.16e-04,GO:0008026,ATP-dependent helicase activity;5.16e-04,GO:0004004,ATP-dependent RNA helicase activity;3.44e-03,GO:0016866,intramolecular transferase activity;3.55e-04,GO:0009982,pseudouridine synthase activity;2.33e-02,GO:0008649,rRNA methyltransferase activity;2.33e-02,GO:0070037,rRNA (pseudouridine) methyltransferase activity;4.71e-02,MI:cel-miR-255,MI:cel-miR-255;4.90e-02,MI:cel-miR-790,MI:cel-miR-790;4.64e-02,MI:cel-miR-791,MI:cel-miR-791;4.75e-02,MI:cel-miR-60,MI:cel-miR-60;4.73e-02,MI:cel-miR-246,MI:cel-miR-246;5.00e-02,MI:cel-miR-360,MI:cel-miR-360;4.02e-02,MI:cel-miR-47,MI:cel-miR-47;3.24e-02,MI:cel-miR-796,MI:cel-miR-796;4.99e-02,MI:cel-miR-239b,MI:cel-miR-239b;4.75e-02,MI:cel-miR-57,MI:cel-miR-57;4.59e-02,MI:cel-miR-2,MI:cel-miR-2;3.89e-02,MI:cel-miR-793,MI:cel-miR-793;4.46e-02,MI:cel-miR-85,MI:cel-miR-85;4.74e-02,MI:cel-miR-359,MI:cel-miR-359;4.14e-02,MI:cel-miR-73,MI:cel-miR-73;4.24e-02,MI:cel-miR-262,MI:cel-miR-262;4.29e-02,MI:cel-miR-59,MI:cel-miR-59;4.57e-02,MI:cel-miR-270,MI:cel-miR-270;4.18e-02,MI:cel-miR-264,MI:cel-miR-264;4.55e-02,MI:cel-miR-230,MI:cel-miR-230;4.62e-02,MI:cel-miR-239a,MI:cel-miR-239a;4.10e-02,MI:cel-miR-71,MI:cel-miR-71;3.44e-02,MI:cel-miR-258,MI:cel-miR-258	P05455,Q12788,O43143,Q08J23,Q8NHQ9,Q5TAP6,Q8IY81,Q9BQ67,Q9UNX4,Q9NY93,Q9Y3T9,Q8WTT2,Q96G21,O15213,Q13610,P55327,Q9NZM5,Q9NY61,O00541,Q9NVP1,Q9Y221,Q9H7B2,O00566,Q15020,Q9GZL7,Q9NXH9,P56182,Q9UKD2,P46087,Q9H583,Q14690,Q99848,Q14137,Q15397,Q92979,Q9NVN8,Q96D46,Q9NQ55,Q9GZR7,Q9Y2X3,Q8NI36,Q9H0A0,Q9NV31,Q9BZE4,Q15050,Q96PZ0,P40429,P53041,Q9NY12,Q9BSC4,Q9H9Y2,O60832,Q8TDN6,Q5JTH9,O00567,Q9NW13	OMIM:614153,SPINOCEREBELLAR ATAXIA 36; SCA36;OMIM:611091,MENTAL RETARDATION, AUTOSOMAL RECESSIVE 5; MRT5;OMIM:137760,GLAUCOMA, PRIMARY OPEN ANGLE; POAG;OMIM:609887,GLAUCOMA 1, OPEN ANGLE, G; GLC1G;OMIM:612079,ALOPECIA, NEUROLOGIC DEFECTS, AND ENDOCRINOPATHY SYNDROME; ANES;OMIM:209850,AUTISM;OMIM:305000,DYSKERATOSIS CONGENITA, X-LINKED; DKCX;OMIM:211180,BOWEN-CONRADI SYNDROME; BWCNS;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0012849,('autistic disorder',),19,0.0000;DOID:0001441,('spinocerebellar ataxia',),21,0.0000;DOID:0060308,('autosomal recessive non-syndromic intellectual disability',),52,0.0000;DOID:0002729,('dyskeratosis congenita',),45,0.0000;DOID:0005419,('schizophrenia',),16,0.0000;DOID:0001070,('primary open angle glaucoma',),41,0.0000;DOID:0050684,('Bowen-Conradi syndrome',),42,0.0000;DOID:0001067,('open-angle glaucoma',),41,0.0000	CORUM:563
T13C2.4,ZK270.2,T23F11.1,F48E3.3	0.0500,MI:cel-miR-356,MI:cel-miR-356;0.0463,MI:cel-miR-264,MI:cel-miR-264;0.0422,MI:cel-miR-243,MI:cel-miR-243;0.0496,MI:cel-miR-256,MI:cel-miR-256;0.0480,MI:cel-miR-392,MI:cel-miR-392;0.0477,MI:cel-miR-59,MI:cel-miR-59;0.0425,MI:cel-miR-793,MI:cel-miR-793	Q9NYU2,Q9NP77			
F54E12.2,Y56A3A.27,C04H5.6		O60231,Q13472	OMIM:211980,LUNG CANCER		
R01H2.6,F25H2.8,R09B3.4,M7.1,F39B2.2,D1022.1	0.05,MI:cel-miR-38,MI:cel-miR-38	Q7Z7E8,Q969M7,Q13404,P62837,P68036,Q9Y385			
F56D12.1,T08B1.3,T05H4.13,K04F1.15,F13D12.4,F54D8.3,F45H10.1	0.0456,MI:cel-lin-4,MI:cel-lin-4;0.0500,MI:cel-miR-228,MI:cel-miR-228	P51649,Q02252,P05091,P30038,P30838	OMIM:211980,LUNG CANCER;OMIM:271980,SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD;OMIM:610251,ALCOHOL SENSITIVITY, ACUTE;OMIM:239510,HYPERPROLINEMIA, TYPE II; HYRPRO2;OMIM:614105,METHYLMALONATE SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; MMSDHD;OMIM:601665,OBESITY;OMIM:133239,ESOPHAGEAL CANCER;OMIM:236795,3-HYDROXYISOBUTYRIC ACIDURIA;OMIM:103780,ALCOHOL DEPENDENCE;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:260350,PANCREATIC CANCER	DOID:0001324,('lung cancer',),2,0.0014	
W05B10.1,ZK131.8,H02I12.6,R08C7.3,F45E1.6,T23D8.6,C50F4.7,B0041.4,Y54G2A.25,C50F4.5,B0035.10	0.05,MI:cel-miR-793,MI:cel-miR-793	Q99880,P58876,P0C0S5,P68431,P84243,P62805,P36578,P32004	OMIM:304100,CORPUS CALLOSUM, PARTIAL AGENESIS OF, X-LINKED;OMIM:123155,HYDROCEPHALUS, AUTOSOMAL DOMINANT; HDCPH1;OMIM:303350,MASA SYNDROME;OMIM:142623,HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1;OMIM:307000,HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS;OMIM:236600,HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 1; HYC1		
H02I12.1,H12C20.2,H26D21.2,ZK337.1,B0218.6	0.05,MI:cel-miR-356,MI:cel-miR-356	Q6YHK3,Q9BWP8,P43246,P54278	OMIM:158320,MUIR-TORRE SYNDROME; MRTES;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:613659,GASTRIC CANCER;OMIM:400042,SPERMATOGENIC FAILURE, Y-LINKED, 1; SPGFY1;OMIM:120435,LYNCH SYNDROME I;OMIM:265050,3MC SYNDROME 2; 3MC2;OMIM:614337,COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 4; HNPCC4;OMIM:176807,PROSTATE CANCER;OMIM:276300,MISMATCH REPAIR CANCER SYNDROME; MMRCS;OMIM:167000,OVARIAN CANCER;OMIM:608089,ENDOMETRIAL CANCER;OMIM:114480,BREAST CANCER;OMIM:260350,PANCREATIC CANCER	DOID:0001612,('breast cancer',),3,0.0035;DOID:0001520,('colon carcinoma',),4,0.0041;DOID:0009256,('colorectal cancer',),4,0.0035	
Y76B12C.7,F32D1.9,F43G6.5,R06A4.9,Y67H2A.1,F36F2.3	0.00455,GO:0043631,RNA polyadenylation;0.05000,GO:0016071,mRNA metabolic process;0.01360,GO:0031123,RNA 3'-end processing;0.04320,GO:0006397,mRNA processing;0.00682,GO:0031124,mRNA 3'-end processing;0.00455,GO:0006378,mRNA polyadenylation;0.01820,GO:0016779,nucleotidyltransferase activity;0.00455,GO:0070566,adenylyltransferase activity;0.00455,GO:0004652,polynucleotide adenylyltransferase activity;0.04990,MI:cel-miR-233,MI:cel-miR-233;0.04500,MI:cel-miR-67,MI:cel-miR-67;0.04460,MI:cel-miR-1019,MI:cel-miR-1019;0.05000,MI:cel-miR-82,MI:cel-miR-82;0.03780,MI:cel-miR-271,MI:cel-miR-271;0.04070,MI:cel-miR-37,MI:cel-miR-37;0.04790,MI:cel-miR-80,MI:cel-miR-80;0.04080,MI:cel-miR-262,MI:cel-miR-262;0.04800,MI:cel-miR-786,MI:cel-miR-786;0.02980,MI:cel-miR-796,MI:cel-miR-796;0.04380,MI:cel-miR-229,MI:cel-miR-229	Q9UKF6,Q10570,Q7Z6E9			CORUM:1141
T09B4.9,T19B4.4,F45G2.8,C37H5.8,F22B7.5,C34C12.8	0.01370,GO:0070585,protein localization to mitochondrion;0.01370,GO:0072655,establishment of protein localization to mitochondrion;0.01820,GO:0017038,protein import;0.01370,GO:0006839,mitochondrial transport;0.01370,GO:1990542,mitochondrial transmembrane transport;0.01820,GO:0071806,protein transmembrane transport;0.01820,GO:0065002,intracellular protein transmembrane transport;0.01820,GO:0044743,intracellular protein transmembrane import;0.01370,GO:0006626,protein targeting to mitochondrion;0.01370,GO:0030150,protein import into mitochondrial matrix;0.04550,GO:0044455,mitochondrial membrane part;0.05000,GO:0019866,organelle inner membrane;0.05000,GO:0005743,mitochondrial inner membrane;0.01210,GO:0005739,mitochondrion;0.03190,GO:0098798,mitochondrial protein complex;0.03190,GO:0098800,inner mitochondrial membrane protein complex;0.00912,GO:0005744,mitochondrial inner membrane presequence translocase complex;0.05000,MI:cel-miR-79,MI:cel-miR-79;0.04740,MI:cel-miR-261,MI:cel-miR-261	P38646,Q9HAV7,O43615,Q96EY1,Q9Y3D7,Q9Y5T4	OMIM:613320,SPONDYLOMETAPHYSEAL DYSPLASIA, MEGARBANE-DAGHER-MELKI TYPE; SMDMDM		
D1014.3,Y57G11C.4,F56A8.7,C07G1.1	0.050000,MI:cel-miR-61,MI:cel-miR-61;0.041800,MI:cel-miR-793,MI:cel-miR-793;0.000708,MI:cel-miR-1018,MI:cel-miR-1018;0.044500,MI:cel-miR-71,MI:cel-miR-71	Q16623,P54920,P98073,Q96AJ9	OMIM:219700,CYSTIC FIBROSIS; CF;OMIM:226200,ENTEROKINASE DEFICIENCY		
Y116A8C.35,Y92C3B.2,F37H8.5,Y47G6A.20	0.0393,MI:cel-miR-1020,MI:cel-miR-1020;0.0500,MI:cel-miR-353,MI:cel-miR-353;0.0308,MI:cel-miR-795,MI:cel-miR-795;0.0339,MI:cel-miR-354,MI:cel-miR-354;0.0303,MI:cel-miR-56*,MI:cel-miR-56*	Q01081,P13284,P26368,Q9UHX1	OMIM:126200,MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO; MS;OMIM:615583,VERHEIJ SYNDROME; VRJS;OMIM:181500,SCHIZOPHRENIA; SCZD		
F53F10.3,Y46G5A.31		P13807,O95563	OMIM:611556,GLYCOGEN STORAGE DISEASE 0, MUSCLE; GSD0B		
C42D8.3,F31D4.2		Q9H993,Q9NVE7			
C10G8.5,Y97E10B.7		P57103			
F22B8.6,Y55F3AM.12					
C36A4.8,T28C6.7					
Y53H1A.1,C07H6.4		O15042,Q8TF01			
F39B2.7,F52H3.2		Q969Y2,Q9Y2Z2	OMIM:616198,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 23; COXPD23;OMIM:614702,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 10; COXPD10		
F55A11.2,Y51H7C.6		Q13190,Q9H9E3	OMIM:613489,CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIj; CDG2J		
R09B3.5,R07E5.14		Q96A72,Q9Y5S9	OMIM:274000,THROMBOCYTOPENIA-ABSENT RADIUS SYNDROME; TAR		
B0495.2,ZC504.3		P21127			
Y65B4BR.5,Y39G10AR.8,T01C3.6,ZC434.2,F59A2.3,Y37E3.7,M01F1.2,T05H4.6,ZK131.8,K04D7.1,R11D1.8,Y24D9A.4,Y105E8A.16,F54H12.6,Y45F10D.12,Y71A12B.1,F31E3.5,W08E3.3,Y43B11AR.4,F10E7.7,C56C10.8,F37C12.4,Y48B6A.2,F10B5.1,F55A8.2,F25H2.11,C23G10.3,Y37E3.8,Y48G8AL.8,R13A5.8,F53G12.10,F37C12.11,F40F11.1,T08B2.10,F56F3.5,T05E11.1,F53A3.3,F42C5.8,T07A9.11,T05F1.3,R151.3,Y71F9AL.13,Y57G11C.16,C37A2.7,C09D4.5,JC8.3,T22F3.4,K11H12.2,F54C9.5,F07D10.1,E04A4.8,C32E8.2,D1007.6,F37C12.9,C04F12.4,H06H21.3,T24B8.1,K02B2.5,C54C6.1,ZK652.4,W09C5.6,H06I04.4,F52B5.6,F39B2.6,D1007.12,Y41D4B.5,Y106G6H.3,ZK328.2,F54E7.2,F56E10.4,ZK1010.1,F36A2.6,F28D1.7,C26F1.9,F40F8.10,F28C6.7,F13B10.2,C42C1.14,C27A2.2,W01D2.1,T23D8.6,F55D10.2,F25H2.10,F45F2.3,C53H9.1,C49H3.11,C26F1.4,C50F4.7,C16A3.9,C14B9.7,C09H10.2,C06B8.8,B0513.3,B0412.4,B0393.1,B0336.10,B0250.1,B0041.4	5.00e-02,GO:0043170,macromolecule metabolic process;1.71e-03,GO:0010467,gene expression;1.64e-02,GO:0019538,protein metabolic process;3.95e-02,GO:0044260,cellular macromolecule metabolic process;1.21e-02,GO:0044267,cellular protein metabolic process;1.96e-03,GO:0009058,biosynthetic process;8.74e-03,GO:0006807,nitrogen compound metabolic process;6.82e-03,GO:0034641,cellular nitrogen compound metabolic process;7.39e-05,GO:0043603,cellular amide metabolic process;5.28e-04,GO:1901564,organonitrogen compound metabolic process;5.87e-05,GO:0006518,peptide metabolic process;1.65e-03,GO:1901576,organic substance biosynthetic process;8.69e-05,GO:1901566,organonitrogen compound biosynthetic process;3.54e-04,GO:0009059,macromolecule biosynthetic process;1.08e-03,GO:0044249,cellular biosynthetic process;3.42e-04,GO:0044271,cellular nitrogen compound biosynthetic process;1.40e-05,GO:0043604,amide biosynthetic process;1.03e-05,GO:0043043,peptide biosynthetic process;3.54e-04,GO:0034645,cellular macromolecule biosynthetic process;9.23e-06,GO:0006412,translation;2.95e-03,GO:0002181,cytoplasmic translation;3.22e-02,GO:0006413,translational initiation;2.95e-03,GO:0001731,formation of translation preinitiation complex;2.40e-02,GO:0043228,non-membrane-bounded organelle;9.26e-03,GO:1990904,ribonucleoprotein complex;2.40e-02,GO:0043232,intracellular non-membrane-bounded organelle;9.26e-03,GO:0030529,intracellular ribonucleoprotein complex;3.61e-03,GO:0005829,cytosol;6.10e-05,GO:0044445,cytosolic part;2.23e-04,GO:0005840,ribosome;1.46e-04,GO:0044391,ribosomal subunit;4.07e-05,GO:0015934,large ribosomal subunit;2.44e-05,GO:0022626,cytosolic ribosome;4.07e-06,GO:0022625,cytosolic large ribosomal subunit;8.53e-05,GO:0005198,structural molecule activity;4.07e-05,GO:0003735,structural constituent of ribosome;2.10e-02,GO:0005488,binding;2.59e-04,GO:1901363,heterocyclic compound binding;2.59e-04,GO:0097159,organic cyclic compound binding;8.69e-05,GO:0003676,nucleic acid binding;4.57e-05,GO:0003723,RNA binding;2.35e-02,GO:0044822,poly(A) RNA binding;2.93e-02,GO:0008135,translation factor activity, RNA binding;1.76e-02,GO:0003743,translation initiation factor activity;5.00e-02,MI:cel-miR-356,MI:cel-miR-356	P62701,P08865,P61313,P62891,Q9Y3U8,P63244,Q07020,P62424,P36578,P61513,P62263,P62081,P62987,P61254,P46776,P05387,P25398,P18077,P62888,P49207,P26373,P62829,P05388,P62753,P0CW22,Q15029,Q07021,Q13765,P62244,P61353,P32969,P62851,P61927,P61247,P40429,P46777,Q9NTK5,P46783,P23396,P13693,P62249,Q02878,Q05639,P62495,P39023,Q96K17,P62269,P46778,P62979,P62750,P62241,P27635,P62277,P60866,P30050,P62910,P62805,P62273,P62280,P62847,P83731,P62854,P50914,P84098,P46782,P42766,P24534,O14602,P42677,P18124,Q13976,Q969Q0,P46779,P39019,P41091,P63220,P62913,P63173,P62906,P18621,Q02543,P62841,P05386,P62917,P62266,P62857,P62899,P35268,P46781,P15880	OMIM:612561,DIAMOND-BLACKFAN ANEMIA 6; DBA6;OMIM:606164,DIAMOND-BLACKFAN ANEMIA 15 WITH MANDIBULOFACIAL DYSOSTOSIS; DBA15;OMIM:615885,HYPOTRICHOSIS 12; HYPT12;OMIM:605389,HYPOTRICHOSIS 1; HYPT1;OMIM:610629,DIAMOND-BLACKFAN ANEMIA 3; DBA3;OMIM:300847,AUTISM, SUSCEPTIBILITY TO, X-LINKED 5; AUTSX5;OMIM:154500,TREACHER COLLINS SYNDROME 1; TCS1;OMIM:615909,DIAMOND-BLACKFAN ANEMIA 13; DBA13;OMIM:271400,ASPLENIA, ISOLATED CONGENITAL; ICAS;OMIM:610536,MANDIBULOFACIAL DYSOSTOSIS, GUION-ALMEIDA TYPE; MFDGA;OMIM:300495,AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:609135,APLASTIC ANEMIA;OMIM:105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1;OMIM:614900,DIAMOND-BLACKFAN ANEMIA 11; DBA11;OMIM:615436,AORTIC ANEURYSM, FAMILIAL THORACIC 8; AAT8;OMIM:612528,DIAMOND-BLACKFAN ANEMIA 5; DBA5;OMIM:612563,DIAMOND-BLACKFAN ANEMIA 8; DBA8;OMIM:613309,DIAMOND-BLACKFAN ANEMIA 10; DBA10;OMIM:615550,DIAMOND-BLACKFAN ANEMIA 12; DBA12;OMIM:209850,AUTISM;OMIM:612562,DIAMOND-BLACKFAN ANEMIA 7; DBA7;OMIM:153550,CHROMOSOME 5q DELETION SYNDROME;OMIM:613308,DIAMOND-BLACKFAN ANEMIA 9; DBA9	DOID:0012849,('autistic disorder',),97,0.0001;DOID:0004535,('hypotrichosis',),9,0.0238;DOID:0012449,('aplastic anemia',),79,0.0000;DOID:0014004,('thoracic aortic aneurysm',),74,0.0000;DOID:0001339,('Diamond-Blackfan anemia',),95,0.0000;DOID:0002908,('Treacher Collins syndrome',),31,0.0000	
F20C5.2,F56B3.8		O15066,Q5T653			
B0478.1,C02H7.3		P53779,Q8WXG6	OMIM:231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD;OMIM:209850,AUTISM		
C14A4.14,C25A1.1		P82650,Q9GZU8	OMIM:611719,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 5; COXPD5		
C52E4.2,Y56A3A.3		P30046,P14174	OMIM:261550,PERSISTENT MULLERIAN DUCT SYNDROME, TYPES I AND II; PMDS;OMIM:604302,RHEUMATOID ARTHRITIS, SYSTEMIC JUVENILE		
C34G6.2,W02C12.3		P19484			
C10G8.7,Y105E8A.10		Q9HCG7,Q15475	OMIM:614409,SPASTIC PARAPLEGIA 46, AUTOSOMAL RECESSIVE; SPG46;OMIM:605192,DEAFNESS, AUTOSOMAL DOMINANT 23; DFNA23;OMIM:608389,BRANCHIOOTIC SYNDROME 3; BOS3	DOID:0050564,('autosomal dominant nonsyndromic deafness',),2,0.0340	
C25E10.2,K06G5.2					
F25G6.8,ZK512.4		P49458,P37108			
C50H11.15,F41B5.3		P20813	OMIM:614546,EFAVIRENZ, POOR METABOLISM OF;OMIM:601626,LEUKEMIA, ACUTE MYELOID; AML		
Y37D8A.9,Y95B8A.12		Q9UBU8,Q6ZR37			
F26E4.4,W06E11.1		Q9NVU0			
T04G9.5,Y71F9AM.6		P43307,P43308			
R10E11.2,ZK637.8		Q93050,P27449			
C47D12.2,Y105E8A.1		P55822,Q7RTS9	OMIM:156530,METATROPIC DYSPLASIA;OMIM:223800,DYGGVE-MELCHIOR-CLAUSEN DISEASE; DMC;OMIM:607326,SMITH-MCCORT DYSPLASIA 1; SMC1		
F14F7.3,R08F11.3		P51589			
T16H12.5,Y80D3A.2		O60306,O43791	OMIM:176807,PROSTATE CANCER	DOID:0010283,('prostate cancer',),2,0.0085	
C07D10.4,Y59A8B.8		Q99747			
R07E4.1,T23G7.4		Q96KP1			
F52C12.2,Y49F6B.2,F30A10.9		Q9Y324,Q9UJK0			
T19B4.3,R07H5.8,M106.4,K02F2.2,F38B2.4,Y39E4B.1,W02D3.2,C06G3.5	0.01010,GO:0043094,cellular metabolic compound salvage;0.00252,GO:0042440,pigment metabolic process;0.00252,GO:0046148,pigment biosynthetic process;0.05000,GO:0019439,aromatic compound catabolic process;0.03760,GO:1901657,glycosyl compound metabolic process;0.02010,GO:1901659,glycosyl compound biosynthetic process;0.00754,GO:0009112,nucleobase metabolic process;0.05000,GO:0046700,heterocycle catabolic process;0.05000,GO:1901361,organic cyclic compound catabolic process;0.05000,GO:0044270,cellular nitrogen compound catabolic process;0.04500,GO:0034655,nucleobase-containing compound catabolic process;0.05000,GO:0072521,purine-containing compound metabolic process;0.01760,GO:0072523,purine-containing compound catabolic process;0.02510,GO:0072522,purine-containing compound biosynthetic process;0.00754,GO:0043101,purine-containing compound salvage;0.00754,GO:0006144,purine nucleobase metabolic process;0.00252,GO:0046100,hypoxanthine metabolic process;0.00252,GO:0046112,nucleobase biosynthetic process;0.00252,GO:0009113,purine nucleobase biosynthetic process;0.00252,GO:0043096,purine nucleobase salvage;0.00252,GO:0046101,hypoxanthine biosynthetic process;0.00252,GO:0043103,hypoxanthine salvage;0.03010,GO:1901136,carbohydrate derivative catabolic process;0.01010,GO:1901658,glycosyl compound catabolic process;0.03760,GO:0009116,nucleoside metabolic process;0.03260,GO:0009119,ribonucleoside metabolic process;0.03010,GO:0042278,purine nucleoside metabolic process;0.02510,GO:0046128,purine ribonucleoside metabolic process;0.00503,GO:0046085,adenosine metabolic process;0.00503,GO:0046102,inosine metabolic process;0.01010,GO:0009164,nucleoside catabolic process;0.00503,GO:0042454,ribonucleoside catabolic process;0.01010,GO:0006152,purine nucleoside catabolic process;0.00503,GO:0046130,purine ribonucleoside catabolic process;0.00503,GO:0006154,adenosine catabolic process;0.02010,GO:0009163,nucleoside biosynthetic process;0.02010,GO:0042455,ribonucleoside biosynthetic process;0.01260,GO:0042451,purine nucleoside biosynthetic process;0.01260,GO:0046129,purine ribonucleoside biosynthetic process;0.00503,GO:0046103,inosine biosynthetic process;0.00503,GO:0019239,deaminase activity;0.00754,GO:0016810,hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds;0.00503,GO:0016814,hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines;0.00503,GO:0004000,adenosine deaminase activity;0.05000,MI:cel-miR-124,MI:cel-miR-124	P49915,P00568,P07741,Q02127,P00813,P55263,P61221,P23526	OMIM:612631,ADENYLATE KINASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO;OMIM:613752,HYPERMETHIONINEMIA WITH S-ADENOSYLHOMOCYSTEINE HYDROLASE DEFICIENCY;OMIM:263750,POSTAXIAL ACROFACIAL DYSOSTOSIS; POADS;OMIM:102700,SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY;OMIM:250850,METHIONINE ADENOSYLTRANSFERASE DEFICIENCY;OMIM:209850,AUTISM;OMIM:614300,HYPERMETHIONINEMIA DUE TO ADENOSINE KINASE DEFICIENCY;OMIM:601626,LEUKEMIA, ACUTE MYELOID; AML;OMIM:614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0050544,('hypermethioninemia',),7,0.0000;DOID:0000583,('hemolytic anemia',),4,0.0045;DOID:0012849,('autistic disorder',),7,0.0000	
K04E7.2,Y37E3.11		Q99447			
C44B7.9,Y42H9AR.3		Q9H1K0,P28288	OMIM:214100,PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER); PBD1A;OMIM:616278,BILE ACID SYNTHESIS DEFECT, CONGENITAL, 5; CBAS5		
R12E2.3,Y54G2A.31,F40G9.3,C41D11.2	0.05,MI:cel-miR-38,MI:cel-miR-38	P61088,P51665,O15372,P61086			
T04A11.1,ZK20.5,T09A5.9,F56C9.1	0.05,MI:cel-miR-38,MI:cel-miR-38	Q15435,P48556,P62136			
F11A10.7,F57B10.8,C01F6.5,C16A3.8	0.0100,GO:0000460,maturation of 5.8S rRNA;0.0075,GO:0000466,maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);0.0500,GO:0071826,ribonucleoprotein complex subunit organization;0.0025,GO:0000966,RNA 5'-end processing;0.0250,GO:0070925,organelle assembly;0.0025,GO:0034471,ncRNA 5'-end processing;0.0025,GO:0000967,rRNA 5'-end processing;0.0425,GO:0042274,ribosomal small subunit biogenesis;0.0400,GO:0030490,maturation of SSU-rRNA;0.0300,GO:0000462,maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);0.0450,GO:0022618,ribonucleoprotein complex assembly;0.0200,GO:0042255,ribosome assembly;0.0075,GO:0000028,ribosomal small subunit assembly;0.0025,GO:0034462,small-subunit processome assembly;0.0350,GO:0090305,nucleic acid phosphodiester bond hydrolysis;0.0275,GO:0090501,RNA phosphodiester bond hydrolysis;0.0100,GO:0000469,cleavage involved in rRNA processing;0.0200,GO:0090502,RNA phosphodiester bond hydrolysis, endonucleolytic;0.0050,GO:0000478,endonucleolytic cleavage involved in rRNA processing;0.0050,GO:0000479,endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);0.0025,GO:0000480,endonucleolytic cleavage in 5'-ETS of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);0.0025,GO:0000472,endonucleolytic cleavage to generate mature 5'-end of SSU-rRNA from (SSU-rRNA, 5.8S rRNA, LSU-rRNA);0.0025,GO:0000447,endonucleolytic cleavage in ITS1 to separate SSU-rRNA from 5.8S rRNA and LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);0.0500,MI:cel-miR-47,MI:cel-miR-47	P42696,Q9ULW3,Q8NI27			
D2096.8,Y39B6A.14,F55F10.1,C34B2.6	0.02730,GO:0006515,misfolded or incompletely synthesized protein catabolic process;0.00455,GO:0051131,chaperone-mediated protein complex assembly;0.02730,GO:0004176,ATP-dependent peptidase activity;0.02730,GO:0001067,regulatory region nucleic acid binding;0.05000,GO:0003677,DNA binding;0.00909,GO:0003697,single-stranded DNA binding;0.02730,GO:0000975,regulatory region DNA binding;0.02730,GO:0044212,transcription regulatory region DNA binding;0.00455,GO:0070361,mitochondrial light strand promoter anti-sense binding;0.05000,MI:cel-miR-36,MI:cel-miR-36	P36776,Q9NU22,P55209,Q9NVU7	OMIM:600373,CODAS SYNDROME;OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),2,0.0000	
W09D10.3,Y71H2AM.23,Y116A8C.27,F40G9.2,F29C12.4	0.0308,MI:cel-miR-796,MI:cel-miR-796;0.0494,MI:cel-miR-87,MI:cel-miR-87;0.0468,MI:cel-miR-791,MI:cel-miR-791;0.0419,MI:cel-miR-787,MI:cel-miR-787;0.0500,MI:cel-miR-799,MI:cel-miR-799;0.0428,MI:cel-miR-231,MI:cel-miR-231	P52815,P49411,Q96RP9,Q8N5M1,Q14061	OMIM:610678,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4; COXPD4;OMIM:256000,LEIGH SYNDROME; LS;OMIM:604273,MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 1; MC5DN1;OMIM:609060,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1; COXPD1	DOID:0050768,('mitochondrial complex V (ATP synthase) deficiency, nuclear type 1',),3,0.0237	
Y57A10A.23,R05H5.3,C14B9.2,Y54E10A.3,B0403.4	0.0278,GO:0010033,response to organic substance;0.0144,GO:0035966,response to topologically incorrect protein;0.0133,GO:0006986,response to unfolded protein;0.0244,GO:0070887,cellular response to chemical stimulus;0.0222,GO:0071310,cellular response to organic substance;0.0500,GO:0033554,cellular response to stress;0.0133,GO:0035967,cellular response to topologically incorrect protein;0.0133,GO:0034620,cellular response to unfolded protein;0.0244,GO:0034976,response to endoplasmic reticulum stress;0.0133,GO:0030968,endoplasmic reticulum unfolded protein response;0.0189,GO:0006457,protein folding;0.0289,GO:0016853,isomerase activity;0.0144,GO:0016860,intramolecular oxidoreductase activity;0.0133,GO:0016864,intramolecular oxidoreductase activity, transposing S-S bonds;0.0133,GO:0003756,protein disulfide isomerase activity;0.0415,MI:cel-miR-1018,MI:cel-miR-1018	P13667,O43396,Q15084,O95881	OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),3,0.0000	
K12G11.3,T09F3.3,T01G1.3,T21B10.2,ZK520.5,Y87G2A.8,Y75B12B.5,Y75B12B.2,Y17G7B.7,T12F5.5,T03F1.3,F33H1.2,K10B3.8,K10B3.7,B0495.7	0.0292,MI:cel-miR-785,MI:cel-miR-785;0.0396,MI:cel-miR-1,MI:cel-miR-1;0.0500,MI:cel-miR-54,MI:cel-miR-54;0.0281,MI:cel-miR-796,MI:cel-miR-796;0.0406,MI:cel-miR-85,MI:cel-miR-85;0.0420,MI:cel-miR-67,MI:cel-miR-67;0.0162,MI:cel-miR-265,MI:cel-miR-265;0.0363,MI:cel-miR-72,MI:cel-miR-72;0.0480,MI:cel-miR-51,MI:cel-miR-51;0.0380,MI:cel-miR-39,MI:cel-miR-39;0.0381,MI:cel-miR-787,MI:cel-miR-787;0.0404,MI:cel-miR-242,MI:cel-miR-242	P00558,Q92615,P06733,P04406,O94979,P30405,P06744,Q7Z2K6,P60174	OMIM:613470,HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO GLUCOSE PHOSPHATE ISOMERASE DEFICIENCY;OMIM:300653,PHOSPHOGLYCERATE KINASE 1 DEFICIENCY;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:615512,TRIOSEPHOSPHATE ISOMERASE DEFICIENCY; TPID	DOID:0002861,('congenital nonspherocytic hemolytic anemia',),10,0.0000;DOID:0050884,('triosephosphate isomerase deficiency',),7,0.0000;DOID:0005419,('schizophrenia',),13,0.0000	
Y39B6A.37,Y71H2B.10,Y105E8A.9,K11D2.3,F55A12.7,F29G9.3	0.0451,MI:cel-miR-67,MI:cel-miR-67;0.0500,MI:cel-miR-250,MI:cel-miR-250;0.0487,MI:cel-miR-43,MI:cel-miR-43;0.0448,MI:cel-miR-2,MI:cel-miR-2	O43747,Q10567,Q9BXS5,P56377	OMIM:304340,PETTIGREW SYNDROME; PGS		
C32F10.2,K07A1.12,ZK637.7,M03C11.4,C09G4.5		Q08999,Q09028,O75530,Q5TKA1,O14929			
F59B2.3,R06C7.3,F38E11.3,T12A2.1,C47E12.8	0.0425,MI:cel-miR-251,MI:cel-miR-251;0.0489,MI:cel-miR-242,MI:cel-miR-242;0.0500,MI:cel-miR-232,MI:cel-miR-232;0.0462,MI:cel-miR-262,MI:cel-miR-262	Q14117,Q9Y303,Q9Y2T3,Q96NU7	OMIM:222748,DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD		CORUM:1200
T12A2.2,ZK686.3,M01A10.3,T22D1.4,T09A5.11,Y63D3A.6,Y57G11C.15	0.05,MI:cel-miR-797,MI:cel-miR-797	P39656,P04843,Q9UGP8,Q9H9S3,Q8TCJ2,Q13454	OMIM:174050,POLYCYSTIC LIVER DISEASE; PCLD;OMIM:614507,CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ir; CDG1R;OMIM:615597,CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ix; CDG1X;OMIM:611093,MENTAL RETARDATION, AUTOSOMAL RECESSIVE 7; MRT7;OMIM:209850,AUTISM;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),7,0.0000;DOID:0012849,('autistic disorder',),6,0.0000	CORUM:1768;CORUM:1767
F43G9.5,F13H10.2,EEED8.8,C50F4.16,D1046.1	0.0431,MI:cel-miR-243,MI:cel-miR-243;0.0500,MI:cel-miR-1,MI:cel-miR-1	O43809,Q86X67,Q16630,Q9BW91			
Y39A3CR.4,Y66D12A.22,DY3.1,C06G3.11	0.05,MI:cel-miR-797,MI:cel-miR-797	Q9Y5J7,O60220,Q9Y5L4,P62072	OMIM:304700,MOHR-TRANEBJAERG SYNDROME; MTS	DOID:0050757,('deafness dystonia syndrome',),4,0.0034;DOID:0050867,('Jensen syndrome',),4,0.0034	
F31D4.3,ZC455.10,C50F2.6,C05C8.3	0.05,MI:cel-miR-784,MI:cel-miR-784	Q02790			
K10B4.6,T20G5.1,C09G12.8,C56G7.1	0.0500,MI:cel-miR-84,MI:cel-miR-84;0.0436,MI:cel-miR-1018,MI:cel-miR-1018	P56705,P63000,P19105,Q00610	OMIM:167000,OVARIAN CANCER;OMIM:611812,46,XX SEX REVERSAL WITH DYSGENESIS OF KIDNEYS, ADRENALS, AND LUNGS; SERKAL;OMIM:109730,AORTIC VALVE DISEASE 1; AOVD1;OMIM:158330,MULLERIAN APLASIA AND HYPERANDROGENISM		
T03F6.1,F09E10.3,Y32H12A.3,C56G2.6	0.0500,MI:cel-miR-1,MI:cel-miR-1;0.0352,MI:cel-miR-796,MI:cel-miR-796	P09417,Q96LJ7,Q53GQ0	OMIM:261630,HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C;OMIM:261600,PHENYLKETONURIA; PKU	DOID:0009281,('phenylketonuria',),4,0.0011	
Y23H5A.7,Y65B4BR.5,C43G2.2,C56C10.8	0.0500,MI:cel-miR-41,MI:cel-miR-41;0.0427,MI:cel-miR-1018,MI:cel-miR-1018	P49589,Q96K17,Q13765			
M106.3,Y38C1AA.11,R107.2,F48E8.3	0.0374,MI:cel-miR-785,MI:cel-miR-785;0.0431,MI:cel-miR-62,MI:cel-miR-62;0.0399,MI:cel-miR-86,MI:cel-miR-86;0.0500,MI:cel-miR-253,MI:cel-miR-253;0.0500,MI:cel-miR-79,MI:cel-miR-79	Q8N8N7,P30041,Q8IW45			
F28F8.6,T04C10.2,M7.1,C02C6.1	0.0500,MI:cel-miR-49,MI:cel-miR-49;0.0480,MI:cel-miR-83,MI:cel-miR-83;0.0488,MI:cel-miR-256,MI:cel-miR-256	Q05193,Q9Y6I3,P54252,P62837	OMIM:109150,MACHADO-JOSEPH DISEASE; MJD	DOID:0001440,('Machado-Joseph disease',),4,0.0034	
F46E10.9,F49H12.5,Y52E8A.3,B0403.4	0.0500,MI:cel-miR-249,MI:cel-miR-249;0.0365,MI:cel-miR-1018,MI:cel-miR-1018;0.0468,MI:cel-miR-59,MI:cel-miR-59;0.0015,MI:cel-miR-60,MI:cel-miR-60;0.0374,MI:cel-miR-86,MI:cel-miR-86	Q9H3N1,Q15084			
Y110A2AL.8,H06O01.1,C32D5.8,C09H6.2	0.0458,MI:cel-miR-78,MI:cel-miR-78;0.0500,MI:cel-miR-799,MI:cel-miR-799	P30101			
Y48B6A.13,T02G5.8,ZC116.2,Y38C9B.1,K02F2.2,T05G5.10,E04A4.7,F54C9.1,C31E10.7,F25B4.6	0.012300,GO:0051186,cofactor metabolic process;0.012300,GO:0006732,coenzyme metabolic process;0.036800,GO:0019637,organophosphate metabolic process;0.024600,GO:0090407,organophosphate biosynthetic process;0.011400,GO:0006790,sulfur compound metabolic process;0.001750,GO:0035383,thioester metabolic process;0.041200,GO:0006629,lipid metabolic process;0.001750,GO:0006637,acyl-CoA metabolic process;0.001750,GO:0006084,acetyl-CoA metabolic process;0.027200,GO:0044255,cellular lipid metabolic process;0.002630,GO:0006720,isoprenoid metabolic process;0.010500,GO:0008610,lipid biosynthetic process;0.009650,GO:0006644,phospholipid metabolic process;0.000877,GO:0046490,isopentenyl diphosphate metabolic process;0.007890,GO:0008654,phospholipid biosynthetic process;0.000877,GO:0008299,isoprenoid biosynthetic process;0.000877,GO:0009240,isopentenyl diphosphate biosynthetic process;0.000877,GO:0019287,isopentenyl diphosphate biosynthetic process, mevalonate pathway;0.037700,GO:0005829,cytosol;0.007020,GO:0016829,lyase activity;0.003510,GO:0016830,carbon-carbon lyase activity;0.001750,GO:0016831,carboxy-lyase activity;0.000877,GO:0004163,diphosphomevalonate decarboxylase activity;0.036200,MI:cel-miR-241,MI:cel-miR-241;0.041400,MI:cel-miR-252,MI:cel-miR-252;0.040800,MI:cel-miR-62,MI:cel-miR-62;0.044100,MI:cel-miR-65,MI:cel-miR-65;0.048000,MI:cel-miR-1,MI:cel-miR-1;0.039100,MI:cel-miR-48,MI:cel-miR-48;0.047900,MI:cel-miR-63,MI:cel-miR-63;0.041900,MI:cel-miR-795,MI:cel-miR-795;0.045200,MI:cel-miR-64,MI:cel-miR-64;0.047900,MI:cel-miR-83,MI:cel-miR-83;0.049600,MI:cel-miR-229,MI:cel-miR-229;0.042900,MI:cel-miR-251,MI:cel-miR-251;0.048100,MI:cel-miR-66,MI:cel-miR-66;0.041500,MI:cel-miR-90,MI:cel-miR-90;0.037900,MI:cel-miR-86,MI:cel-miR-86	P24752,P53602,P63241,P99999,P00167,P54868,P23526	OMIM:613752,HYPERMETHIONINEMIA WITH S-ADENOSYLHOMOCYSTEINE HYDROLASE DEFICIENCY;OMIM:250790,METHEMOGLOBINEMIA TYPE IV;OMIM:605911,3-HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE-2 DEFICIENCY; HMGCS2D;OMIM:202110,ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY;OMIM:612004,THROMBOCYTOPENIA 4; THC4;OMIM:250850,METHIONINE ADENOSYLTRANSFERASE DEFICIENCY;OMIM:203750,ALPHA-METHYLACETOACETIC ACIDURIA	DOID:0014723,('beta-ketothiolase deficiency',),9,0.0000;DOID:0050544,('hypermethioninemia',),6,0.0000	
T21C9.2,Y55F3AM.15,K09B11.9,Y38C1AA.2	0.0500,MI:cel-miR-260,MI:cel-miR-260;0.0406,MI:cel-miR-1,MI:cel-miR-1	O60763,Q9BT78,Q9P1Q0,Q9UNS2			
M01E5.5,T24G10.2,F54C4.2,F55A3.3	0.05,GO:0008134,transcription factor binding;0.05,MI:cel-miR-56*,MI:cel-miR-56*	P63272,Q9Y5B9,P11387	OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),4,0.0000	CORUM:728;CORUM:2179;CORUM:2174;CORUM:726;CORUM:727
T16G1.11,C17G10.9,F36G9.12,F09B9.1	0.0500,GO:0005852,eukaryotic translation initiation factor 3 complex;0.0479,MI:cel-miR-80,MI:cel-miR-80;0.0448,MI:cel-miR-238,MI:cel-miR-238;0.0498,MI:cel-miR-239b,MI:cel-miR-239b;0.0453,MI:cel-miR-239a,MI:cel-miR-239a;0.0486,MI:cel-miR-237,MI:cel-miR-237;0.0500,MI:cel-miR-82,MI:cel-miR-82;0.0434,MI:cel-miR-356,MI:cel-miR-356	Q9Y262,Q9UBQ5			CORUM:4392;CORUM:4389;CORUM:742;CORUM:4403
T16G1.11,C17G10.9,F53C11.2,F36G9.12	0.0500,GO:0005852,eukaryotic translation initiation factor 3 complex;0.0500,MI:cel-miR-356,MI:cel-miR-356;0.0454,MI:cel-miR-261,MI:cel-miR-261	Q9Y262,Q9UBQ5			CORUM:4392;CORUM:4389;CORUM:742;CORUM:4403
Y34D9A.6,R05H10.5,F26E4.12,ZK430.3,C15F1.7,ZK652.11	0.0483,MI:cel-miR-264,MI:cel-miR-264;0.0500,MI:cel-miR-253,MI:cel-miR-253	P00441,P35754,O00244	OMIM:105400,AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1		
R11A8.5,Y34D9A.6,R05H10.5,F26E4.12,ZK430.3,C15F1.7	0.0483,MI:cel-miR-264,MI:cel-miR-264;0.0500,MI:cel-miR-253,MI:cel-miR-253	P00441,Q9H7Z7,P35754	OMIM:105400,AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1		
Y113G7B.23,Y71H2AM.17,F01G4.1,F15B10.2,C01G8.9	0.0500,MI:cel-miR-789,MI:cel-miR-789;0.0377,MI:cel-miR-793,MI:cel-miR-793	P51531,Q92922,O14497,Q969G3,O95786	OMIM:601358,NICOLAIDES-BARAITSER SYNDROME; NCBRS;OMIM:135900,COFFIN-SIRIS SYNDROME; CSS;OMIM:616298,SINGLETON-MERTEN SYNDROME 2; SGMRT2;OMIM:614607,MENTAL RETARDATION, AUTOSOMAL DOMINANT 14; MRD14;OMIM:209850,AUTISM;OMIM:607174,MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO;OMIM:182250,SINGLETON-MERTEN SYNDROME 1; SGMRT1;OMIM:156240,MESOTHELIOMA, MALIGNANT; MESOM;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0012849,('autistic disorder',),5,0.0000;DOID:0001925,('Coffin-Siris syndrome',),4,0.0137;DOID:0005419,('schizophrenia',),3,0.0000;DOID:0001790,('malignant mesothelioma',),5,0.0036	
ZK180.4,F57H12.1,F19H8.3,B0336.2,C04G6.3	0.0500,MI:cel-miR-246,MI:cel-miR-246;0.0487,MI:cel-miR-254,MI:cel-miR-254;0.0481,MI:cel-miR-77,MI:cel-miR-77;0.0396,MI:cel-miR-793,MI:cel-miR-793	P84085,P36405,P84077,Q9Y6B6,Q13393	OMIM:246700,CHYLOMICRON RETENTION DISEASE; CMRD		CORUM:3063;CORUM:570;CORUM:711;CORUM:1237;CORUM:713;CORUM:189;CORUM:1230;CORUM:710;CORUM:86;CORUM:1251;CORUM:1252;CORUM:566;CORUM:807;CORUM:806;CORUM:555;CORUM:803;CORUM:238;CORUM:778;CORUM:808;CORUM:564;CORUM:714
MTCE.21,C44C1.5,C54G4.8,F42G8.12,C05D11.12	0.0500,MI:cel-miR-229,MI:cel-miR-229;0.0448,MI:cel-miR-261,MI:cel-miR-261	P00156,Q16134,P47985,P08574	OMIM:231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD;OMIM:607426,COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1;OMIM:615453,MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 6; MC3DN6		
Y47G6A.11,T28A8.7,F10G7.3,ZK1127.11,Y43F4B.6	0.05,MI:cel-miR-64,MI:cel-miR-64	P52701,O95239,O15457,P40692	OMIM:158320,MUIR-TORRE SYNDROME; MRTES;OMIM:300923,MENTAL RETARDATION, X-LINKED 100; MRX100;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:211980,LUNG CANCER;OMIM:614350,COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5; HNPCC5;OMIM:609310,COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 2; HNPCC2;OMIM:162200,NEUROFIBROMATOSIS, TYPE I; NF1;OMIM:613659,GASTRIC CANCER;OMIM:176807,PROSTATE CANCER;OMIM:276300,MISMATCH REPAIR CANCER SYNDROME; MMRCS;OMIM:167000,OVARIAN CANCER;OMIM:608089,ENDOMETRIAL CANCER;OMIM:114480,BREAST CANCER	DOID:0008712,('neurofibromatosis',),5,0.0059;DOID:0001612,('breast cancer',),5,0.0138;DOID:0050465,('Muir-Torre syndrome',),5,0.0069;DOID:0009256,('colorectal cancer',),5,0.0059;DOID:0001520,('colon carcinoma',),5,0.0069;DOID:0001324,('lung cancer',),2,0.0038	
T04D1.4,R107.8,W06F12.1,W02D3.9	0.05,MI:cel-miR-360,MI:cel-miR-360	Q04727,Q9UBE8,Q9P2D1	OMIM:612370,HYPOGONADOTROPIC HYPOGONADISM 5 WITH OR WITHOUT ANOSMIA; HH5;OMIM:214800,CHARGE SYNDROME;OMIM:209850,AUTISM;OMIM:192430,VELOCARDIOFACIAL SYNDROME;OMIM:244200,HYPOGONADOTROPIC HYPOGONADISM 3 WITH OR WITHOUT ANOSMIA; HH3;OMIM:146110,HYPOGONADOTROPIC HYPOGONADISM 7 WITH OR WITHOUT ANOSMIA; HH7	DOID:0012583,('velocardiofacial syndrome',),4,0.0247;DOID:0050834,('CHARGE syndrome',),4,0.0132;DOID:0012849,('autistic disorder',),4,0.0000	CORUM:4392;CORUM:4389;CORUM:742;CORUM:4403
R05F9.6,C37C3.8,F21D5.1,Y43F4B.5,C06G3.5	7.58e-03,GO:1901135,carbohydrate derivative metabolic process;1.68e-02,GO:0006040,amino sugar metabolic process;1.35e-02,GO:0009225,nucleotide-sugar metabolic process;6.76e-03,GO:0006047,UDP-N-acetylglucosamine metabolic process;3.54e-03,GO:0009056,catabolic process;3.10e-03,GO:1901575,organic substance catabolic process;4.01e-02,GO:1901136,carbohydrate derivative catabolic process;1.86e-04,GO:0009058,biosynthetic process;1.47e-04,GO:1901576,organic substance biosynthetic process;1.29e-02,GO:1901362,organic cyclic compound biosynthetic process;3.60e-03,GO:1901137,carbohydrate derivative biosynthetic process;3.38e-03,GO:0046349,amino sugar biosynthetic process;8.36e-05,GO:0044249,cellular biosynthetic process;1.35e-02,GO:0043094,cellular metabolic compound salvage;1.29e-02,GO:0018130,heterocycle biosynthetic process;1.14e-02,GO:0019438,aromatic compound biosynthetic process;2.64e-02,GO:0044271,cellular nitrogen compound biosynthetic process;3.35e-02,GO:0072522,purine-containing compound biosynthetic process;1.01e-02,GO:0009112,nucleobase metabolic process;1.01e-02,GO:0006144,purine nucleobase metabolic process;3.38e-03,GO:0046100,hypoxanthine metabolic process;7.88e-03,GO:0044710,single-organism metabolic process;3.38e-03,GO:0042440,pigment metabolic process;6.81e-05,GO:0044712,single-organism catabolic process;2.76e-04,GO:0044711,single-organism biosynthetic process;3.38e-03,GO:0046148,pigment biosynthetic process;3.38e-03,GO:0046112,nucleobase biosynthetic process;3.38e-03,GO:0009113,purine nucleobase biosynthetic process;3.38e-03,GO:0046101,hypoxanthine biosynthetic process;5.00e-02,GO:1901657,glycosyl compound metabolic process;1.35e-02,GO:1901658,glycosyl compound catabolic process;2.69e-02,GO:1901659,glycosyl compound biosynthetic process;5.00e-02,GO:0009116,nucleoside metabolic process;4.34e-02,GO:0009119,ribonucleoside metabolic process;4.01e-02,GO:0042278,purine nucleoside metabolic process;3.35e-02,GO:0046128,purine ribonucleoside metabolic process;6.76e-03,GO:0046085,adenosine metabolic process;6.76e-03,GO:0046102,inosine metabolic process;1.35e-02,GO:0009164,nucleoside catabolic process;6.76e-03,GO:0042454,ribonucleoside catabolic process;1.12e-03,GO:0044281,small molecule metabolic process;1.06e-03,GO:0044282,small molecule catabolic process;3.17e-03,GO:0055114,oxidation-reduction process;3.82e-04,GO:0006091,generation of precursor metabolites and energy;3.82e-04,GO:0015980,energy derivation by oxidation of organic compounds;4.20e-05,GO:0006112,energy reserve metabolic process;5.82e-03,GO:0005975,carbohydrate metabolic process;4.77e-03,GO:0044723,single-organism carbohydrate metabolic process;1.45e-03,GO:0005996,monosaccharide metabolic process;7.01e-06,GO:0019318,hexose metabolic process;7.01e-06,GO:0006006,glucose metabolic process;7.01e-06,GO:0006012,galactose metabolic process;7.01e-06,GO:0016051,carbohydrate biosynthetic process;6.99e-05,GO:0016052,carbohydrate catabolic process;4.20e-05,GO:0044724,single-organism carbohydrate catabolic process;2.10e-05,GO:0046365,monosaccharide catabolic process;7.01e-06,GO:0019320,hexose catabolic process;7.01e-06,GO:0019388,galactose catabolic process;3.82e-04,GO:0044262,cellular carbohydrate metabolic process;7.01e-06,GO:0034637,cellular carbohydrate biosynthetic process;1.10e-02,GO:0034654,nucleobase-containing compound biosynthetic process;1.01e-02,GO:0043101,purine-containing compound salvage;3.38e-03,GO:0043096,purine nucleobase salvage;3.38e-03,GO:0043103,hypoxanthine salvage;3.38e-03,GO:0009226,nucleotide-sugar biosynthetic process;3.38e-03,GO:0006048,UDP-N-acetylglucosamine biosynthetic process;2.69e-02,GO:0009163,nucleoside biosynthetic process;2.69e-02,GO:0042455,ribonucleoside biosynthetic process;1.68e-02,GO:0042451,purine nucleoside biosynthetic process;1.68e-02,GO:0046129,purine ribonucleoside biosynthetic process;6.76e-03,GO:0046103,inosine biosynthetic process;2.70e-02,GO:0009059,macromolecule biosynthetic process;2.70e-02,GO:0034645,cellular macromolecule biosynthetic process;2.35e-02,GO:0072523,purine-containing compound catabolic process;1.35e-02,GO:0006152,purine nucleoside catabolic process;6.76e-03,GO:0046130,purine ribonucleoside catabolic process;6.76e-03,GO:0006154,adenosine catabolic process;4.20e-05,GO:0005976,polysaccharide metabolic process;4.20e-05,GO:0044042,glucan metabolic process;4.20e-05,GO:0044264,cellular polysaccharide metabolic process;4.20e-05,GO:0006073,cellular glucan metabolic process;4.20e-05,GO:0005977,glycogen metabolic process;7.01e-06,GO:0000271,polysaccharide biosynthetic process;7.01e-06,GO:0033692,cellular polysaccharide biosynthetic process;7.01e-06,GO:0009250,glucan biosynthetic process;7.01e-06,GO:0005978,glycogen biosynthetic process;3.65e-02,GO:0044444,cytoplasmic part;1.17e-04,GO:0005829,cytosol;6.76e-03,GO:0019239,deaminase activity;1.01e-02,GO:0016810,hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds;6.76e-03,GO:0016814,hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines;6.76e-03,GO:0004000,adenosine deaminase activity;2.49e-05,GO:0016853,isomerase activity;9.69e-08,GO:0016866,intramolecular transferase activity;9.70e-09,GO:0016868,intramolecular transferase activity, phosphotransferases;7.01e-06,GO:0004614,phosphoglucomutase activity;3.38e-03,GO:0004610,phosphoacetylglucosamine mutase activity	P36871,Q96G03,O95394,Q9Y316,P00813	OMIM:614921,CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T;OMIM:209850,AUTISM;OMIM:102700,SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY;OMIM:243700,HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL RECESSIVE;OMIM:615816,IMMUNODEFICIENCY 23; IMD23;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005212,('congenital disorder of glycosylation',),5,0.0022	
H24K24.3,W09H1.5,R04B5.5,K12G11.3,F39B2.3,D2063.1	0.05000,GO:1901615,organic hydroxy compound metabolic process;0.04620,GO:0006066,alcohol metabolic process;0.01160,GO:0016614,oxidoreductase activity, acting on CH-OH group of donors;0.00772,GO:0016616,oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor;0.00386,GO:0004022,alcohol dehydrogenase (NAD) activity;0.00386,GO:0004024,alcohol dehydrogenase activity, zinc-dependent;0.00386,GO:0051903,S-(hydroxymethyl)glutathione dehydrogenase activity;0.05000,MI:cel-miR-253,MI:cel-miR-253	P11766,Q00796,Q08257,Q9BV79			
H24K24.3,W09H1.5,R04B5.5,K12G11.3,Y50D4C.2,D2063.1	0.05000,GO:1901615,organic hydroxy compound metabolic process;0.04620,GO:0006066,alcohol metabolic process;0.01160,GO:0016614,oxidoreductase activity, acting on CH-OH group of donors;0.00772,GO:0016616,oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor;0.00386,GO:0051903,S-(hydroxymethyl)glutathione dehydrogenase activity;0.00386,GO:0004022,alcohol dehydrogenase (NAD) activity;0.00386,GO:0004024,alcohol dehydrogenase activity, zinc-dependent;0.05000,MI:cel-miR-253,MI:cel-miR-253	P11766,Q00796,Q9BV79			
F12F6.7,R04F11.3,F10C2.4,Y43F4B.4	0.01790,GO:0006974,cellular response to DNA damage stimulus;0.05000,GO:0006259,DNA metabolic process;0.02140,GO:0006260,DNA replication;0.01960,GO:0006261,DNA-dependent DNA replication;0.00357,GO:0045005,DNA-dependent DNA replication maintenance of fidelity;0.01430,GO:0006281,DNA repair;0.00357,GO:0006284,base-excision repair;0.00179,GO:0006287,base-excision repair, gap-filling;0.00357,GO:0006289,nucleotide-excision repair;0.00179,GO:0006297,nucleotide-excision repair, DNA gap filling;0.00179,GO:0045004,DNA replication proofreading;0.00536,GO:0071897,DNA biosynthetic process;0.02500,GO:0090305,nucleic acid phosphodiester bond hydrolysis;0.00357,GO:0032993,protein-DNA complex;0.02680,GO:0061695,transferase complex, transferring phosphorus-containing groups;0.00357,GO:0042575,DNA polymerase complex;0.01790,GO:0005694,chromosome;0.01790,GO:0044427,chromosomal part;0.00893,GO:0005657,replication fork;0.00357,GO:0030894,replisome;0.00893,GO:0000228,nuclear chromosome;0.00893,GO:0044454,nuclear chromosome part;0.00714,GO:0043596,nuclear replication fork;0.00357,GO:0043601,nuclear replisome;0.00179,GO:0043625,delta DNA polymerase complex;0.02500,GO:0004518,nuclease activity;0.01070,GO:0004536,deoxyribonuclease activity;0.01250,GO:0004527,exonuclease activity;0.01070,GO:0016796,exonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 5'-phosphomonoesters;0.00536,GO:0004529,exodeoxyribonuclease activity;0.00536,GO:0016895,exodeoxyribonuclease activity, producing 5'-phosphomonoesters;0.01070,GO:0008408,3'-5' exonuclease activity;0.00357,GO:0008296,3'-5'-exodeoxyribonuclease activity;0.01430,GO:0016779,nucleotidyltransferase activity;0.00536,GO:0034061,DNA polymerase activity;0.00536,GO:0003887,DNA-directed DNA polymerase activity;0.03970,MI:cel-miR-258,MI:cel-miR-258;0.05000,MI:cel-miR-354,MI:cel-miR-354	Q96EE3,P28340,P49005	OMIM:612591,COLORECTAL CANCER, SUSCEPTIBILITY TO, 10; CRCS10;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:615381,MANDIBULAR HYPOPLASIA, DEAFNESS, PROGEROID FEATURES, AND LIPODYSTROPHY SYNDROME; MDPL	DOID:0009256,('colorectal cancer',),2,0.0000;DOID:0001520,('colon carcinoma',),2,0.0000	
CD4.4,C09G12.9,Y87G2A.10,K08E3.6	0.0427,MI:cel-miR-258,MI:cel-miR-258;0.0500,MI:cel-miR-36,MI:cel-miR-36	Q99816,Q9H0H5,Q9UK41,Q9H9H4	OMIM:114480,BREAST CANCER	DOID:0001612,('breast cancer',),3,0.0006	
F56B6.4,T25E12.5,T14F9.3		P07686,P46976	OMIM:616199,POLYGLUCOSAN BODY MYOPATHY 2; PGBM2;OMIM:613507,GLYCOGEN STORAGE DISEASE XV; GSD15;OMIM:268800,SANDHOFF DISEASE	DOID:0050579,('glycogen storage disease XV',),3,0.0042	
F08F8.4,F58F6.4,C54G10.2		Q56NI9,P35250,P35251	OMIM:268300,ROBERTS SYNDROME; RBS;OMIM:269000,SC PHOCOMELIA SYNDROME;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),3,0.0000;DOID:0050536,('SC phocomelia syndrome',),3,0.0018;DOID:0005325,('Roberts syndrome',),3,0.0018	
C18G1.5,C11G6.1,B0414.3		Q5VWG9			
Y48B6A.13,T02G5.8,ZC116.2,K02F2.2,T05G5.10,Y17G7B.4,W02D3.6,E04A4.7,F54C9.1,C31E10.7,F25B4.6	0.012300,GO:0051186,cofactor metabolic process;0.012300,GO:0006732,coenzyme metabolic process;0.036800,GO:0019637,organophosphate metabolic process;0.024600,GO:0090407,organophosphate biosynthetic process;0.011400,GO:0006790,sulfur compound metabolic process;0.001750,GO:0035383,thioester metabolic process;0.001750,GO:0006637,acyl-CoA metabolic process;0.001750,GO:0006084,acetyl-CoA metabolic process;0.041200,GO:0006629,lipid metabolic process;0.027200,GO:0044255,cellular lipid metabolic process;0.002630,GO:0006720,isoprenoid metabolic process;0.010500,GO:0008610,lipid biosynthetic process;0.000877,GO:0008299,isoprenoid biosynthetic process;0.009650,GO:0006644,phospholipid metabolic process;0.000877,GO:0046490,isopentenyl diphosphate metabolic process;0.007890,GO:0008654,phospholipid biosynthetic process;0.000877,GO:0009240,isopentenyl diphosphate biosynthetic process;0.000877,GO:0019287,isopentenyl diphosphate biosynthetic process, mevalonate pathway;0.037700,GO:0005829,cytosol;0.007020,GO:0016829,lyase activity;0.003510,GO:0016830,carbon-carbon lyase activity;0.001750,GO:0016831,carboxy-lyase activity;0.000877,GO:0004163,diphosphomevalonate decarboxylase activity;0.050000,MI:cel-miR-86,MI:cel-miR-86	P54868,P24752,P49366,P63241,P99999,P00167,P53602,P23526	OMIM:613752,HYPERMETHIONINEMIA WITH S-ADENOSYLHOMOCYSTEINE HYDROLASE DEFICIENCY;OMIM:250790,METHEMOGLOBINEMIA TYPE IV;OMIM:605911,3-HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE-2 DEFICIENCY; HMGCS2D;OMIM:202110,ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY;OMIM:612004,THROMBOCYTOPENIA 4; THC4;OMIM:250850,METHIONINE ADENOSYLTRANSFERASE DEFICIENCY;OMIM:203750,ALPHA-METHYLACETOACETIC ACIDURIA	DOID:0014723,('beta-ketothiolase deficiency',),10,0.0000;DOID:0050544,('hypermethioninemia',),8,0.0000	
T12D8.4,ZK370.2,F28H6.1,C12D8.10	0.0465,MI:cel-miR-85,MI:cel-miR-85;0.0500,MI:cel-miR-1020,MI:cel-miR-1020	Q15797,P31749	OMIM:114500,COLORECTAL CANCER; CRC;OMIM:615109,COWDEN SYNDROME 6; CWS6;OMIM:114480,BREAST CANCER;OMIM:612359,COWDEN SYNDROME 2; CWS2;OMIM:600794,NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A;OMIM:167000,OVARIAN CANCER;OMIM:176920,PROTEUS SYNDROME;OMIM:601472,CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2D; CMT2D;OMIM:178600,PULMONARY HYPERTENSION, PRIMARY, 1; PPH1;OMIM:181500,SCHIZOPHRENIA; SCZD		
T12D8.4,ZK370.2,C43E11.11,F28H6.1	0.0465,MI:cel-miR-85,MI:cel-miR-85;0.0500,MI:cel-miR-1020,MI:cel-miR-1020	Q15797,Q9UP83	OMIM:613612,CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi; CDG2I;OMIM:178600,PULMONARY HYPERTENSION, PRIMARY, 1; PPH1;OMIM:600794,NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A;OMIM:601472,CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2D; CMT2D		CORUM:3556;CORUM:3551;CORUM:3522;CORUM:3552
Y87G2A.5,Y45G12C.2,D1053.1,R107.7,Y71F9AL.5,C02D5.3	0.0422,MI:cel-lsy-6,MI:cel-lsy-6;0.0500,MI:cel-miR-354,MI:cel-miR-354	P09211,O43708,P26640	OMIM:167000,OVARIAN CANCER;OMIM:211980,LUNG CANCER;OMIM:114480,BREAST CANCER;OMIM:603165,DERMATITIS, ATOPIC	DOID:0001324,('lung cancer',),3,0.0036;DOID:0001612,('breast cancer',),3,0.0025	
ZK328.7,C55B6.2,T25F10.5,C50B6.2,C09H10.6	0.00244,GO:0032990,cell part morphogenesis;0.04270,GO:0070727,cellular macromolecule localization;0.04390,GO:0008104,protein localization;0.00122,GO:0031503,protein complex localization;0.04020,GO:0045184,establishment of protein localization;0.04270,GO:0034613,cellular protein localization;0.02320,GO:0033365,protein localization to organelle;0.00122,GO:0061512,protein localization to cilium;0.04020,GO:0015031,protein transport;0.00854,GO:0007017,microtubule-based process;0.04150,GO:0006928,movement of cell or subcellular component;0.00488,GO:0007018,microtubule-based movement;0.05000,GO:0046907,intracellular transport;0.03900,GO:1902582,single-organism intracellular transport;0.00122,GO:0030705,cytoskeleton-dependent intracellular transport;0.00122,GO:0010970,microtubule-based transport;0.03900,GO:0006886,intracellular protein transport;0.00122,GO:0098840,protein transport along microtubule;0.00366,GO:0030030,cell projection organization;0.00122,GO:0044782,cilium organization;0.00122,GO:0042073,intraciliary transport;0.00122,GO:0035721,intraciliary retrograde transport;0.00244,GO:0048858,cell projection morphogenesis;0.00122,GO:0060271,cilium morphogenesis;0.00122,GO:0030990,intraciliary transport particle;0.00122,GO:0030991,intraciliary transport particle A;0.00610,GO:0042995,cell projection;0.00244,GO:0005929,cilium;0.04400,MI:cel-miR-85,MI:cel-miR-85;0.05000,MI:cel-miR-257,MI:cel-miR-257	P49321,Q13217,Q8TAM2,Q7Z4L5	OMIM:615985,BARDET-BIEDL SYNDROME 8; BBS8;OMIM:613819,SHORT-RIB THORACIC DYSPLASIA 4 WITH OR WITHOUT POLYDACTYLY; SRTD4;OMIM:613820,NEPHRONOPHTHISIS 12; NPHP12;OMIM:249000,MECKEL SYNDROME, TYPE 1; MKS1;OMIM:613464,RETINITIS PIGMENTOSA 51; RP51;OMIM:209900,BARDET-BIEDL SYNDROME 1; BBS1;OMIM:616192,ATAXIA, COMBINED CEREBELLAR AND PERIPHERAL, WITH HEARING LOSS AND DIABETES MELLITUS; ACPHD;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP;OMIM:213300,JOUBERT SYNDROME 1; JBTS1	DOID:0010584,('retinitis pigmentosa',),3,0.0000;DOID:0050572,('cone-rod dystrophy',),3,0.0008	
LLC1.3,W02F12.5,T22B11.5,F27D4.5		P36957,P09622,Q02218,P21953	OMIM:248600,MAPLE SYRUP URINE DISEASE; MSUD;OMIM:203740,ALPHA-KETOGLUTARATE DEHYDROGENASE DEFICIENCY;OMIM:246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD;OMIM:250800,METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE	DOID:0009269,('maple syrup urine disease',),4,0.0465	CORUM:2920
T20H4.5,Y45G12B.1,Y54F10AM.5,C30H7.2	0.00503,GO:0042493,response to drug;0.01510,GO:0009141,nucleoside triphosphate metabolic process;0.01510,GO:0009144,purine nucleoside triphosphate metabolic process;0.01260,GO:0009199,ribonucleoside triphosphate metabolic process;0.01260,GO:0009205,purine ribonucleoside triphosphate metabolic process;0.01760,GO:0009123,nucleoside monophosphate metabolic process;0.01260,GO:0009126,purine nucleoside monophosphate metabolic process;0.01760,GO:0009161,ribonucleoside monophosphate metabolic process;0.01260,GO:0009167,purine ribonucleoside monophosphate metabolic process;0.03760,GO:1901657,glycosyl compound metabolic process;0.03760,GO:0009116,nucleoside metabolic process;0.03260,GO:0009119,ribonucleoside metabolic process;0.02760,GO:0006091,generation of precursor metabolites and energy;0.02760,GO:0015980,energy derivation by oxidation of organic compounds;0.01760,GO:0045333,cellular respiration;0.01010,GO:0022900,electron transport chain;0.01010,GO:0022904,respiratory electron transport chain;0.05000,GO:0072521,purine-containing compound metabolic process;0.03010,GO:0042278,purine nucleoside metabolic process;0.02510,GO:0046128,purine ribonucleoside metabolic process;0.03010,GO:0006163,purine nucleotide metabolic process;0.03510,GO:0019693,ribose phosphate metabolic process;0.03260,GO:0009259,ribonucleotide metabolic process;0.02510,GO:0009150,purine ribonucleotide metabolic process;0.01260,GO:0046034,ATP metabolic process;0.01010,GO:0006119,oxidative phosphorylation;0.01010,GO:0042773,ATP synthesis coupled electron transport;0.01010,GO:0042775,mitochondrial ATP synthesis coupled electron transport;0.00754,GO:0006120,mitochondrial electron transport, NADH to ubiquinone;0.04250,GO:0006457,protein folding;0.03260,GO:0016860,intramolecular oxidoreductase activity;0.03010,GO:0016864,intramolecular oxidoreductase activity, transposing S-S bonds;0.03010,GO:0003756,protein disulfide isomerase activity	P28331,O00217,Q9BS26,P51970	OMIM:252010,MITOCHONDRIAL COMPLEX I DEFICIENCY;OMIM:256000,LEIGH SYNDROME; LS		CORUM:1111;CORUM:1098;CORUM:1099;CORUM:1107;CORUM:1100;CORUM:1108
M04B2.1,T04C10.1,R02D3.2,Y54E10A.2	0.0479,MI:cel-miR-80,MI:cel-miR-80;0.0417,MI:cel-miR-392,MI:cel-miR-392;0.0500,MI:cel-miR-82,MI:cel-miR-82	Q13627,Q8WTW3,Q9Y462,Q96MW5	OMIM:611209,CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G;OMIM:614104,MENTAL RETARDATION, AUTOSOMAL DOMINANT 7; MRD7;OMIM:611182,CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIh; CDG2H;OMIM:300495,AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2;OMIM:300803,MENTAL RETARDATION, X-LINKED 97; MRX97	DOID:0012849,('autistic disorder',),4,0.0000	
T04A11.6,W06D4.6,Y48E1B.13,EEED8.16	0.0390,MI:cel-miR-86,MI:cel-miR-86;0.0499,MI:cel-miR-63,MI:cel-miR-63;0.0457,MI:cel-miR-72,MI:cel-miR-72;0.0432,MI:cel-miR-74,MI:cel-miR-74;0.0500,MI:cel-miR-58,MI:cel-miR-58;0.0469,MI:cel-miR-64,MI:cel-miR-64;0.0380,MI:cel-miR-50,MI:cel-miR-50;0.0457,MI:cel-miR-65,MI:cel-miR-65;0.0473,MI:cel-miR-264,MI:cel-miR-264;0.0469,MI:cel-miR-73,MI:cel-miR-73	Q92698,Q7Z569,Q6UXS9	OMIM:114480,BREAST CANCER;OMIM:605027,LYMPHOMA, NON-HODGKIN, FAMILIAL	DOID:0001612,('breast cancer',),3,0.0013	
F20B6.2,T14F9.1,H28O16.1,Y69A2AR.18,Y49A3A.2,Y110A7A.12,F58F12.1,F27C1.7,C34E10.6,ZK970.4,F55H2.2,F46F11.5,C17H12.14	0.05000,GO:0098660,inorganic ion transmembrane transport;0.01760,GO:0009123,nucleoside monophosphate metabolic process;0.01260,GO:0009126,purine nucleoside monophosphate metabolic process;0.01760,GO:0009161,ribonucleoside monophosphate metabolic process;0.01260,GO:0009167,purine ribonucleoside monophosphate metabolic process;0.01510,GO:0009141,nucleoside triphosphate metabolic process;0.01510,GO:0009144,purine nucleoside triphosphate metabolic process;0.01260,GO:0009199,ribonucleoside triphosphate metabolic process;0.01260,GO:0009205,purine ribonucleoside triphosphate metabolic process;0.03760,GO:1901657,glycosyl compound metabolic process;0.02010,GO:1901659,glycosyl compound biosynthetic process;0.03260,GO:1901293,nucleoside phosphate biosynthetic process;0.00754,GO:0009124,nucleoside monophosphate biosynthetic process;0.00252,GO:0009127,purine nucleoside monophosphate biosynthetic process;0.00754,GO:0009156,ribonucleoside monophosphate biosynthetic process;0.00252,GO:0009168,purine ribonucleoside monophosphate biosynthetic process;0.00252,GO:0009142,nucleoside triphosphate biosynthetic process;0.00252,GO:0009145,purine nucleoside triphosphate biosynthetic process;0.00252,GO:0009201,ribonucleoside triphosphate biosynthetic process;0.00252,GO:0009206,purine ribonucleoside triphosphate biosynthetic process;0.05000,GO:0072521,purine-containing compound metabolic process;0.03010,GO:0006163,purine nucleotide metabolic process;0.02510,GO:0072522,purine-containing compound biosynthetic process;0.03510,GO:0019693,ribose phosphate metabolic process;0.03260,GO:0009259,ribonucleotide metabolic process;0.02510,GO:0009150,purine ribonucleotide metabolic process;0.02010,GO:0046390,ribose phosphate biosynthetic process;0.03510,GO:0098655,cation transmembrane transport;0.03510,GO:0098662,inorganic cation transmembrane transport;0.00503,GO:1902600,hydrogen ion transmembrane transport;0.00252,GO:0015985,energy coupled proton transport, down electrochemical gradient;0.03760,GO:0009116,nucleoside metabolic process;0.03260,GO:0009119,ribonucleoside metabolic process;0.03010,GO:0042278,purine nucleoside metabolic process;0.02510,GO:0046128,purine ribonucleoside metabolic process;0.01260,GO:0046034,ATP metabolic process;0.02010,GO:0009163,nucleoside biosynthetic process;0.02010,GO:0042455,ribonucleoside biosynthetic process;0.01260,GO:0042451,purine nucleoside biosynthetic process;0.01260,GO:0046129,purine ribonucleoside biosynthetic process;0.03260,GO:0009165,nucleotide biosynthetic process;0.02010,GO:0009260,ribonucleotide biosynthetic process;0.01510,GO:0006164,purine nucleotide biosynthetic process;0.01260,GO:0009152,purine ribonucleotide biosynthetic process;0.00252,GO:0006754,ATP biosynthetic process;0.00252,GO:0015986,ATP synthesis coupled proton transport;0.04500,GO:0031975,envelope;0.04500,GO:0031967,organelle envelope;0.04010,GO:0005740,mitochondrial envelope;0.03510,GO:0098796,membrane protein complex;0.00252,GO:0016469,proton-transporting two-sector ATPase complex;0.00252,GO:0045259,proton-transporting ATP synthase complex;0.00252,GO:0033178,proton-transporting two-sector ATPase complex, catalytic domain;0.02760,GO:0019866,organelle inner membrane;0.00666,GO:0005739,mitochondrion;0.01760,GO:0098798,mitochondrial protein complex;0.00252,GO:0045261,proton-transporting ATP synthase complex, catalytic core F(1);0.03010,GO:0031966,mitochondrial membrane;0.02510,GO:0044455,mitochondrial membrane part;0.02760,GO:0005743,mitochondrial inner membrane;0.01760,GO:0098800,inner mitochondrial membrane protein complex;0.00252,GO:0005753,mitochondrial proton-transporting ATP synthase complex;0.00252,GO:0000275,mitochondrial proton-transporting ATP synthase complex, catalytic core F(1);0.05000,MI:cel-miR-1,MI:cel-miR-1	Q9UI12,P21281,P48047,P25705,P30049,Q9Y5K8,P36542,P06576,P36543,P38606,Q16864,O95670	OMIM:615228,MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 4; MC5DN4;OMIM:616045,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 22; COXPD22;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0060333,('mitochondrial complex V (ATP synthase) deficiency nuclear type 4',),11,0.0000;DOID:0005419,('schizophrenia',),12,0.0000	
Y71F9AM.5,C15H11.3		Q9NPJ8,Q9UBU9			
C53A5.3,F55A11.1		Q13547,Q8NI22	OMIM:613625,FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 2; F5F8D2		
C33C12.9,C04H5.1		Q9UI30,Q9Y5N5			
C27F2.10,Y119D3B.15		Q5JVF3			
T20B3.1,Y67D2.2		Q70CQ3,Q9UKG9	OMIM:209850,AUTISM		
K03E6.3,M04F3.4		O75340			
F28B12.3,Y54F10BM.1		Q99986	OMIM:607596,PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A		
F53A2.4,T03F6.5		P43034,Q9Y266	OMIM:300067,LISSENCEPHALY, X-LINKED, 1; LISX1;OMIM:213000,CEREBELLAR HYPOPLASIA;OMIM:247200,MILLER-DIEKER LISSENCEPHALY SYNDROME; MDLS;OMIM:607432,LISSENCEPHALY 1; LIS1		
W05B10.1,R08C7.3,C47D12.1,F45E1.6,T23D8.6,C50F4.7,C50F4.5,B0035.10	0.05,MI:cel-miR-793,MI:cel-miR-793	Q99880,Q9Y4A5,P68431,P62805,P84243,P0C0S5	OMIM:209850,AUTISM;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0012849,('autistic disorder',),6,0.0000;DOID:0005419,('schizophrenia',),6,0.0000	
C30B5.4,R08D7.1		Q9Y388,Q9BRD0			
Y65B4A.6,ZK430.1,ZK1127.5,Y46E12BL.2,ZK430.7,Y105E8B.3,Y39A1A.14,Y61A9LA.10,Y52B11A.10,F57B9.5,C06E1.10,F10G7.1,F58E10.3,B0280.9	3.12e-03,GO:1901360,organic cyclic compound metabolic process;3.39e-03,GO:0044085,cellular component biogenesis;1.05e-03,GO:0022613,ribonucleoprotein complex biogenesis;6.35e-04,GO:0042254,ribosome biogenesis;2.62e-03,GO:0006725,cellular aromatic compound metabolic process;2.95e-03,GO:0046483,heterocycle metabolic process;8.73e-03,GO:0006807,nitrogen compound metabolic process;6.36e-03,GO:0034641,cellular nitrogen compound metabolic process;2.56e-03,GO:0006139,nucleobase-containing compound metabolic process;1.17e-03,GO:0090304,nucleic acid metabolic process;6.90e-04,GO:0016070,RNA metabolic process;9.49e-04,GO:0034660,ncRNA metabolic process;3.44e-04,GO:0016072,rRNA metabolic process;1.06e-03,GO:0010467,gene expression;6.51e-05,GO:0006396,RNA processing;8.04e-04,GO:0034470,ncRNA processing;3.44e-04,GO:0006364,rRNA processing;2.51e-02,GO:0000469,cleavage involved in rRNA processing;5.00e-02,GO:0090502,RNA phosphodiester bond hydrolysis, endonucleolytic;1.26e-02,GO:0000478,endonucleolytic cleavage involved in rRNA processing;1.26e-02,GO:0000479,endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);3.76e-02,GO:0001510,RNA methylation;2.51e-02,GO:0000154,rRNA modification;6.31e-03,GO:0031167,rRNA methylation;6.31e-03,GO:0070475,rRNA base methylation;1.11e-04,GO:0031974,membrane-enclosed lumen;4.93e-03,GO:0043226,organelle;2.93e-04,GO:0043228,non-membrane-bounded organelle;2.74e-03,GO:0043227,membrane-bounded organelle;1.52e-04,GO:0044422,organelle part;9.24e-05,GO:0043233,organelle lumen;4.20e-03,GO:0043229,intracellular organelle;2.93e-04,GO:0043232,intracellular non-membrane-bounded organelle;5.46e-05,GO:0044446,intracellular organelle part;9.24e-05,GO:0070013,intracellular organelle lumen;2.32e-03,GO:0043231,intracellular membrane-bounded organelle;3.03e-05,GO:0005634,nucleus;1.80e-06,GO:0044428,nuclear part;3.49e-05,GO:0031981,nuclear lumen;7.98e-06,GO:0005730,nucleolus;6.31e-03,GO:0080008,Cul4-RING E3 ubiquitin ligase complex;1.87e-03,GO:0032991,macromolecular complex;4.17e-05,GO:1990904,ribonucleoprotein complex;4.17e-05,GO:0030529,intracellular ribonucleoprotein complex;1.43e-04,GO:0030684,preribosome;7.17e-05,GO:0032040,small-subunit processome;3.14e-02,GO:0034388,Pwp2p-containing subcomplex of 90S preribosome;4.38e-02,GO:0004540,ribonuclease activity;2.51e-02,GO:0004519,endonuclease activity;2.51e-02,GO:0004521,endoribonuclease activity;2.67e-02,GO:0003676,nucleic acid binding;1.77e-02,GO:0003723,RNA binding;4.38e-02,GO:0019843,rRNA binding;3.14e-02,GO:0008173,RNA methyltransferase activity;6.31e-03,GO:0008649,rRNA methyltransferase activity;6.31e-03,GO:0070037,rRNA (pseudouridine) methyltransferase activity;4.20e-02,MI:cel-miR-784,MI:cel-miR-784;4.39e-02,MI:cel-miR-245,MI:cel-miR-245;3.63e-02,MI:cel-miR-56*,MI:cel-miR-56*;3.89e-02,MI:cel-miR-72,MI:cel-miR-72;3.68e-02,MI:cel-miR-243,MI:cel-miR-243;4.09e-02,MI:cel-miR-787,MI:cel-miR-787;5.00e-02,MI:cel-miR-82,MI:cel-miR-82	Q2NL82,Q9NV06,Q8IY37,Q13895,Q9H583,Q5C9Z4,Q9Y5J1,Q92979,Q92841,Q5JTH9,P38919,Q9BVS4	OMIM:211180,BOWEN-CONRADI SYNDROME; BWCNS;OMIM:268305,ROBIN SEQUENCE WITH CLEFT MANDIBLE AND LIMB ANOMALIES;OMIM:209850,AUTISM	DOID:0050684,('Bowen-Conradi syndrome',),8,0.0000;DOID:0012849,('autistic disorder',),10,0.0000	
Y40D12A.2,M117.2,F52D10.3		P63104	OMIM:181500,SCHIZOPHRENIA; SCZD		
K04D7.1,R03G5.1,F25H5.4,F57B9.6,W08E3.3,F54A3.4,F37C12.11,C05D11.10,F40F11.1,D1007.6,Y41D4B.5,F54E7.2,B0393.1	0.0497,MI:cel-miR-49,MI:cel-miR-49;0.0500,MI:cel-miR-249,MI:cel-miR-249	Q9Y2R5,P63220,Q05639,P08865,P13639,P62280,Q14240,P25398,P62857,P46783,P63244,Q9NTK5	OMIM:609306,SPINOCEREBELLAR ATAXIA 26; SCA26;OMIM:606164,DIAMOND-BLACKFAN ANEMIA 15 WITH MANDIBULOFACIAL DYSOSTOSIS; DBA15;OMIM:105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1;OMIM:271400,ASPLENIA, ISOLATED CONGENITAL; ICAS;OMIM:609135,APLASTIC ANEMIA;OMIM:613308,DIAMOND-BLACKFAN ANEMIA 9; DBA9		
T03F6.2,Y54E10BR.4,T10B5.3,Y23H5B.5,C16A3.6	0.0250,GO:0006356,regulation of transcription from RNA polymerase I promoter;0.0250,GO:0045943,positive regulation of transcription from RNA polymerase I promoter;0.0471,MI:cel-miR-797,MI:cel-miR-797;0.0423,MI:cel-miR-261,MI:cel-miR-261;0.0447,MI:cel-miR-392,MI:cel-miR-392;0.0462,MI:cel-miR-256,MI:cel-miR-256;0.0500,MI:cel-miR-1020,MI:cel-miR-1020;0.0430,MI:cel-miR-227,MI:cel-miR-227	Q5F1R6,Q8TED0,Q9ULX3,Q9BXY0			
ZK430.1,ZK858.7,W02A11.1,Y39A1A.14,W07E6.2,W02B12.10,ZC376.5,F55A12.8,ZK795.3,C44E4.4,B0280.9,C15H11.8,B0035.12	2.01e-03,GO:1901360,organic cyclic compound metabolic process;1.69e-03,GO:0006725,cellular aromatic compound metabolic process;5.00e-02,GO:0043170,macromolecule metabolic process;6.85e-04,GO:0010467,gene expression;4.47e-02,GO:0043412,macromolecule modification;3.65e-02,GO:0044085,cellular component biogenesis;1.72e-02,GO:0022613,ribonucleoprotein complex biogenesis;1.24e-02,GO:0042254,ribosome biogenesis;1.90e-03,GO:0046483,heterocycle metabolic process;5.63e-03,GO:0006807,nitrogen compound metabolic process;3.05e-05,GO:0032259,methylation;4.10e-03,GO:0034641,cellular nitrogen compound metabolic process;1.65e-03,GO:0006139,nucleobase-containing compound metabolic process;7.57e-04,GO:0090304,nucleic acid metabolic process;3.74e-02,GO:0044260,cellular macromolecule metabolic process;2.78e-06,GO:0043414,macromolecule methylation;4.45e-04,GO:0016070,RNA metabolic process;1.15e-05,GO:0034660,ncRNA metabolic process;8.32e-03,GO:0016072,rRNA metabolic process;1.01e-03,GO:0006399,tRNA metabolic process;1.05e-05,GO:0009451,RNA modification;4.65e-07,GO:0001510,RNA methylation;4.19e-05,GO:0006396,RNA processing;8.13e-03,GO:0036260,RNA capping;8.13e-03,GO:0009452,7-methylguanosine RNA capping;4.07e-03,GO:0036265,RNA (guanine-N7)-methylation;9.20e-06,GO:0034470,ncRNA processing;7.32e-04,GO:0008033,tRNA processing;4.01e-04,GO:0006400,tRNA modification;6.73e-05,GO:0030488,tRNA methylation;8.32e-03,GO:0006364,rRNA processing;1.62e-02,GO:0000154,rRNA modification;4.07e-03,GO:0031167,rRNA methylation;4.07e-03,GO:0070475,rRNA base methylation;3.93e-02,GO:0043226,organelle;4.74e-03,GO:0043228,non-membrane-bounded organelle;3.34e-02,GO:0044422,organelle part;2.55e-02,GO:0043227,membrane-bounded organelle;2.34e-03,GO:0031974,membrane-enclosed lumen;2.04e-03,GO:0043233,organelle lumen;3.24e-05,GO:0032991,macromolecular complex;1.14e-03,GO:1990904,ribonucleoprotein complex;3.96e-04,GO:0043234,protein complex;2.08e-02,GO:1902494,catalytic complex;1.14e-02,GO:1990234,transferase complex;1.12e-05,GO:0034708,methyltransferase complex;1.12e-05,GO:0043527,tRNA methyltransferase complex;4.07e-03,GO:0031515,tRNA (m1A) methyltransferase complex;3.50e-02,GO:0043229,intracellular organelle;4.74e-03,GO:0043232,intracellular non-membrane-bounded organelle;1.90e-02,GO:0044446,intracellular organelle part;2.04e-03,GO:0070013,intracellular organelle lumen;2.25e-02,GO:0043231,intracellular membrane-bounded organelle;8.15e-04,GO:0005634,nucleus;2.75e-03,GO:0044428,nuclear part;9.99e-04,GO:0031981,nuclear lumen;3.39e-04,GO:0005730,nucleolus;1.32e-03,GO:0044452,nucleolar part;1.14e-03,GO:0030529,intracellular ribonucleoprotein complex;9.21e-05,GO:0030684,preribosome;4.62e-05,GO:0032040,small-subunit processome;1.16e-03,GO:0030686,90S preribosome;1.22e-02,GO:0034457,Mpp10 complex;2.02e-02,GO:0034388,Pwp2p-containing subcomplex of 90S preribosome;1.88e-03,GO:0016741,transferase activity, transferring one-carbon groups;1.88e-03,GO:0008168,methyltransferase activity;1.50e-03,GO:0008757,S-adenosylmethionine-dependent methyltransferase activity;1.12e-04,GO:0008173,RNA methyltransferase activity;1.22e-02,GO:0008175,tRNA methyltransferase activity;4.07e-03,GO:0016423,tRNA (guanine) methyltransferase activity;4.07e-03,GO:0008176,tRNA (guanine-N7-)-methyltransferase activity;4.07e-03,GO:0008649,rRNA methyltransferase activity;4.07e-03,GO:0070037,rRNA (pseudouridine) methyltransferase activity;3.42e-02,GO:1901363,heterocyclic compound binding;3.42e-02,GO:0097159,organic cyclic compound binding;1.72e-02,GO:0003676,nucleic acid binding;1.14e-02,GO:0003723,RNA binding;4.41e-02,GO:0030515,snoRNA binding;2.35e-04,GO:0019843,rRNA binding;8.13e-03,GO:0042134,rRNA primary transcript binding;3.63e-02,MI:cel-miR-56*,MI:cel-miR-56*;3.71e-02,MI:cel-miR-793,MI:cel-miR-793;3.44e-02,MI:cel-miR-48,MI:cel-miR-48;3.01e-02,MI:cel-miR-796,MI:cel-miR-796;5.00e-02,MI:cel-miR-82,MI:cel-miR-82	P05455,Q9NXH9,Q9UBP6,Q96G21,Q96FX7,Q9H583,Q9Y5J1,Q92979,Q9NVX2,Q9P1U0,Q9H0A0,Q15020,Q9UJA5	OMIM:211180,BOWEN-CONRADI SYNDROME; BWCNS	DOID:0050684,('Bowen-Conradi syndrome',),10,0.0000	
T23G11.7,Y34D9A.10,D2030.2,C37C3.3	0.05000,GO:0034622,cellular macromolecular complex assembly;0.00606,GO:0048284,organelle fusion;0.02270,GO:0070271,protein complex biogenesis;0.03640,GO:0071822,protein complex subunit organization;0.02420,GO:0032879,regulation of localization;0.02270,GO:0051049,regulation of transport;0.02880,GO:0016192,vesicle-mediated transport;0.01210,GO:0060627,regulation of vesicle-mediated transport;0.02120,GO:0061024,membrane organization;0.01670,GO:0044802,single-organism membrane organization;0.00909,GO:0061025,membrane fusion;0.00606,GO:0044801,single-organism membrane fusion;0.00606,GO:0090174,organelle membrane fusion;0.00455,GO:0016050,vesicle organization;0.00455,GO:0006906,vesicle fusion;0.02270,GO:0006461,protein complex assembly;0.01820,GO:0043623,cellular protein complex assembly;0.00303,GO:0035493,SNARE complex assembly;0.04550,GO:0005773,vacuole;0.03640,GO:0000323,lytic vacuole;0.01210,GO:0005768,endosome;0.01060,GO:0000149,SNARE binding;0.05000,MI:cel-miR-231,MI:cel-miR-231;0.04890,MI:cel-miR-787,MI:cel-miR-787	O75351,O76031	OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),2,0.0000	
ZC84.3,ZK792.6,T24F1.1,K03E6.6		O75122,P01112,Q7L523	OMIM:163200,SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM;OMIM:109800,BLADDER CANCER;OMIM:162900,NEVUS, EPIDERMAL;OMIM:218040,COSTELLO SYNDROME; CSTLO;OMIM:255300,MYOPATHY, CONGENITAL;OMIM:188470,THYROID CANCER, NONMEDULLARY, 2; NMTC2	DOID:0050469,('Costello syndrome',),3,0.0390	CORUM:149;CORUM:565;CORUM:556;CORUM:1238;CORUM:554;CORUM:3063;CORUM:5614;CORUM:3067;CORUM:711;CORUM:1237;CORUM:713;CORUM:189;CORUM:1230;CORUM:710;CORUM:86;CORUM:1251;CORUM:1252;CORUM:566;CORUM:807;CORUM:806;CORUM:555;CORUM:803;CORUM:238;CORUM:778;CORUM:808;CORUM:564;CORUM:714;CORUM:1413;CORUM:1401;CORUM:1257;CORUM:738;CORUM:691;CORUM:739;CORUM:743;CORUM:570;CORUM:3065;CORUM:3060;CORUM:3064
R07E5.3,M106.5,D2024.6,F41E6.9		P52907,P47756,Q12824,Q9NZZ3	OMIM:601358,NICOLAIDES-BARAITSER SYNDROME; NCBRS;OMIM:162091,SCHWANNOMATOSIS 1; SWNTS1;OMIM:135900,COFFIN-SIRIS SYNDROME; CSS;OMIM:610253,KLEEFSTRA SYNDROME;OMIM:609322,RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1;OMIM:614608,MENTAL RETARDATION, AUTOSOMAL DOMINANT 15; MRD15	DOID:0002129,('atypical teratoid rhabdoid tumor',),4,0.0219;DOID:0001925,('Coffin-Siris syndrome',),4,0.0219;DOID:0003204,('neurilemmomatosis',),4,0.0417	
M106.3,Y38C1AA.11,R107.2,ZK652.9	0.043,MI:cel-miR-62,MI:cel-miR-62;0.050,MI:cel-miR-79,MI:cel-miR-79	Q5HYK3,Q8N8N7,P30041,Q8IW45			
K07C5.8,ZK632.7,D1005.1		Q13033,Q58A45,P53396			CORUM:788;CORUM:789
ZK858.1,W08D2.7,F59C6.4,Y73B6BL.3,F37C12.13,C04G2.6,C14A4.4	0.0441,MI:cel-miR-74,MI:cel-miR-74;0.0390,MI:cel-miR-1018,MI:cel-miR-1018;0.0345,MI:cel-miR-268,MI:cel-miR-268;0.0479,MI:cel-miR-64,MI:cel-miR-64;0.0374,MI:cel-miR-785,MI:cel-miR-785;0.0500,MI:cel-miR-253,MI:cel-miR-253;0.0456,MI:cel-miR-271,MI:cel-miR-271	Q9NQT5,Q9Y2L1,Q13868,Q06265,P42285,Q01780	OMIM:607596,PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A;OMIM:614678,PONTOCEREBELLAR HYPOPLASIA, TYPE 1B; PCH1B	DOID:0060266,('pontocerebellar hypoplasia type 1B',),5,0.0001;DOID:0060265,('pontocerebellar hypoplasia type 1A',),5,0.0001	CORUM:5183
Y39G10AR.8,F11A3.2,ZK1098.4,Y37E3.10,C44C11.1,C37C3.2,K04G2.1,BE0003N10.1	2.37e-02,GO:0006979,response to oxidative stress;4.55e-02,GO:0060255,regulation of macromolecule metabolic process;3.92e-02,GO:0080090,regulation of primary metabolic process;1.19e-03,GO:0009058,biosynthetic process;9.52e-04,GO:1901576,organic substance biosynthetic process;1.40e-02,GO:0009889,regulation of biosynthetic process;5.47e-04,GO:0044249,cellular biosynthetic process;8.24e-03,GO:0006807,nitrogen compound metabolic process;6.00e-03,GO:0034641,cellular nitrogen compound metabolic process;1.57e-05,GO:0043603,cellular amide metabolic process;1.20e-04,GO:0044271,cellular nitrogen compound biosynthetic process;1.67e-06,GO:0043604,amide biosynthetic process;2.13e-04,GO:1901564,organonitrogen compound metabolic process;1.95e-05,GO:1901566,organonitrogen compound biosynthetic process;1.15e-05,GO:0006518,peptide metabolic process;1.11e-06,GO:0043043,peptide biosynthetic process;1.47e-02,GO:0051171,regulation of nitrogen compound metabolic process;4.66e-02,GO:0031323,regulation of cellular metabolic process;1.40e-02,GO:0031326,regulation of cellular biosynthetic process;7.33e-04,GO:0034248,regulation of cellular amide metabolic process;1.78e-02,GO:0034249,negative regulation of cellular amide metabolic process;1.00e-03,GO:0010467,gene expression;1.74e-02,GO:0010468,regulation of gene expression;8.94e-04,GO:0010608,posttranscriptional regulation of gene expression;1.84e-02,GO:0019538,protein metabolic process;1.53e-02,GO:0051246,regulation of protein metabolic process;1.24e-02,GO:0044267,cellular protein metabolic process;1.53e-02,GO:0032268,regulation of cellular protein metabolic process;1.26e-04,GO:0009059,macromolecule biosynthetic process;1.28e-02,GO:0010556,regulation of macromolecule biosynthetic process;1.26e-04,GO:0034645,cellular macromolecule biosynthetic process;1.28e-02,GO:2000112,regulation of cellular macromolecule biosynthetic process;9.55e-07,GO:0006412,translation;7.33e-04,GO:0006417,regulation of translation;1.78e-02,GO:0017148,negative regulation of translation;1.55e-08,GO:0006413,translational initiation;4.93e-05,GO:0006446,regulation of translational initiation;5.96e-03,GO:0045947,negative regulation of translational initiation;5.96e-03,GO:0001731,formation of translation preinitiation complex;6.44e-03,GO:0065009,regulation of molecular function;1.70e-03,GO:0044093,positive regulation of molecular function;6.00e-03,GO:0050790,regulation of catalytic activity;1.47e-03,GO:0051336,regulation of hydrolase activity;1.64e-04,GO:0043087,regulation of GTPase activity;1.22e-02,GO:0048518,positive regulation of biological process;7.83e-03,GO:0009893,positive regulation of metabolic process;1.47e-03,GO:0043085,positive regulation of catalytic activity;3.43e-04,GO:0051345,positive regulation of hydrolase activity;1.64e-04,GO:0043547,positive regulation of GTPase activity;2.96e-02,GO:0009628,response to abiotic stimulus;5.96e-03,GO:0009266,response to temperature stimulus;5.96e-03,GO:0009408,response to heat;4.13e-02,GO:0044707,single-multicellular organism process;4.13e-02,GO:0007275,multicellular organismal development;5.96e-03,GO:0007568,aging;5.96e-03,GO:0010259,multicellular organismal aging;5.96e-03,GO:0008340,determination of adult lifespan;4.13e-02,GO:0019915,lipid storage;5.96e-03,GO:0043614,multi-eIF complex;5.96e-03,GO:0070993,translation preinitiation complex;5.96e-03,GO:0033290,eukaryotic 48S preinitiation complex;2.65e-02,GO:0032991,macromolecular complex;1.19e-02,GO:0043234,protein complex;5.96e-03,GO:0005850,eukaryotic translation initiation factor 2 complex;1.36e-07,GO:0005851,eukaryotic translation initiation factor 2B complex;4.13e-02,GO:0043021,ribonucleoprotein complex binding;2.37e-02,GO:0043022,ribosome binding;5.00e-02,GO:1901363,heterocyclic compound binding;5.00e-02,GO:0097159,organic cyclic compound binding;2.52e-02,GO:0003676,nucleic acid binding;1.67e-02,GO:0003723,RNA binding;4.72e-02,GO:0044822,poly(A) RNA binding;7.33e-04,GO:0008135,translation factor activity, RNA binding;2.46e-04,GO:0003743,translation initiation factor activity;3.37e-03,GO:0098772,molecular function regulator;1.64e-04,GO:0005085,guanyl-nucleotide exchange factor activity;4.81e-02,MI:cel-miR-248,MI:cel-miR-248;5.00e-02,MI:cel-miR-273,MI:cel-miR-273;4.17e-02,MI:cel-miR-266,MI:cel-miR-266;4.06e-02,MI:cel-miR-59,MI:cel-miR-59;5.00e-02,MI:cel-miR-124,MI:cel-miR-124	P55010,Q8TCS8,P20042,P05198,P41091,Q9UI10,P62070,Q14232	OMIM:614932,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 13; COXPD13;OMIM:300495,AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2;OMIM:603896,LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM;OMIM:614934,DEAFNESS, AUTOSOMAL RECESSIVE 70; DFNB70	DOID:0012849,('autistic disorder',),8,0.0000	
C25A1.10,T10B5.3,Y23H5B.5,T10H9.4,B0414.3	0.04620,GO:0000462,maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);0.05000,GO:0010557,positive regulation of macromolecule biosynthetic process;0.04620,GO:0045935,positive regulation of nucleobase-containing compound metabolic process;0.04230,GO:0051254,positive regulation of RNA metabolic process;0.04230,GO:1902680,positive regulation of RNA biosynthetic process;0.04230,GO:1903508,positive regulation of nucleic acid-templated transcription;0.05000,GO:0010628,positive regulation of gene expression;0.00769,GO:0006360,transcription from RNA polymerase I promoter;0.00385,GO:0006356,regulation of transcription from RNA polymerase I promoter;0.04230,GO:0045893,positive regulation of transcription, DNA-templated;0.00385,GO:0045943,positive regulation of transcription from RNA polymerase I promoter;0.00769,GO:0034455,t-UTP complex;0.04230,GO:0030515,snoRNA binding;0.05000,MI:cel-miR-58,MI:cel-miR-58;0.04650,MI:cel-miR-261,MI:cel-miR-261;0.04350,MI:cel-miR-793,MI:cel-miR-793	P23763,Q8TED0,Q14978	OMIM:108600,SPASTIC ATAXIA 1, AUTOSOMAL DOMINANT; SPAX1		
T23H2.1,C46F4.2,F42A8.2,C34B2.7,T07C4.7,C03G5.1	0.0481,MI:cel-miR-87,MI:cel-miR-87;0.0500,MI:cel-miR-82,MI:cel-miR-82;0.0436,MI:cel-miR-356,MI:cel-miR-356;0.0371,MI:cel-miR-795,MI:cel-miR-795;0.0474,MI:cel-lin-4,MI:cel-lin-4;0.0487,MI:cel-miR-237,MI:cel-miR-237;0.0361,MI:cel-miR-62,MI:cel-miR-62;0.0341,MI:cel-miR-794,MI:cel-miR-794;0.0481,MI:cel-miR-786,MI:cel-miR-786;0.0498,MI:cel-miR-269,MI:cel-miR-269;0.0427,MI:cel-miR-266,MI:cel-miR-266;0.0391,MI:cel-miR-72,MI:cel-miR-72;0.0367,MI:cel-miR-90,MI:cel-miR-90	Q99643,P21912,Q8TEM1,O60488,P31040	OMIM:300495,AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2;OMIM:300387,MENTAL RETARDATION, X-LINKED 63; MRX63;OMIM:256000,LEIGH SYNDROME; LS;OMIM:605373,PARAGANGLIOMAS 3; PGL3;OMIM:614165,PARAGANGLIOMAS 5; PGL5;OMIM:168000,PARAGANGLIOMAS 1; PGL1;OMIM:158350,COWDEN SYNDROME 1; CWS1;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:171300,PHEOCHROMOCYTOMA;OMIM:612359,COWDEN SYNDROME 2; CWS2;OMIM:606764,GASTROINTESTINAL STROMAL TUMOR; GIST;OMIM:530000,KEARNS-SAYRE SYNDROME; KSS;OMIM:115310,PARAGANGLIOMAS 4; PGL4;OMIM:252011,MITOCHONDRIAL COMPLEX II DEFICIENCY;OMIM:606864,PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA;OMIM:613642,CARDIOMYOPATHY, DILATED, 1GG; CMD1GG	DOID:0012849,('autistic disorder',),5,0.0000;DOID:0000699,('mitochondrial myopathy',),4,0.0328;DOID:0009253,('gastrointestinal stromal tumor',),4,0.0439;DOID:0005419,('schizophrenia',),6,0.0000	
T01E8.3,T21H3.3,F36D4.3,F29D10.4	0.0500,MI:cel-miR-41,MI:cel-miR-41;0.0485,MI:cel-miR-74,MI:cel-miR-74	Q12965,P62158,Q9Y4I1,P19174	OMIM:214450,GRISCELLI SYNDROME, TYPE 1; GS1;OMIM:614131,FOCAL SEGMENTAL GLOMERULOSCLEROSIS 6; FSGS6		
E04F6.7,F59E11.2		Q9NZC7	OMIM:616211,EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 28; EIEE28;OMIM:614322,SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 12; SCAR12;OMIM:133239,ESOPHAGEAL CANCER		
C46H11.4,F30A10.3		P23677,Q92551			
T04C9.4,Y50D7A.3		P15735,P50461	OMIM:607482,CARDIOMYOPATHY, DILATED, 1M; CMD1M;OMIM:115200,CARDIOMYOPATHY, DILATED, 1A; CMD1A;OMIM:613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C;OMIM:612124,CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 12; CMH12	DOID:0012930,('dilated cardiomyopathy',),2,0.0001	
D2021.1,F43G6.6		O15550	OMIM:300867,KABUKI SYNDROME 2; KABUK2;OMIM:147920,KABUKI SYNDROME 1; KABUK1		
C50C3.7,R09B3.1		P27695	OMIM:211980,LUNG CANCER;OMIM:613659,GASTRIC CANCER;OMIM:266600,INFLAMMATORY BOWEL DISEASE 1; IBD1;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:606579,VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1; VAMAS1		
C38H2.1,F41D9.1		Q96HU1,Q2NKQ1	OMIM:209850,AUTISM		
C04F6.3,C44C1.2		Q13231,Q9BWS9	OMIM:614122,CHITOTRIOSIDASE DEFICIENCY; CHITD;OMIM:114500,COLORECTAL CANCER; CRC	DOID:0009256,('colorectal cancer',),2,0.0000;DOID:0001520,('colon carcinoma',),2,0.0000	
C28F5.4,T10B10.2		P22695	OMIM:615160,MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 5; MC3DN5;OMIM:124000,MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 1; MC3DN1		
C46F11.4,Y105E8A.3		Q86XP3,Q8TAD4	OMIM:209850,AUTISM		
F22E12.4,R06F6.4		Q9NRG4			
T24H7.1,Y47G6A.10,Y37E3.9,F30A10.5,D2030.2	0.0478,MI:cel-miR-1019,MI:cel-miR-1019;0.0500,MI:cel-miR-1020,MI:cel-miR-1020;0.0478,MI:cel-miR-270,MI:cel-miR-270	P35232,O76031,Q9Y4W6,Q9UJZ1,Q99623	OMIM:614487,SPASTIC ATAXIA 5, AUTOSOMAL RECESSIVE; SPAX5;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:114480,BREAST CANCER;OMIM:610246,SPINOCEREBELLAR ATAXIA 28; SCA28	DOID:0001612,('breast cancer',),3,0.0019	
F12F6.5,T04B2.2		O43295	OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),2,0.0000	
F45E6.2,T19E7.2		Q99941,Q14494			
T05A10.1,ZK973.6		Q8NF91	OMIM:612998,EMERY-DREIFUSS MUSCULAR DYSTROPHY 4, AUTOSOMAL DOMINANT; EDMD4;OMIM:115200,CARDIOMYOPATHY, DILATED, 1A; CMD1A;OMIM:610743,SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 8; SCAR8;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:209850,AUTISM		
R08B4.2,T15B12.1					
H24K24.4,K06A1.5		Q8IZ69			
C48E7.11,K08F8.2		P53567			
C28C12.7,F01F1.15		P07602,Q9Y2B0	OMIM:610539,GAUCHER DISEASE, ATYPICAL, DUE TO SAPOSIN C DEFICIENCY;OMIM:611721,COMBINED SAPOSIN DEFICIENCY;OMIM:611722,KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY;OMIM:250100,METACHROMATIC LEUKODYSTROPHY;OMIM:249900,METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),2,0.0000	
D1054.1,ZK370.4		Q6ZV29			
C06H2.2,K02D3.2		Q96DR4,Q9NQZ5			
B0511.7,H28O16.2		Q96EZ8,Q12972			
Y50D7A.4,ZK20.3,Y49E10.1,T04A11.5,ZK20.5,R12E2.3,F56G4.5,F56H1.4,H15N14.2,F54C9.6,F23C8.5,M57.2,K07D4.3,F27D4.1,T22D1.9,F10G8.6,K08F11.3,F23F1.8,C41C4.8,F29G9.5,F23F12.6,F57B9.10,F56F11.4,T06D8.8,C13B4.2,F10G7.8,C23G10.4,C06A1.1,F49C12.8,C30C11.2,B0280.1,C52E4.4,C18F10.7,B0205.3,B0511.10	0.0469,GO:0045732,positive regulation of protein catabolic process;0.0469,GO:1903364,positive regulation of cellular protein catabolic process;0.0469,GO:1903052,positive regulation of proteolysis involved in cellular protein catabolic process;0.0352,GO:1901800,positive regulation of proteasomal protein catabolic process;0.0117,GO:0097354,prenylation;0.0117,GO:0018342,protein prenylation;0.0117,GO:0018344,protein geranylgeranylation;0.0469,GO:0071824,protein-DNA complex subunit organization;0.0352,GO:0065004,protein-DNA complex assembly;0.0352,GO:0070897,DNA-templated transcriptional preinitiation complex assembly;0.0235,GO:0051123,RNA polymerase II transcriptional preinitiation complex assembly;0.0352,GO:2000142,regulation of DNA-templated transcription, initiation;0.0352,GO:0060260,regulation of transcription initiation from RNA polymerase II promoter;0.0235,GO:0045898,regulation of RNA polymerase II transcriptional preinitiation complex assembly;0.0352,GO:2000144,positive regulation of DNA-templated transcription, initiation;0.0352,GO:0060261,positive regulation of transcription initiation from RNA polymerase II promoter;0.0235,GO:0045899,positive regulation of RNA polymerase II transcriptional preinitiation complex assembly;0.0101,GO:0044712,single-organism catabolic process;0.0500,GO:0044444,cytoplasmic part;0.0117,GO:0005968,Rab-protein geranylgeranyltransferase complex;0.0352,GO:0000502,proteasome complex;0.0235,GO:0031597,cytosolic proteasome complex;0.0235,GO:0031595,nuclear proteasome complex;0.0235,GO:0022624,proteasome accessory complex;0.0235,GO:0005838,proteasome regulatory particle;0.0235,GO:0008540,proteasome regulatory particle, base subcomplex;0.0235,GO:0036402,proteasome-activating ATPase activity;0.0235,GO:0017025,TBP-class protein binding;0.0500,MI:cel-miR-248,MI:cel-miR-248	P43686,O43242,Q92696,P53384,P35998,Q9UNM6,P55036,Q99460,P53611,P55072,P46459,P30039,P38117,P54578,P48556,Q9BXJ9,O00487,Q9Y276,Q8IZ07,P17980,O00231,P62191,Q15008,P13804,P51665,Q7L2H7,O00232,P54727,P62333,P62195,Q13200,Q96IV0,P60228	OMIM:261900,PILI TORTI, EARLY-ONSET;OMIM:124000,MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 1; MC3DN1;OMIM:603358,GRACILE SYNDROME;OMIM:167320,INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA 1; IBMPFD1;OMIM:104300,ALZHEIMER DISEASE; AD;OMIM:310300,EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1;OMIM:160750,MYOSITIS;OMIM:262000,BJORNSTAD SYNDROME; BJS;OMIM:600361,HEREDITARY MOTOR AND SENSORY NEUROPATHY V;OMIM:211980,LUNG CANCER;OMIM:613954,AMYOTROPHIC LATERAL SCLEROSIS 14 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS14;OMIM:615273,CONGENITAL DISORDER OF DEGLYCOSYLATION; CDDG;OMIM:256000,LEIGH SYNDROME; LS;OMIM:231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD;OMIM:245570,EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT MENTAL RETARDATION; FESD;OMIM:181430,SCAPULOPERONEAL MYOPATHY, MYH7-RELATED; SPMM;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:147421,INCLUSION BODY MYOSITIS	DOID:0060253,('scapuloperoneal myopathy',),17,0.0000;DOID:0050881,('inclusion body myopathy with Paget disease of bone and frontotemporal dementia',),17,0.0000;DOID:0005419,('schizophrenia',),21,0.0000;DOID:0000633,('myositis',),17,0.0000;DOID:0050677,('Bjornstad syndrome',),26,0.0000;DOID:0060205,('amyotrophic lateral sclerosis type 14',),17,0.0000;DOID:0003652,('Leigh disease',),26,0.0000;DOID:0011726,('Emery-Dreifuss muscular dystrophy',),17,0.0000;DOID:0003429,('inclusion body myositis',),17,0.0000;DOID:0001324,('lung cancer',),34,0.0000	
T27F6.5,Y38A8.2,Y110A7A.14,T20F5.2,C36B1.4,Y51H7C.9,ZK945.2,Y105E8B.8,C05D11.2,K08D12.1,F25H2.9,K05C4.1,F39H11.5,CD4.6,D1054.2,C47B2.4,C15H11.7,C02F5.9	0.03910,GO:1901565,organonitrogen compound catabolic process;0.03910,GO:0044712,single-organism catabolic process;0.01960,GO:0044282,small molecule catabolic process;0.05000,GO:0006082,organic acid metabolic process;0.05000,GO:0043436,oxoacid metabolic process;0.05000,GO:0019752,carboxylic acid metabolic process;0.01300,GO:0016054,organic acid catabolic process;0.01300,GO:0046395,carboxylic acid catabolic process;0.01960,GO:0006520,cellular amino acid metabolic process;0.00652,GO:0009063,cellular amino acid catabolic process;0.01740,GO:1901605,alpha-amino acid metabolic process;0.00652,GO:0009066,aspartate family amino acid metabolic process;0.00326,GO:0006566,threonine metabolic process;0.00652,GO:1901606,alpha-amino acid catabolic process;0.00435,GO:0009068,aspartate family amino acid catabolic process;0.00326,GO:0006567,threonine catabolic process;0.00978,GO:0009069,serine family amino acid metabolic process;0.00326,GO:0009071,serine family amino acid catabolic process;0.00543,GO:0006563,L-serine metabolic process;0.00217,GO:0006565,L-serine catabolic process;0.00870,GO:0016829,lyase activity;0.00326,GO:0016840,carbon-nitrogen lyase activity;0.00326,GO:0016841,ammonia-lyase activity;0.00326,GO:0003941,L-serine ammonia-lyase activity;0.00217,GO:0004794,L-threonine ammonia-lyase activity;0.03590,GO:0043168,anion binding;0.02500,GO:0048037,cofactor binding;0.01410,GO:0030170,pyridoxal phosphate binding;0.04180,MI:cel-miR-258,MI:cel-miR-258;0.05000,MI:cel-miR-253*,MI:cel-miR-253*;0.04920,MI:cel-miR-271,MI:cel-miR-271;0.04440,MI:cel-lsy-6,MI:cel-lsy-6	P28072,O14818,P25788,P49720,Q86YB8,P20618,P28066,P25789,Q99436,P49721,P60900,P28062,P25787,Q9H269,P28070,Q7L3T8,P25786	OMIM:256040,AUTOINFLAMMATION, LIPODYSTROPHY, AND DERMATOSIS SYNDROME; ALDD;OMIM:603956,CERVICAL CANCER;OMIM:608446,MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO;OMIM:203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A;OMIM:114500,COLORECTAL CANCER; CRC	DOID:0002893,('cervix carcinoma',),7,0.0060;DOID:0001442,('Alpers syndrome',),18,0.0000;DOID:0001520,('colon carcinoma',),7,0.0287;DOID:0009256,('colorectal cancer',),7,0.0217	
T21B10.7,Y55F3AR.3,F54A3.3,ZK616.4,T10B5.5,T05C12.7,K01C8.10,F42G9.6,F01F1.8,C07G2.3	0.0466,MI:cel-miR-231,MI:cel-miR-231;0.0378,MI:cel-miR-794,MI:cel-miR-794;0.0448,MI:cel-miR-227,MI:cel-miR-227;0.0500,MI:cel-miR-270,MI:cel-miR-270;0.0473,MI:cel-miR-63,MI:cel-miR-63;0.0476,MI:cel-miR-266,MI:cel-miR-266;0.0441,MI:cel-miR-261,MI:cel-miR-261	P50991,P49368,P48643,P78371,P40227,Q8NCG7,Q99832,O94805,P50990,P17987	OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:256840,NEUROPATHY, HEREDITARY SENSORY, WITH SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE	DOID:0005419,('schizophrenia',),3,0.0000	CORUM:104;CORUM:2686;CORUM:2685
F40F8.9,ZK593.7,Y71G12B.14,Y62E10A.12,T10G3.6,Y73B6BL.32,F28F8.3,F32A5.7	0.05,MI:cel-miR-262,MI:cel-miR-262	O15116,Q9Y333,Q9Y4Y9,P62312,Q9Y4Z0,Q9UK45,O95777,P62310	OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),5,0.0000	CORUM:126
Y71F9AL.16,K07C5.1,Y6D11A.2,Y79H2A.6,Y37D8A.1,M01B12.3,ZK1248.3,C35D10.16		Q9UBC2,O15145,Q92747,P61160,P59998,O15511,P61158,O15144			CORUM:1182
F59A3.3,K08E4.1,H27M09.2,Y77E11A.6,C36B1.3,Y97E10AR.5,Y37E3.3,W01G7.3,F36A4.7,F26F4.11,F23B2.13,Y39B6A.36,W03F9.5,C42D4.8,C26E6.4,C06A1.5,C01F1.1	0.03240,GO:0071822,protein complex subunit organization;0.02030,GO:0070271,protein complex biogenesis;0.04590,GO:0065003,macromolecular complex assembly;0.02030,GO:0006461,protein complex assembly;0.01220,GO:0044087,regulation of cellular component biogenesis;0.04320,GO:0009893,positive regulation of metabolic process;0.05000,GO:0032774,RNA biosynthetic process;0.05000,GO:0097659,nucleic acid-templated transcription;0.04460,GO:0048522,positive regulation of cellular process;0.01490,GO:0051130,positive regulation of cellular component organization;0.01890,GO:0051173,positive regulation of nitrogen compound metabolic process;0.01890,GO:0009891,positive regulation of biosynthetic process;0.02970,GO:0010604,positive regulation of macromolecule metabolic process;0.01760,GO:0010628,positive regulation of gene expression;0.00811,GO:0044089,positive regulation of cellular component biogenesis;0.00811,GO:0043254,regulation of protein complex assembly;0.00811,GO:0031334,positive regulation of protein complex assembly;0.04590,GO:0019219,regulation of nucleobase-containing compound metabolic process;0.04050,GO:0051252,regulation of RNA metabolic process;0.03380,GO:0031325,positive regulation of cellular metabolic process;0.01890,GO:0031328,positive regulation of cellular biosynthetic process;0.01620,GO:0045935,positive regulation of nucleobase-containing compound metabolic process;0.01490,GO:0051254,positive regulation of RNA metabolic process;0.01760,GO:0010557,positive regulation of macromolecule biosynthetic process;0.05000,GO:0006351,transcription, DNA-templated;0.00811,GO:0006354,DNA-templated transcription, elongation;0.01080,GO:0006352,DNA-templated transcription, initiation;0.03380,GO:0006366,transcription from RNA polymerase II promoter;0.00676,GO:0006367,transcription initiation from RNA polymerase II promoter;0.00811,GO:0006368,transcription elongation from RNA polymerase II promoter;0.03920,GO:2001141,regulation of RNA biosynthetic process;0.03920,GO:1903506,regulation of nucleic acid-templated transcription;0.03920,GO:0006355,regulation of transcription, DNA-templated;0.00405,GO:2000142,regulation of DNA-templated transcription, initiation;0.03110,GO:0006357,regulation of transcription from RNA polymerase II promoter;0.00405,GO:0060260,regulation of transcription initiation from RNA polymerase II promoter;0.00676,GO:0032784,regulation of DNA-templated transcription, elongation;0.00676,GO:0034243,regulation of transcription elongation from RNA polymerase II promoter;0.01490,GO:1902680,positive regulation of RNA biosynthetic process;0.01490,GO:1903508,positive regulation of nucleic acid-templated transcription;0.01490,GO:0045893,positive regulation of transcription, DNA-templated;0.00405,GO:2000144,positive regulation of DNA-templated transcription, initiation;0.00541,GO:0032786,positive regulation of DNA-templated transcription, elongation;0.01080,GO:0045944,positive regulation of transcription from RNA polymerase II promoter;0.00405,GO:0060261,positive regulation of transcription initiation from RNA polymerase II promoter;0.00541,GO:0032968,positive regulation of transcription elongation from RNA polymerase II promoter;0.02030,GO:0061695,transferase complex, transferring phosphorus-containing groups;0.01220,GO:0030880,RNA polymerase complex;0.01220,GO:0000428,DNA-directed RNA polymerase complex;0.01220,GO:0055029,nuclear DNA-directed RNA polymerase complex;0.00676,GO:0005667,transcription factor complex;0.00541,GO:0044798,nuclear transcription factor complex;0.00541,GO:0090575,RNA polymerase II transcription factor complex;0.01890,GO:0005654,nucleoplasm;0.01490,GO:0044451,nucleoplasm part;0.00541,GO:0016591,DNA-directed RNA polymerase II, holoenzyme;0.00135,GO:0005674,transcription factor TFIIF complex;0.00811,GO:0000988,transcription factor activity, protein binding;0.00270,GO:0000990,transcription factor activity, core RNA polymerase binding;0.00270,GO:0000991,transcription factor activity, core RNA polymerase II binding	P30876,Q96A35,P52434,Q9Y2Y1,P52435,P19387,P24928,P61218,P53803,P35269,O14802,Q00403,P13984,O00267,P19388,P62875,P36954	OMIM:607694,LEUKODYSTROPHY, HYPOMYELINATING, 7, WITH OR WITHOUT OLIGODONTIA AND/OR HYPOGONADOTROPIC HYPOGONADISM; HLD7;OMIM:217990,CORPUS CALLOSUM, AGENESIS OF;OMIM:146110,HYPOGONADOTROPIC HYPOGONADISM 7 WITH OR WITHOUT ANOSMIA; HH7;OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),9,0.0000	CORUM:27
K07A1.10,T06G6.9,R151.9,H20J04.5,F21C3.5,C08F8.1,B0035.4	0.05,MI:cel-miR-74,MI:cel-miR-74	Q99471,Q9NQP4,O60925,O15212,Q9UHV9,P61758			
T27F2.1,F37C12.1,M03F8.3,Y69A2AR.21,R186.7,F53B7.3,F49D11.1,D1054.15,D1081.8,C50F2.3,C50C3.6,T12A2.7,F33A8.1	1.37e-03,GO:1901360,organic cyclic compound metabolic process;5.00e-02,GO:0071840,cellular component organization or biogenesis;2.77e-03,GO:0044085,cellular component biogenesis;8.49e-04,GO:0022613,ribonucleoprotein complex biogenesis;1.29e-03,GO:0046483,heterocycle metabolic process;4.10e-02,GO:0043170,macromolecule metabolic process;2.99e-02,GO:0044260,cellular macromolecule metabolic process;4.53e-04,GO:0010467,gene expression;1.14e-03,GO:0006725,cellular aromatic compound metabolic process;4.00e-03,GO:0006807,nitrogen compound metabolic process;2.87e-03,GO:0034641,cellular nitrogen compound metabolic process;1.12e-03,GO:0006139,nucleobase-containing compound metabolic process;5.02e-04,GO:0090304,nucleic acid metabolic process;2.92e-04,GO:0016070,RNA metabolic process;1.43e-07,GO:0016071,mRNA metabolic process;2.65e-05,GO:0006396,RNA processing;6.00e-08,GO:0008380,RNA splicing;3.57e-08,GO:0000375,RNA splicing, via transesterification reactions;2.68e-08,GO:0000377,RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;7.60e-08,GO:0006397,mRNA processing;2.68e-08,GO:0000398,mRNA splicing, via spliceosome;2.88e-02,GO:0016043,cellular component organization;6.46e-04,GO:0043933,macromolecular complex subunit organization;3.20e-05,GO:0071826,ribonucleoprotein complex subunit organization;4.20e-04,GO:0022607,cellular component assembly;1.67e-04,GO:0065003,macromolecular complex assembly;1.52e-04,GO:0034622,cellular macromolecular complex assembly;2.29e-05,GO:0022618,ribonucleoprotein complex assembly;2.05e-05,GO:0000393,spliceosomal conformational changes to generate catalytic conformation;9.88e-03,GO:0000349,generation of catalytic spliceosome for first transesterification step;9.88e-03,GO:0000350,generation of catalytic spliceosome for second transesterification step;1.23e-04,GO:0000245,spliceosomal complex assembly;9.88e-03,GO:0006376,mRNA splice site selection;9.88e-03,GO:0000389,mRNA 3'-splice site recognition;8.10e-04,GO:0032991,macromolecular complex;1.69e-05,GO:1990904,ribonucleoprotein complex;1.69e-05,GO:0030529,intracellular ribonucleoprotein complex;2.59e-04,GO:0043234,protein complex;6.86e-10,GO:0000974,Prp19 complex;3.16e-02,GO:0043226,organelle;1.98e-02,GO:0043227,membrane-bounded organelle;1.97e-03,GO:0044422,organelle part;2.78e-02,GO:0043229,intracellular organelle;8.67e-04,GO:0044446,intracellular organelle part;1.73e-02,GO:0043231,intracellular membrane-bounded organelle;5.42e-04,GO:0005634,nucleus;5.72e-05,GO:0044428,nuclear part;3.57e-08,GO:0005681,spliceosomal complex;6.14e-05,GO:0071010,prespliceosome;2.47e-09,GO:0071013,catalytic step 2 spliceosome;6.14e-05,GO:0071011,precatalytic spliceosome;1.13e-07,GO:0071014,post-mRNA release spliceosomal complex;9.88e-03,GO:0071020,post-spliceosomal complex;6.86e-10,GO:0071012,catalytic step 1 spliceosome	Q9BW85,Q9BZJ0,Q9HCS7,Q99459,O60508,Q9ULR0,Q6P2Q9,Q8WUD4,Q9HCG8,O43660,Q9H307,O75934,Q13573	OMIM:600059,RETINITIS PIGMENTOSA 13; RP13;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP	DOID:0050572,('cone-rod dystrophy',),3,0.0002;DOID:0010584,('retinitis pigmentosa',),3,0.0000	CORUM:112;CORUM:33
Y56A3A.1,ZC518.3,F57B9.2,T20B12.2,Y56A3A.20,C26E6.3	0.0500,MI:cel-miR-273,MI:cel-miR-273;0.0385,MI:cel-miR-71,MI:cel-miR-71;0.0443,MI:cel-miR-70,MI:cel-miR-70	A5YKK6,O75175,Q96LI5,Q9UIV1,Q92600,P20226	OMIM:168600,PARKINSON DISEASE, LATE-ONSET; PD;OMIM:607136,SPINOCEREBELLAR ATAXIA 17; SCA17		CORUM:5596
F45G2.4,Y71F9AL.17,Y25C1A.5,T14G10.5,F38E11.5,F59E10.3,C13B9.3	0.0496,MI:cel-miR-797,MI:cel-miR-797;0.0500,MI:cel-miR-232,MI:cel-miR-232;0.0412,MI:cel-miR-252,MI:cel-miR-252;0.0496,MI:cel-miR-229,MI:cel-miR-229;0.0442,MI:cel-miR-38,MI:cel-miR-38;0.0368,MI:cel-miR-1018,MI:cel-miR-1018	P53618,P48444,O14579,P53621,P61923,Q9UBF2			
W09B6.2,Y71A12B.9,Y47G6A.6		Q9Y6I4,P49848,Q92831	OMIM:122470,CORNELIA DE LANGE SYNDROME 1; CDLS1		
W02A11.2,C27F2.5,C37C3.3,C01A2.4	0.05,MI:cel-miR-74,MI:cel-miR-74	Q9UQN3,Q9BRG1,Q96H20	OMIM:600795,FRONTOTEMPORAL DEMENTIA, CHROMOSOME 3-LINKED; FTD3;OMIM:600274,FRONTOTEMPORAL DEMENTIA; FTD;OMIM:614696,AMYOTROPHIC LATERAL SCLEROSIS 17; ALS17		CORUM:310;CORUM:1005;CORUM:1004
T06E6.2,Y81G3A.3,ZC168.4,T05G5.3	0.0500,MI:cel-miR-124,MI:cel-miR-124;0.0430,MI:cel-miR-245,MI:cel-miR-245;0.0408,MI:cel-miR-392,MI:cel-miR-392;0.0458,MI:cel-miR-34,MI:cel-miR-34	Q9P2K8,P14635,P06493	OMIM:265450,PULMONARY VENOOCCLUSIVE DISEASE 1, AUTOSOMAL DOMINANT; PVOD1;OMIM:234810,PULMONARY VENOOCCLUSIVE DISEASE 2, AUTOSOMAL RECESSIVE; PVOD2	DOID:0005453,('pulmonary venoocclusive disease',),3,0.0130	
T20H4.5,ZK1058.2,Y45G12B.1,F54F2.1	0.00208,GO:0042493,response to drug;0.05000,GO:1901135,carbohydrate derivative metabolic process;0.01560,GO:1901657,glycosyl compound metabolic process;0.04370,GO:0019637,organophosphate metabolic process;0.01460,GO:0019693,ribose phosphate metabolic process;0.03120,GO:0055086,nucleobase-containing small molecule metabolic process;0.02500,GO:0006753,nucleoside phosphate metabolic process;0.00625,GO:0009141,nucleoside triphosphate metabolic process;0.00625,GO:0009144,purine nucleoside triphosphate metabolic process;0.00521,GO:0009199,ribonucleoside triphosphate metabolic process;0.00521,GO:0009205,purine ribonucleoside triphosphate metabolic process;0.00729,GO:0009123,nucleoside monophosphate metabolic process;0.00521,GO:0009126,purine nucleoside monophosphate metabolic process;0.00729,GO:0009161,ribonucleoside monophosphate metabolic process;0.00521,GO:0009167,purine ribonucleoside monophosphate metabolic process;0.02500,GO:0009117,nucleotide metabolic process;0.01350,GO:0009259,ribonucleotide metabolic process;0.01150,GO:0006091,generation of precursor metabolites and energy;0.03230,GO:0055114,oxidation-reduction process;0.01150,GO:0015980,energy derivation by oxidation of organic compounds;0.00729,GO:0045333,cellular respiration;0.00417,GO:0022900,electron transport chain;0.00417,GO:0022904,respiratory electron transport chain;0.02080,GO:0072521,purine-containing compound metabolic process;0.01250,GO:0006163,purine nucleotide metabolic process;0.01040,GO:0009150,purine ribonucleotide metabolic process;0.01560,GO:0009116,nucleoside metabolic process;0.01350,GO:0009119,ribonucleoside metabolic process;0.01250,GO:0042278,purine nucleoside metabolic process;0.01040,GO:0046128,purine ribonucleoside metabolic process;0.00521,GO:0046034,ATP metabolic process;0.00417,GO:0006119,oxidative phosphorylation;0.00417,GO:0042773,ATP synthesis coupled electron transport;0.00417,GO:0042775,mitochondrial ATP synthesis coupled electron transport;0.00313,GO:0006120,mitochondrial electron transport, NADH to ubiquinone;0.03910,MI:cel-miR-83,MI:cel-miR-83;0.04730,MI:cel-miR-124,MI:cel-miR-124;0.04380,MI:cel-miR-44,MI:cel-miR-44;0.04080,MI:cel-miR-49,MI:cel-miR-49;0.04140,MI:cel-miR-270,MI:cel-miR-270;0.04110,MI:cel-miR-230,MI:cel-miR-230;0.04180,MI:cel-miR-247,MI:cel-miR-247;0.05000,MI:cel-miR-54,MI:cel-miR-54;0.04790,MI:cel-miR-51,MI:cel-miR-51;0.04990,MI:cel-miR-53,MI:cel-miR-53;0.04090,MI:cel-miR-61,MI:cel-miR-61	P28331,O00217,P53708,P05556	OMIM:252010,MITOCHONDRIAL COMPLEX I DEFICIENCY;OMIM:191830,RENAL HYPODYSPLASIA/APLASIA 1; RHDA1;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:256000,LEIGH SYNDROME; LS		
C32D5.9,Y55F3AM.4,M7.5,T08B2.7		Q9H0R8,O95352,P40939,Q9NT62	OMIM:609015,MITOCHONDRIAL TRIFUNCTIONAL PROTEIN DEFICIENCY; MTPD;OMIM:143100,HUNTINGTON DISEASE; HD;OMIM:609016,LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY		
R10E11.1,R07B7.1,Y39A1A.15,F53H8.2	0.05,MI:cel-miR-784,MI:cel-miR-784	P49407,Q09472,Q96P47,P51798	OMIM:611490,OSTEOPETROSIS,  AUTOSOMAL RECESSIVE 4; OPTB4;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:613684,RUBINSTEIN-TAYBI SYNDROME 2; RSTS2;OMIM:180849,RUBINSTEIN-TAYBI SYNDROME 1; RSTS1;OMIM:166600,OSTEOPETROSIS, AUTOSOMAL DOMINANT 2; OPTA2;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0001520,('colon carcinoma',),4,0.0018;DOID:0009256,('colorectal cancer',),4,0.0014;DOID:0005419,('schizophrenia',),4,0.0000;DOID:0001933,('Rubinstein-Taybi syndrome',),4,0.0097	
Y51H4A.17,F54A5.3,F59G1.5,F49B2.5	0.0401,MI:cel-miR-59,MI:cel-miR-59;0.0500,MI:cel-miR-51,MI:cel-miR-51	P42685,P29353,P42229			
R05D8.8,M03A8.1,F53C11.3,T05C12.3	0.0389,GO:0051704,multi-organism process;0.0389,GO:0009607,response to biotic stimulus;0.0500,GO:0009605,response to external stimulus;0.0389,GO:0043207,response to external biotic stimulus;0.0389,GO:0051707,response to other organism;0.0389,GO:0009617,response to bacterium;0.0375,GO:0098542,defense response to other organism;0.0375,GO:0042742,defense response to bacterium;0.0319,GO:0050829,defense response to Gram-negative bacterium;0.0500,MI:cel-miR-228,MI:cel-miR-228;0.0010,MI:cel-miR-79,MI:cel-miR-79;0.0449,MI:cel-miR-255,MI:cel-miR-255;0.0437,MI:cel-miR-247,MI:cel-miR-247	Q16698			
Y39A1A.15,F46B3.5,Y110A2AL.8,C09H6.2	0.05,MI:cel-miR-235,MI:cel-miR-235	Q96P47			
H20J04.2,Y71F9B.7,F37A4.8,F25H2.13	0.0500,MI:cel-miR-58,MI:cel-miR-58;0.0427,MI:cel-miR-252,MI:cel-miR-252;0.0380,MI:cel-miR-1018,MI:cel-miR-1018;0.0494,MI:cel-miR-784,MI:cel-miR-784;0.0403,MI:cel-miR-48,MI:cel-miR-48;0.0371,MI:cel-miR-241,MI:cel-miR-241	Q9NRL2,Q9NZ71,P28370	OMIM:615190,DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 5; DKCB5		
R07E4.6,ZK909.2,H42K12.1,T01H8.1		O15530,P31321,P17612,Q15418	OMIM:615830,PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 4; PPNAD4		
T04D1.3,Y57G11C.22		Q9NRD5,Q99961	OMIM:601626,LEUKEMIA, ACUTE MYELOID; AML;OMIM:102530,SPERMATOGENIC FAILURE 6; SPGF6;OMIM:181800,SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 1; IS1		
F58B4.5,F59B1.8					
C54E4.2,F47E1.2		Q08629,Q9UIG8			
F14D12.6,F26H11.5		P08913,O15247	OMIM:300886,MENTAL RETARDATION, X-LINKED, SYNDROMIC 32; MRXS32		
B0035.14,M142.5		Q3MHD2,Q9NXW2			
C18H9.3,Y116A8C.32		Q15637	OMIM:612964,PREMATURE OVARIAN FAILURE 7; POF7;OMIM:613957,SPERMATOGENIC FAILURE 8; SPGF8;OMIM:612965,46,XY SEX REVERSAL 3; SRXY3		
C26C6.2,Y69A2AR.2		Q9NPQ8,P09471	OMIM:615473,EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 17; EIEE17		
F14D12.5,Y46G5A.1					
B0024.10,F23C8.4		Q9BZE9	OMIM:606243,ALVEOLAR SOFT PART SARCOMA; ASPS		
C38H2.2,ZK669.2		Q9NS00			
W02G9.1,Y37H9A.6,K06H7.9		Q13907,Q9UKK9			
K08C7.5,K02F3.6,F25C8.2		Q8IUS5			
H42K12.1,T01H8.1,B0545.1		Q05655,O15530,Q15418	OMIM:615559,AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III; ALPS3;OMIM:152700,SYSTEMIC LUPUS ERYTHEMATOSUS; SLE;OMIM:109100,AUTOIMMUNE DISEASE		
E04A4.4,Y53F4B.39,Y17G7B.3		Q53H82,Q9BQ52,Q16775	OMIM:176807,PROSTATE CANCER;OMIM:614731,PROSTATE CANCER, HEREDITARY, 2; HPC2;OMIM:615440,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 17; COXPD17;OMIM:600082,PROSTATIC HYPERPLASIA, BENIGN; BPH		
F48F7.1,K12H4.8,T07D3.7		Q9UPY3,Q9UKV8	OMIM:601200,PLEUROPULMONARY BLASTOMA; PPB;OMIM:138800,GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS; MNG1;OMIM:209850,AUTISM;OMIM:273300,TESTICULAR GERM CELL TUMOR; TGCT;OMIM:180295,RHABDOMYOSARCOMA, EMBRYONAL, 2; RMSE2;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0012849,('autistic disorder',),2,0.0000;DOID:0005419,('schizophrenia',),2,0.0000	
C14F5.5,H34C03.2,C30F8.4		Q13107,Q05397,P62993			
C50F7.4,ZK6.7,Y48G1C.2		P41240,Q96I99			
F32A11.7,F55D10.1,C06G3.9		O94874,O00754	OMIM:248500,MANNOSIDOSIS, ALPHA B, LYSOSOMAL; MANSA;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0003413,('alpha-mannosidosis',),2,0.0327	
Y67H2A.1,F09G2.4,Y32F6A.3,F36F2.3,C33H5.7,M03C11.2	0.00158,MI:cel-miR-82,MI:cel-miR-82;0.00174,MI:cel-miR-81,MI:cel-miR-81;0.04740,MI:cel-miR-791,MI:cel-miR-791;0.04180,MI:cel-let-7,MI:cel-let-7;0.00145,MI:cel-miR-80,MI:cel-miR-80;0.04420,MI:cel-miR-1,MI:cel-miR-1;0.03120,MI:cel-miR-796,MI:cel-miR-796;0.04650,MI:cel-miR-1019,MI:cel-miR-1019;0.05000,MI:cel-miR-786,MI:cel-miR-786;0.04690,MI:cel-miR-67,MI:cel-miR-67;0.03830,MI:cel-miR-795,MI:cel-miR-795;0.04260,MI:cel-miR-262,MI:cel-miR-262	P51003,Q9P2I0,Q6UXN9,Q9UKF6,A8MPP1,Q7Z6E9			
F59B8.2,F43G9.1,F54H12.1,F35G12.2,C37E2.1,C34F6.8,C30F12.7,T02G5.4	0.0427,MI:cel-miR-63,MI:cel-miR-63;0.0469,MI:cel-miR-255,MI:cel-miR-255;0.0425,MI:cel-miR-240,MI:cel-miR-240;0.0451,MI:cel-miR-78,MI:cel-miR-78;0.0500,MI:cel-miR-235,MI:cel-miR-235;0.0435,MI:cel-miR-256,MI:cel-miR-256;0.0174,MI:cel-miR-265,MI:cel-miR-265;0.0406,MI:cel-miR-264,MI:cel-miR-264;0.0442,MI:cel-miR-245,MI:cel-miR-245;0.0454,MI:cel-miR-77,MI:cel-miR-77	P48735,O75874,P50213,P51553,O43837,Q99798	OMIM:613657,D-2-HYDROXYGLUTARIC ACIDURIA 2; D2HGA2;OMIM:612572,RETINITIS PIGMENTOSA 46; RP46;OMIM:616289,OPTIC ATROPHY 9; OPA9;OMIM:137800,GLIOMA SUSCEPTIBILITY 1; GLM1;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP;OMIM:614559,INFANTILE CEREBELLAR-RETINAL DEGENERATION; ICRD;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0010584,('retinitis pigmentosa',),4,0.0000;DOID:0050575,('D-2-hydroxyglutaric aciduria',),3,0.0196;DOID:0050883,('infantile cerebellar-retinal degeneration',),6,0.0000;DOID:0005419,('schizophrenia',),6,0.0000;DOID:0050572,('cone-rod dystrophy',),4,0.0011;DOID:0003070,('malignant glioma',),8,0.0031	CORUM:1144
ZK430.1,Y53C12B.2,R13A5.12,F54E12.5,K12H4.3,Y46E12BL.2,T22H9.1,K09H9.6,ZK546.14,T06E6.1,ZK945.3,ZK430.7,F58B3.4,R05H10.2,Y39B6A.14,Y54H5A.1,T19A6.2,T07A9.9,Y66H1A.4,K01G5.5,T25G3.3,W02B12.10,Y45F10D.7,Y71G12B.8,W07E6.1,ZK1127.4,C16C10.2,Y54E10A.10,Y75B8A.7,T10B5.3,Y94H6A.5,Y73E7A.2,Y61A9LA.10,Y48G1A.4,Y48B6A.1,F54C9.9,Y39B6A.33,F55F8.5,F23B12.7,H06I04.3,F32E10.1,C48E7.3,W09C5.1,F13H8.2,T04A8.6,K01C8.9,F10E7.5,ZK512.2,W01B11.3,E02H1.1,K07C5.4,JC8.2,F55F8.2,C05C8.2,T07A9.8,F55F8.3,F27C1.6,F11A10.7,C24H12.4,C16A3.6,C16A3.3,C15H11.9,C07E3.2,Y53C12B.1,F28D1.1,C48B6.2,C18A3.3,T26E3.4,C47E12.7,C43E11.9,C37H5.5,C02F5.3,T18H9.7,F44G4.1,B0280.9,C03D6.8,B0336.10,K09E9.2,B0511.6,B0035.12	4.81e-02,GO:1990481,mRNA pseudouridine synthesis;4.81e-02,GO:0036265,RNA (guanine-N7)-methylation;2.62e-11,GO:0046483,heterocycle metabolic process;1.12e-02,GO:0043933,macromolecular complex subunit organization;1.62e-03,GO:0071826,ribonucleoprotein complex subunit organization;2.66e-04,GO:0043170,macromolecule metabolic process;7.10e-05,GO:0044260,cellular macromolecule metabolic process;4.12e-09,GO:0010467,gene expression;1.41e-11,GO:0006725,cellular aromatic compound metabolic process;1.98e-06,GO:0071840,cellular component organization or biogenesis;3.61e-12,GO:0044085,cellular component biogenesis;4.06e-15,GO:0022613,ribonucleoprotein complex biogenesis;1.87e-16,GO:0042254,ribosome biogenesis;1.62e-06,GO:0042274,ribosomal small subunit biogenesis;1.43e-05,GO:0042273,ribosomal large subunit biogenesis;3.55e-11,GO:1901360,organic cyclic compound metabolic process;7.07e-09,GO:0006807,nitrogen compound metabolic process;1.41e-09,GO:0034641,cellular nitrogen compound metabolic process;1.27e-11,GO:0006139,nucleobase-containing compound metabolic process;2.00e-13,GO:0090304,nucleic acid metabolic process;1.13e-14,GO:0016070,RNA metabolic process;2.16e-15,GO:0034660,ncRNA metabolic process;4.81e-02,GO:0016073,snRNA metabolic process;4.81e-02,GO:0016074,snoRNA metabolic process;4.81e-02,GO:0033979,box H/ACA snoRNA metabolic process;2.04e-16,GO:0016072,rRNA metabolic process;1.32e-04,GO:0010501,RNA secondary structure unwinding;5.64e-13,GO:0006396,RNA processing;7.95e-16,GO:0034470,ncRNA processing;4.81e-02,GO:0043144,snoRNA processing;4.81e-02,GO:0034964,box H/ACA snoRNA processing;4.81e-02,GO:0031126,snoRNA 3'-end processing;4.81e-02,GO:0000495,box H/ACA snoRNA 3'-end processing;2.04e-16,GO:0006364,rRNA processing;2.14e-05,GO:0000470,maturation of LSU-rRNA;1.03e-03,GO:0000463,maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);1.07e-06,GO:0030490,maturation of SSU-rRNA;5.90e-06,GO:0000462,maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);8.11e-03,GO:0009451,RNA modification;4.81e-02,GO:0040031,snRNA modification;4.81e-02,GO:0031120,snRNA pseudouridine synthesis;6.01e-03,GO:0000154,rRNA modification;3.64e-02,GO:0022607,cellular component assembly;1.25e-02,GO:0065003,macromolecular complex assembly;1.12e-02,GO:0034622,cellular macromolecular complex assembly;1.05e-03,GO:0022618,ribonucleoprotein complex assembly;3.41e-02,GO:0006996,organelle organization;8.20e-05,GO:0070925,organelle assembly;2.82e-05,GO:0042255,ribosome assembly;8.42e-05,GO:0000027,ribosomal large subunit assembly;4.81e-02,GO:0046015,regulation of transcription by glucose;4.81e-02,GO:0045814,negative regulation of gene expression, epigenetic;4.81e-02,GO:0006342,chromatin silencing;4.81e-02,GO:0000183,chromatin silencing at rDNA;4.81e-02,GO:0043467,regulation of generation of precursor metabolites and energy;4.81e-02,GO:0043457,regulation of cellular respiration;4.81e-02,GO:1901857,positive regulation of cellular respiration;4.81e-02,GO:0080008,Cul4-RING E3 ubiquitin ligase complex;6.79e-08,GO:0043226,organelle;1.00e-19,GO:0043228,non-membrane-bounded organelle;4.62e-09,GO:0043227,membrane-bounded organelle;3.27e-08,GO:0043229,intracellular organelle;1.00e-19,GO:0043232,intracellular non-membrane-bounded organelle;2.12e-09,GO:0043231,intracellular membrane-bounded organelle;1.07e-18,GO:0005634,nucleus;4.10e-10,GO:0032991,macromolecular complex;3.14e-15,GO:1990904,ribonucleoprotein complex;2.58e-05,GO:0043234,protein complex;2.19e-22,GO:0031974,membrane-enclosed lumen;1.26e-12,GO:0044422,organelle part;6.53e-23,GO:0043233,organelle lumen;1.18e-14,GO:0044446,intracellular organelle part;9.12e-22,GO:0044428,nuclear part;4.81e-02,GO:0005677,chromatin silencing complex;6.53e-23,GO:0070013,intracellular organelle lumen;1.01e-25,GO:0031981,nuclear lumen;2.70e-30,GO:0005730,nucleolus;9.54e-14,GO:0044452,nucleolar part;3.14e-15,GO:0030529,intracellular ribonucleoprotein complex;9.98e-21,GO:0030684,preribosome;8.79e-17,GO:0032040,small-subunit processome;3.05e-03,GO:0030687,preribosome, large subunit precursor;3.63e-14,GO:0030686,90S preribosome;3.05e-03,GO:0034457,Mpp10 complex;8.31e-09,GO:0034388,Pwp2p-containing subcomplex of 90S preribosome;4.81e-02,GO:0070545,PeBoW complex;4.81e-02,GO:0005697,telomerase holoenzyme complex;9.88e-03,GO:0005732,small nucleolar ribonucleoprotein complex;4.81e-02,GO:0031428,box C/D snoRNP complex;4.81e-02,GO:0072588,box H/ACA RNP complex;4.81e-02,GO:0031429,box H/ACA snoRNP complex;4.81e-02,GO:0000792,heterochromatin;4.81e-02,GO:0033553,rDNA heterochromatin;4.81e-02,GO:0042393,histone binding;4.81e-02,GO:0035064,methylated histone binding;4.81e-02,GO:0016423,tRNA (guanine) methyltransferase activity;4.81e-02,GO:0008176,tRNA (guanine-N7-)-methyltransferase activity;1.32e-02,GO:0016817,hydrolase activity, acting on acid anhydrides;1.32e-02,GO:0016818,hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides;1.32e-02,GO:0016462,pyrophosphatase activity;1.32e-02,GO:0017111,nucleoside-triphosphatase activity;1.68e-03,GO:0016887,ATPase activity;1.27e-03,GO:0042623,ATPase activity, coupled;2.11e-04,GO:0008186,RNA-dependent ATPase activity;3.22e-04,GO:0004386,helicase activity;2.11e-04,GO:0070035,purine NTP-dependent helicase activity;2.11e-04,GO:0008026,ATP-dependent helicase activity;2.11e-04,GO:0003724,RNA helicase activity;2.11e-04,GO:0004004,ATP-dependent RNA helicase activity;5.00e-02,GO:0044877,macromolecular complex binding;6.16e-04,GO:0097159,organic cyclic compound binding;6.16e-04,GO:1901363,heterocyclic compound binding;4.39e-05,GO:0003676,nucleic acid binding;8.51e-06,GO:0003723,RNA binding;3.50e-06,GO:0030515,snoRNA binding;2.02e-02,GO:0019843,rRNA binding;5.00e-02,MI:cel-miR-797,MI:cel-miR-797	Q9BYG3,Q13823,Q96EU6,Q8WTT2,Q9H9Y2,Q9Y3T9,Q12788,Q9Y2X3,Q8NHQ9,Q9UNQ2,Q5TAP6,Q8N9T8,Q9BSC4,Q9GZL7,P42696,Q9H446,Q9NRX1,Q9NY93,Q9UNX4,P56182,Q9UBP6,Q9NV06,P78316,O15213,Q13610,P55039,Q9NZM5,O43159,O95478,O00541,P62829,Q9Y221,Q9H7B2,O00566,Q15020,Q9Y282,Q15269,Q8TDD1,Q13601,Q9P287,Q9UKD2,P46087,Q9H583,Q14690,Q9H501,Q14137,Q8NEJ9,Q15397,Q9BZE4,Q9NVN8,Q96D46,Q9Y5J1,Q9NQ55,Q9GZR7,O75683,Q8NI36,Q8TDN6,Q6VY07,Q9NV31,Q9BQ67,Q9UHA3,Q9NVP1,Q9BXY0,Q15050,Q6RFH5,Q9NVU7,Q9NY12,Q9NY61,Q03701,O60832,Q9Y3A2,Q5JTH9,O00567,Q99848,Q9NW13,Q8IY81	OMIM:614153,SPINOCEREBELLAR ATAXIA 36; SCA36;OMIM:137760,GLAUCOMA, PRIMARY OPEN ANGLE; POAG;OMIM:609887,GLAUCOMA 1, OPEN ANGLE, G; GLC1G;OMIM:615009,MENTAL RETARDATION, AUTOSOMAL DOMINANT 17; MRD17;OMIM:209850,AUTISM;OMIM:305000,DYSKERATOSIS CONGENITA, X-LINKED; DKCX;OMIM:612079,ALOPECIA, NEUROLOGIC DEFECTS, AND ENDOCRINOPATHY SYNDROME; ANES;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:187500,TETRALOGY OF FALLOT; TOF	DOID:0001441,('spinocerebellar ataxia',),30,0.0000;DOID:0002729,('dyskeratosis congenita',),61,0.0000;DOID:0005419,('schizophrenia',),20,0.0000;DOID:0006419,('tetralogy of Fallot',),55,0.0000;DOID:0001067,('open-angle glaucoma',),58,0.0000;DOID:0001070,('primary open angle glaucoma',),58,0.0000	
T20B3.2,K12F2.1,ZK721.2,W03F8.1,F58G4.1,T22E5.5,F53A9.10,T18D3.4,R06C7.10,F11C3.3,ZK673.7,F42E11.4,C14F5.3	0.05,MI:cel-miR-785,MI:cel-miR-785	P48788,P19429,P13533	OMIM:115210,CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 1; RCM1;OMIM:613252,CARDIOMYOPATHY, DILATED, 1EE; CMD1EE;OMIM:272120,SUDDEN INFANT DEATH SYNDROME;OMIM:611880,CARDIOMYOPATHY, DILATED, 2A; CMD2A;OMIM:614089,ATRIAL SEPTAL DEFECT 3; ASD3;OMIM:115200,CARDIOMYOPATHY, DILATED, 1A; CMD1A;OMIM:115080,CARDIAC CONDUCTION DEFECT;OMIM:614090,SICK SINUS SYNDROME 3, SUSCEPTIBILITY TO; SSS3;OMIM:601680,ARTHROGRYPOSIS, DISTAL, TYPE 2B; DA2B;OMIM:613251,CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 14; CMH14;OMIM:613690,CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 7; CMH7;OMIM:613286,CARDIOMYOPATHY, DILATED, 1FF; CMD1FF	DOID:0009007,('sudden infant death syndrome',),11,0.0003;DOID:0000397,('restrictive cardiomyopathy',),11,0.0000	
F59A7.8,K07G5.2,C47D12.8		Q92889,P23025	OMIM:615272,FANCONI ANEMIA, COMPLEMENTATION GROUP Q; FANCQ;OMIM:278760,XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F; XPF;OMIM:114480,BREAST CANCER;OMIM:610965,XFE PROGEROID SYNDROME; XFEPS;OMIM:278700,XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A; XPA		
C29F9.7,T21D12.4		Q13418,Q9HBI1	OMIM:115200,CARDIOMYOPATHY, DILATED, 1A; CMD1A	DOID:0012930,('dilated cardiomyopathy',),2,0.0000	
B0336.6,F28D1.10		Q9Y2A7,Q9NYB9	OMIM:209850,AUTISM		
F20H11.2,Y113G7B.12		Q9Y2G9			
C40H1.1,F43D2.1		Q8N1B3	OMIM:300707,TOE SYNDACTYLY, TELECANTHUS, AND ANOGENITAL AND RENAL MALFORMATIONS; STAR		
K10C2.4,ZK688.3		P16930,Q6P587	OMIM:276700,TYROSINEMIA, TYPE I; TYRSN1	DOID:0050726,('tyrosinemia type I',),2,0.0172	
F16B3.1,ZK1321.2		P16389,Q8NCM2	OMIM:545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF;OMIM:530000,KEARNS-SAYRE SYNDROME; KSS		
C43E11.8,F02E8.5		Q9UPT5,Q676U5	OMIM:266600,INFLAMMATORY BOWEL DISEASE 1; IBD1;OMIM:611081,INFLAMMATORY BOWEL DISEASE 10; IBD10		
F26D11.10,Y8G1A.2					
C25D7.7,F28B4.2		Q12967,P10114			
F38E9.2,F39G3.8		O43897	OMIM:613087,ATRIAL SEPTAL DEFECT 6; ASD6		
T23H2.1,F42A8.2,ZK1320.9,C34B2.7,T07C4.7,F20D6.11,C03G5.1	0.05000,GO:0016265,death;0.05000,GO:0008219,cell death;0.04810,GO:0012501,programmed cell death;0.04810,GO:0006915,apoptotic process;0.00185,GO:0097194,execution phase of apoptosis;0.03330,GO:0031975,envelope;0.03330,GO:0031967,organelle envelope;0.02040,GO:0019866,organelle inner membrane;0.02960,GO:0005740,mitochondrial envelope;0.02220,GO:0031966,mitochondrial membrane;0.02040,GO:0005743,mitochondrial inner membrane;0.05000,MI:cel-miR-82,MI:cel-miR-82;0.04350,MI:cel-miR-356,MI:cel-miR-356;0.03890,MI:cel-miR-72,MI:cel-miR-72;0.04260,MI:cel-miR-266,MI:cel-miR-266;0.03660,MI:cel-miR-90,MI:cel-miR-90;0.04870,MI:cel-miR-237,MI:cel-miR-237;0.04730,MI:cel-lin-4,MI:cel-lin-4;0.03590,MI:cel-miR-62,MI:cel-miR-62;0.04980,MI:cel-miR-269,MI:cel-miR-269;0.03690,MI:cel-miR-795,MI:cel-miR-795	Q99643,Q96NN9,P21912,Q8TEM1,P31040	OMIM:168000,PARAGANGLIOMAS 1; PGL1;OMIM:256000,LEIGH SYNDROME; LS;OMIM:605373,PARAGANGLIOMAS 3; PGL3;OMIM:614165,PARAGANGLIOMAS 5; PGL5;OMIM:158350,COWDEN SYNDROME 1; CWS1;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:171300,PHEOCHROMOCYTOMA;OMIM:612359,COWDEN SYNDROME 2; CWS2;OMIM:606764,GASTROINTESTINAL STROMAL TUMOR; GIST;OMIM:530000,KEARNS-SAYRE SYNDROME; KSS;OMIM:115310,PARAGANGLIOMAS 4; PGL4;OMIM:252011,MITOCHONDRIAL COMPLEX II DEFICIENCY;OMIM:606864,PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA;OMIM:613642,CARDIOMYOPATHY, DILATED, 1GG; CMD1GG	DOID:0050773,('paraganglioma',),6,0.0312;DOID:0005419,('schizophrenia',),7,0.0000;DOID:0006457,('Cowden disease',),6,0.0231;DOID:0009253,('gastrointestinal stromal tumor',),6,0.0021;DOID:0000699,('mitochondrial myopathy',),6,0.0014	
F15D3.1,D2013.7,K08F11.3,Y59A8A.3	0.05,MI:cel-let-7,MI:cel-let-7	P11532,O00303,Q7L2H7	OMIM:115200,CARDIOMYOPATHY, DILATED, 1A; CMD1A;OMIM:115080,CARDIAC CONDUCTION DEFECT;OMIM:310200,MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD;OMIM:300376,MUSCULAR DYSTROPHY, BECKER TYPE; BMD;OMIM:209850,AUTISM;OMIM:302045,CARDIOMYOPATHY, DILATED, 3B; CMD3B;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0012930,('dilated cardiomyopathy',),4,0.0018;DOID:0011723,('Duchenne muscular dystrophy',),4,0.0020;DOID:0005419,('schizophrenia',),4,0.0000;DOID:0009883,('Becker muscular dystrophy',),4,0.0020;DOID:0012849,('autistic disorder',),4,0.0000	
T23H2.1,F42A8.2,C34B2.7,T07C4.7,C44B7.10,C03G5.1	0.0481,MI:cel-miR-266,MI:cel-miR-266;0.0439,MI:cel-miR-72,MI:cel-miR-72;0.0413,MI:cel-miR-90,MI:cel-miR-90;0.0417,MI:cel-miR-795,MI:cel-miR-795;0.0406,MI:cel-miR-62,MI:cel-miR-62;0.0500,MI:cel-miR-232,MI:cel-miR-232;0.0490,MI:cel-miR-356,MI:cel-miR-356	Q99643,P21912,Q8TEM1,P31040	OMIM:168000,PARAGANGLIOMAS 1; PGL1;OMIM:256000,LEIGH SYNDROME; LS;OMIM:605373,PARAGANGLIOMAS 3; PGL3;OMIM:614165,PARAGANGLIOMAS 5; PGL5;OMIM:158350,COWDEN SYNDROME 1; CWS1;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:171300,PHEOCHROMOCYTOMA;OMIM:612359,COWDEN SYNDROME 2; CWS2;OMIM:606764,GASTROINTESTINAL STROMAL TUMOR; GIST;OMIM:530000,KEARNS-SAYRE SYNDROME; KSS;OMIM:115310,PARAGANGLIOMAS 4; PGL4;OMIM:252011,MITOCHONDRIAL COMPLEX II DEFICIENCY;OMIM:606864,PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA;OMIM:613642,CARDIOMYOPATHY, DILATED, 1GG; CMD1GG	DOID:0000699,('mitochondrial myopathy',),5,0.0076;DOID:0009253,('gastrointestinal stromal tumor',),5,0.0103;DOID:0005419,('schizophrenia',),6,0.0000	
C32E8.11,K04A8.6		Q8IWV8,Q86XK2			
T10B11.1,Y42H9AR.1,C18A3.5,F07A11.4	0.0500,GO:0009894,regulation of catabolic process;0.0500,GO:0031329,regulation of cellular catabolic process;0.0444,GO:0030162,regulation of proteolysis;0.0333,GO:0042176,regulation of protein catabolic process;0.0306,GO:1903362,regulation of cellular protein catabolic process;0.0278,GO:1903050,regulation of proteolysis involved in cellular protein catabolic process;0.0250,GO:0061136,regulation of proteasomal protein catabolic process;0.0250,GO:0070646,protein modification by small protein removal;0.0167,GO:0016579,protein deubiquitination;0.0194,GO:0019783,ubiquitin-like protein-specific protease activity;0.0167,GO:0036459,ubiquitinyl hydrolase activity;0.0167,GO:0004843,ubiquitin-specific protease activity;0.0500,MI:cel-miR-73,MI:cel-miR-73;0.0487,MI:cel-miR-72,MI:cel-miR-72;0.0403,MI:cel-miR-258,MI:cel-miR-258	P61457,O94966,Q9H8Y8,P31483	OMIM:264070,HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D;OMIM:604454,WELANDER DISTAL MYOPATHY; WDM;OMIM:160500,MYOPATHY, DISTAL, 1; MPD1		
Y105E8A.19,Y80D3A.1,T11G6.1,F58B3.5,Y66D12A.23	0.0483,MI:cel-miR-800,MI:cel-miR-800;0.0500,MI:cel-miR-260,MI:cel-miR-260	Q96I59,P23381,P56192,P12081	OMIM:203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A;OMIM:500004,RETINITIS PIGMENTOSA-DEAFNESS SYNDROME;OMIM:256000,LEIGH SYNDROME; LS;OMIM:615486,INTERSTITIAL LUNG AND LIVER DISEASE; ILLD;OMIM:616239,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 24; COXPD24;OMIM:614504,USHER SYNDROME, TYPE IIIB; USH3B;OMIM:616280,CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2U; CMT2U;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0050572,('cone-rod dystrophy',),3,0.0003;DOID:0005419,('schizophrenia',),4,0.0000;DOID:0010584,('retinitis pigmentosa',),3,0.0000	
K12C11.1,R05F9.6,F20H11.3,F21D5.1,Y43F4B.5	1.27e-02,GO:0006040,amino sugar metabolic process;2.55e-03,GO:0046349,amino sugar biosynthetic process;1.02e-02,GO:0009225,nucleotide-sugar metabolic process;5.10e-03,GO:0006047,UDP-N-acetylglucosamine metabolic process;2.55e-03,GO:0009226,nucleotide-sugar biosynthetic process;2.55e-03,GO:0006048,UDP-N-acetylglucosamine biosynthetic process;2.95e-02,GO:0009056,catabolic process;2.70e-02,GO:1901575,organic substance catabolic process;1.70e-03,GO:0009058,biosynthetic process;1.43e-03,GO:1901576,organic substance biosynthetic process;1.42e-02,GO:0009059,macromolecule biosynthetic process;5.49e-03,GO:0044711,single-organism biosynthetic process;9.36e-04,GO:0044249,cellular biosynthetic process;1.42e-02,GO:0034645,cellular macromolecule biosynthetic process;2.19e-03,GO:0044712,single-organism catabolic process;2.98e-03,GO:0005975,carbohydrate metabolic process;2.44e-03,GO:0044723,single-organism carbohydrate metabolic process;3.53e-06,GO:0016051,carbohydrate biosynthetic process;3.53e-05,GO:0016052,carbohydrate catabolic process;2.12e-05,GO:0044724,single-organism carbohydrate catabolic process;1.93e-04,GO:0006091,generation of precursor metabolites and energy;1.62e-03,GO:0055114,oxidation-reduction process;1.93e-04,GO:0015980,energy derivation by oxidation of organic compounds;2.12e-05,GO:0006112,energy reserve metabolic process;1.39e-02,GO:0044281,small molecule metabolic process;7.35e-04,GO:0005996,monosaccharide metabolic process;3.53e-06,GO:0019318,hexose metabolic process;3.53e-06,GO:0006006,glucose metabolic process;3.53e-06,GO:0006012,galactose metabolic process;5.36e-04,GO:0044282,small molecule catabolic process;1.06e-05,GO:0046365,monosaccharide catabolic process;3.53e-06,GO:0019320,hexose catabolic process;3.53e-06,GO:0019388,galactose catabolic process;2.12e-05,GO:0005976,polysaccharide metabolic process;2.12e-05,GO:0044042,glucan metabolic process;3.53e-06,GO:0000271,polysaccharide biosynthetic process;1.93e-04,GO:0044262,cellular carbohydrate metabolic process;2.12e-05,GO:0044264,cellular polysaccharide metabolic process;2.12e-05,GO:0006073,cellular glucan metabolic process;2.12e-05,GO:0005977,glycogen metabolic process;3.53e-06,GO:0034637,cellular carbohydrate biosynthetic process;3.53e-06,GO:0033692,cellular polysaccharide biosynthetic process;3.53e-06,GO:0009250,glucan biosynthetic process;3.53e-06,GO:0005978,glycogen biosynthetic process;1.09e-02,GO:0044444,cytoplasmic part;3.01e-05,GO:0005829,cytosol;6.35e-06,GO:0016853,isomerase activity;2.44e-08,GO:0016866,intramolecular transferase activity;2.44e-09,GO:0016868,intramolecular transferase activity, phosphotransferases;3.53e-06,GO:0004614,phosphoglucomutase activity;2.55e-03,GO:0004610,phosphoacetylglucosamine mutase activity	P36871,P12955,Q96G03,O95394,P40926	OMIM:243700,HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL RECESSIVE;OMIM:615816,IMMUNODEFICIENCY 23; IMD23;OMIM:614921,CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T;OMIM:170100,PROLIDASE DEFICIENCY	DOID:0005212,('congenital disorder of glycosylation',),4,0.0109	CORUM:1729
T04C12.5,T04C12.4,F20G4.3,C56G2.7,F52B10.1,C06C3.1	0.02610,GO:0071822,protein complex subunit organization;0.01630,GO:0070271,protein complex biogenesis;0.05000,GO:0022607,cellular component assembly;0.03700,GO:0065003,macromolecular complex assembly;0.03590,GO:0034622,cellular macromolecular complex assembly;0.01630,GO:0006461,protein complex assembly;0.01300,GO:0043623,cellular protein complex assembly;0.00109,GO:0043248,proteasome assembly;0.03150,GO:0065009,regulation of molecular function;0.01630,GO:0044093,positive regulation of molecular function;0.03040,GO:0050790,regulation of catalytic activity;0.01520,GO:0051336,regulation of hydrolase activity;0.04350,GO:0048518,positive regulation of biological process;0.03480,GO:0009893,positive regulation of metabolic process;0.02390,GO:0010604,positive regulation of macromolecule metabolic process;0.01520,GO:0043085,positive regulation of catalytic activity;0.00761,GO:0051345,positive regulation of hydrolase activity;0.04890,GO:0051246,regulation of protein metabolic process;0.01630,GO:0051247,positive regulation of protein metabolic process;0.04890,GO:0032268,regulation of cellular protein metabolic process;0.01740,GO:0030162,regulation of proteolysis;0.00435,GO:0052547,regulation of peptidase activity;0.00435,GO:0052548,regulation of endopeptidase activity;0.03590,GO:0048522,positive regulation of cellular process;0.02720,GO:0031325,positive regulation of cellular metabolic process;0.01630,GO:0032270,positive regulation of cellular protein metabolic process;0.00652,GO:0045862,positive regulation of proteolysis;0.00217,GO:0010952,positive regulation of peptidase activity;0.00217,GO:0010950,positive regulation of endopeptidase activity;0.00326,GO:0000502,proteasome complex;0.02280,GO:0098772,molecular function regulator;0.01740,GO:0030234,enzyme regulator activity;0.00326,GO:0008047,enzyme activator activity;0.00435,GO:0061134,peptidase regulator activity;0.00326,GO:0061135,endopeptidase regulator activity;0.00217,GO:0016504,peptidase activator activity;0.00109,GO:0061133,endopeptidase activator activity;0.04150,MI:cel-miR-243,MI:cel-miR-243;0.05000,MI:cel-miR-232,MI:cel-miR-232	P35580,P60709,Q16186,O14974	OMIM:243310,BARAITSER-WINTER SYNDROME 1; BRWS1;OMIM:607371,DYSTONIA, JUVENILE-ONSET; DJO	DOID:0060229,('Baraitser-Winter syndrome',),6,0.0001	
K01H12.1,ZC434.2,T05H4.6,F11A3.2,ZK1098.4,Y37E3.10,K04G2.1	3.22e-02,GO:0010876,lipid localization;3.22e-02,GO:0051235,maintenance of location;2.05e-02,GO:0019915,lipid storage;1.18e-02,GO:0006979,response to oxidative stress;1.47e-02,GO:0009628,response to abiotic stimulus;2.95e-03,GO:0009266,response to temperature stimulus;2.95e-03,GO:0009408,response to heat;2.05e-02,GO:0044707,single-multicellular organism process;2.95e-03,GO:0007568,aging;2.05e-02,GO:0007275,multicellular organismal development;2.95e-03,GO:0010259,multicellular organismal aging;2.95e-03,GO:0008340,determination of adult lifespan;1.63e-03,GO:0065009,regulation of molecular function;4.25e-04,GO:0044093,positive regulation of molecular function;5.00e-02,GO:0043170,macromolecule metabolic process;3.95e-02,GO:0044260,cellular macromolecule metabolic process;1.71e-03,GO:0010467,gene expression;1.64e-02,GO:0019538,protein metabolic process;1.21e-02,GO:0044267,cellular protein metabolic process;8.74e-03,GO:0006807,nitrogen compound metabolic process;5.28e-04,GO:1901564,organonitrogen compound metabolic process;6.82e-03,GO:0034641,cellular nitrogen compound metabolic process;7.39e-05,GO:0043603,cellular amide metabolic process;5.87e-05,GO:0006518,peptide metabolic process;1.63e-02,GO:0019222,regulation of metabolic process;3.78e-03,GO:0051171,regulation of nitrogen compound metabolic process;2.93e-02,GO:0051172,negative regulation of nitrogen compound metabolic process;1.21e-02,GO:0060255,regulation of macromolecule metabolic process;4.50e-03,GO:0010468,regulation of gene expression;2.23e-04,GO:0010608,posttranscriptional regulation of gene expression;1.04e-02,GO:0080090,regulation of primary metabolic process;3.95e-03,GO:0051246,regulation of protein metabolic process;4.67e-02,GO:0051248,negative regulation of protein metabolic process;1.52e-03,GO:0050790,regulation of catalytic activity;3.69e-04,GO:0051336,regulation of hydrolase activity;4.07e-05,GO:0043087,regulation of GTPase activity;3.12e-03,GO:0048518,positive regulation of biological process;1.99e-03,GO:0009893,positive regulation of metabolic process;3.69e-04,GO:0043085,positive regulation of catalytic activity;8.53e-05,GO:0051345,positive regulation of hydrolase activity;4.07e-05,GO:0043547,positive regulation of GTPase activity;1.96e-03,GO:0009058,biosynthetic process;3.61e-03,GO:0009889,regulation of biosynthetic process;1.65e-03,GO:1901576,organic substance biosynthetic process;8.69e-05,GO:1901566,organonitrogen compound biosynthetic process;3.54e-04,GO:0009059,macromolecule biosynthetic process;3.28e-03,GO:0010556,regulation of macromolecule biosynthetic process;1.08e-03,GO:0044249,cellular biosynthetic process;3.42e-04,GO:0044271,cellular nitrogen compound biosynthetic process;1.40e-05,GO:0043604,amide biosynthetic process;1.03e-05,GO:0043043,peptide biosynthetic process;3.54e-04,GO:0034645,cellular macromolecule biosynthetic process;9.23e-06,GO:0006412,translation;3.22e-02,GO:0009890,negative regulation of biosynthetic process;2.64e-02,GO:0010558,negative regulation of macromolecule biosynthetic process;1.24e-02,GO:0031323,regulation of cellular metabolic process;3.61e-03,GO:0031326,regulation of cellular biosynthetic process;3.28e-03,GO:2000112,regulation of cellular macromolecule biosynthetic process;3.95e-03,GO:0032268,regulation of cellular protein metabolic process;1.83e-04,GO:0034248,regulation of cellular amide metabolic process;8.83e-03,GO:0034249,negative regulation of cellular amide metabolic process;1.83e-04,GO:0006417,regulation of translation;4.67e-02,GO:0032269,negative regulation of cellular protein metabolic process;3.22e-02,GO:0031327,negative regulation of cellular biosynthetic process;2.64e-02,GO:2000113,negative regulation of cellular macromolecule biosynthetic process;2.64e-02,GO:0010629,negative regulation of gene expression;8.83e-03,GO:0017148,negative regulation of translation;4.65e-07,GO:0006413,translational initiation;1.22e-05,GO:0006446,regulation of translational initiation;2.95e-03,GO:0045947,negative regulation of translational initiation;2.65e-03,GO:0032991,macromolecular complex;1.13e-03,GO:0043234,protein complex;1.26e-02,GO:0044444,cytoplasmic part;2.95e-03,GO:0043614,multi-eIF complex;2.95e-03,GO:0005850,eukaryotic translation initiation factor 2 complex;1.13e-08,GO:0005851,eukaryotic translation initiation factor 2B complex;3.22e-02,GO:0005840,ribosome;2.95e-03,GO:0070993,translation preinitiation complex;2.95e-03,GO:0033290,eukaryotic 48S preinitiation complex;2.93e-02,GO:0008135,translation factor activity, RNA binding;1.76e-02,GO:0003743,translation initiation factor activity;4.38e-02,GO:0042802,identical protein binding;8.48e-04,GO:0098772,molecular function regulator;4.07e-05,GO:0005085,guanyl-nucleotide exchange factor activity;3.22e-02,GO:0044877,macromolecular complex binding;2.05e-02,GO:0043021,ribonucleoprotein complex binding;1.18e-02,GO:0043022,ribosome binding;2.35e-02,GO:0044822,poly(A) RNA binding;4.06e-02,MI:cel-miR-59,MI:cel-miR-59;5.00e-02,MI:cel-miR-273,MI:cel-miR-273;4.81e-02,MI:cel-miR-248,MI:cel-miR-248;4.17e-02,MI:cel-miR-266,MI:cel-miR-266;5.00e-02,MI:cel-miR-124,MI:cel-miR-124	P62081,P20042,P62495,P05198,Q96FX2,Q9UI10,Q14232	OMIM:612563,DIAMOND-BLACKFAN ANEMIA 8; DBA8;OMIM:603896,LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM		
T01C8.1,ZK930.1		Q99570			
F19B6.4,Y75B8A.4		Q86WA8			
C17E4.5,M110.4,F18H3.3,B0348.6	0.0500,MI:cel-miR-34,MI:cel-miR-34;0.0419,MI:cel-miR-71,MI:cel-miR-71	P06730,Q86U42,Q13310,O43432	OMIM:164300,OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPMD;OMIM:615091,AUTISM, SUSCEPTIBILITY TO, 19; AUTS19	DOID:0011719,('oculopharyngeal muscular dystrophy',),4,0.0011	
F32E10.4,D1086.9,F28B3.8,ZK742.1,Y48G1A.5,ZK84.1,C53D5.6	0.05,MI:cel-miR-233,MI:cel-miR-233	O14980,P55060,O00410,O00629,Q14974			CORUM:2920
F18A1.5,M04F3.1,F10C2.6,T02G5.9,B0464.1	0.04450,MI:cel-miR-242,MI:cel-miR-242;0.05000,MI:cel-miR-789,MI:cel-miR-789;0.03200,MI:cel-miR-785,MI:cel-miR-785;0.04500,MI:cel-miR-245,MI:cel-miR-245;0.00151,MI:cel-miR-257,MI:cel-miR-257	Q15046,P27694,Q6PI48,P14868	OMIM:615281,HYPOMYELINATION WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LEG SPASTICITY; HBSL;OMIM:271900,CANAVAN DISEASE;OMIM:118200,CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B;OMIM:613916,DEAFNESS, AUTOSOMAL RECESSIVE 89; DFNB89;OMIM:613641,CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE B; CMTRIB;OMIM:611105,LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL	DOID:0050565,('autosomal recessive nonsyndromic deafness',),2,0.0020	
F12F6.6,Y39E4A.3,C09E8.3		P12694,P53992	OMIM:248600,MAPLE SYRUP URINE DISEASE; MSUD		
H35B03.2,T23B12.3,Y37D8A.18		P82664,Q9Y399			
R11A8.7,M88.5,T21G5.5		O75179,Q9Y6M1,Q96PU8	OMIM:125853,DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM	DOID:0009352,('type 2 diabetes mellitus',),2,0.0126	
F52F12.3,ZC504.4,C32D5.2		Q7Z2Y5,O43318,O00238	OMIM:112600,BRACHYDACTYLY, TYPE A2; BDA2;OMIM:609441,ACROMESOMELIC DYSPLASIA, DEMIRHAN TYPE; AMDD;OMIM:178600,PULMONARY HYPERTENSION, PRIMARY, 1; PPH1;OMIM:113100,BRACHYDACTYLY, TYPE C; BDC		
F59C6.4,Y73B6BL.3,F37C12.13,B0564.1,F31D4.1	0.0406,MI:cel-miR-794,MI:cel-miR-794;0.0500,MI:cel-miR-253,MI:cel-miR-253;0.0390,MI:cel-miR-1018,MI:cel-miR-1018;0.0441,MI:cel-miR-74,MI:cel-miR-74;0.0345,MI:cel-miR-268,MI:cel-miR-268;0.0479,MI:cel-miR-64,MI:cel-miR-64;0.0374,MI:cel-miR-785,MI:cel-miR-785	Q13868,Q06265,Q15024,Q9NQT5,Q9NPD3	OMIM:607596,PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A;OMIM:614678,PONTOCEREBELLAR HYPOPLASIA, TYPE 1B; PCH1B	DOID:0060266,('pontocerebellar hypoplasia type 1B',),5,0.0001;DOID:0060265,('pontocerebellar hypoplasia type 1A',),5,0.0001	
F38E9.5,K08E3.4,K11E8.1,C38C3.5,C04F6.4	0.0486,MI:cel-miR-256,MI:cel-miR-256;0.0500,MI:cel-miR-232,MI:cel-miR-232;0.0453,MI:cel-miR-264,MI:cel-miR-264	Q6IBS0,Q16643,Q9Y281,Q13554	OMIM:610687,NEMALINE MYOPATHY 7; NEM7		CORUM:788;CORUM:789
F11A10.4,R05D3.7,T07D4.3,C28H8.12,C18C4.10	0.05,MI:cel-miR-58,MI:cel-miR-58	Q13561,O60282,Q07866,Q7Z3U7,Q08211	OMIM:615282,CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 2; CDCBM2		
T15H9.6,Y76B12C.7,F32D1.9,R06A4.9,F36F2.3	0.05000,GO:0016071,mRNA metabolic process;0.04320,GO:0006397,mRNA processing;0.00455,GO:0043631,RNA polyadenylation;0.01360,GO:0031123,RNA 3'-end processing;0.00682,GO:0031124,mRNA 3'-end processing;0.00455,GO:0006378,mRNA polyadenylation;0.01820,GO:0016779,nucleotidyltransferase activity;0.00455,GO:0070566,adenylyltransferase activity;0.00455,GO:0004652,polynucleotide adenylyltransferase activity;0.04560,MI:cel-miR-791,MI:cel-miR-791;0.04870,MI:cel-miR-790,MI:cel-miR-790;0.03790,MI:cel-miR-271,MI:cel-miR-271;0.04800,MI:cel-miR-80,MI:cel-miR-80;0.05000,MI:cel-miR-360,MI:cel-miR-360;0.05000,MI:cel-miR-233,MI:cel-miR-233;0.04390,MI:cel-miR-229,MI:cel-miR-229;0.04080,MI:cel-miR-37,MI:cel-miR-37	Q10570,Q7Z6E9			
Y48G10A.1,F25B5.4,F54D8.3,F45H10.1,K04D7.3,F40A3.3,T08H10.1,K07A9.2,C16A3.10	0.01160,GO:0043648,dicarboxylic acid metabolic process;0.01540,GO:0009064,glutamine family amino acid metabolic process;0.00386,GO:0006525,arginine metabolic process;0.00772,GO:0006536,glutamate metabolic process;0.04620,GO:0016054,organic acid catabolic process;0.04620,GO:0046395,carboxylic acid catabolic process;0.02310,GO:0009063,cellular amino acid catabolic process;0.02310,GO:1901606,alpha-amino acid catabolic process;0.00386,GO:0009065,glutamine family amino acid catabolic process;0.00386,GO:0006527,arginine catabolic process;0.00386,GO:0019544,arginine catabolic process to glutamate;0.00386,GO:0006560,proline metabolic process;0.00386,GO:0019493,arginine catabolic process to proline;0.00386,GO:0010121,arginine catabolic process to proline via ornithine;0.05000,GO:0030170,pyridoxal phosphate binding;0.01540,GO:0016769,transferase activity, transferring nitrogenous groups;0.01540,GO:0008483,transaminase activity;0.00386,GO:0004587,ornithine-oxo-acid transaminase activity;0.05000,MI:cel-miR-796,MI:cel-miR-796	P51649,P10768,P05091,P04181,P30086,Q14012,P80404,P0CG48	OMIM:211980,LUNG CANCER;OMIM:271980,SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD;OMIM:258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR;OMIM:610251,ALCOHOL SENSITIVITY, ACUTE;OMIM:601665,OBESITY;OMIM:133239,ESOPHAGEAL CANCER;OMIM:103780,ALCOHOL DEPENDENCE;OMIM:613163,GABA-TRANSAMINASE DEFICIENCY;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:260350,PANCREATIC CANCER	DOID:0060174,('GABA aminotransferase deficiency',),5,0.0002;DOID:0005419,('schizophrenia',),6,0.0000;DOID:0003748,('esophagus squamous cell carcinoma',),7,0.0084;DOID:0050741,('alcohol dependence',),7,0.0084	
Y48G10A.1,K04F1.15,F54D8.3,F45H10.1,K04D7.3,Y24D9A.8,F40A3.3,C16A3.10	0.01540,GO:0009064,glutamine family amino acid metabolic process;0.00386,GO:0006525,arginine metabolic process;0.00386,GO:0006560,proline metabolic process;0.01160,GO:0043648,dicarboxylic acid metabolic process;0.00772,GO:0006536,glutamate metabolic process;0.04620,GO:0016054,organic acid catabolic process;0.04620,GO:0046395,carboxylic acid catabolic process;0.02310,GO:0009063,cellular amino acid catabolic process;0.02310,GO:1901606,alpha-amino acid catabolic process;0.00386,GO:0009065,glutamine family amino acid catabolic process;0.00386,GO:0006527,arginine catabolic process;0.00386,GO:0019493,arginine catabolic process to proline;0.00386,GO:0010121,arginine catabolic process to proline via ornithine;0.00386,GO:0019544,arginine catabolic process to glutamate;0.05000,GO:0030170,pyridoxal phosphate binding;0.01540,GO:0016769,transferase activity, transferring nitrogenous groups;0.01540,GO:0008483,transaminase activity;0.00386,GO:0004587,ornithine-oxo-acid transaminase activity;0.05000,MI:cel-miR-392,MI:cel-miR-392	P51649,P10768,P05091,P04181,P30086,P80404,P37837	OMIM:211980,LUNG CANCER;OMIM:271980,SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD;OMIM:258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR;OMIM:610251,ALCOHOL SENSITIVITY, ACUTE;OMIM:601665,OBESITY;OMIM:133239,ESOPHAGEAL CANCER;OMIM:606003,TRANSALDOLASE DEFICIENCY;OMIM:103780,ALCOHOL DEPENDENCE;OMIM:613163,GABA-TRANSAMINASE DEFICIENCY;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:260350,PANCREATIC CANCER	DOID:0060174,('GABA aminotransferase deficiency',),4,0.0017;DOID:0003748,('esophagus squamous cell carcinoma',),6,0.0278;DOID:0050741,('alcohol dependence',),6,0.0278;DOID:0005419,('schizophrenia',),5,0.0000	
Y71F9B.4,F40F8.9,ZK593.7,Y71G12B.14,Y62E10A.12,T10G3.6,Y73B6BL.32,W08E3.1,F28F8.3,Y49E10.15,Y116A8C.42,T28D9.10,F32A5.7,ZK652.1,C52E4.3,ZK1098.1	0.05,GO:0005634,nucleus;0.05,MI:cel-miR-267,MI:cel-miR-267	P62316,Q9Y333,Q9Y4Z0,O95777,O15116,P62304,P62314,P62308,P62306,P62318,Q9Y4Y9,P62312,O75400,Q9UK45,P62310	OMIM:605389,HYPOTRICHOSIS 1; HYPT1;OMIM:615059,HYPOTRICHOSIS 11; HYPT11;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),12,0.0000	
R09E12.3,Y22D7AL.10,Y22D7AL.5,F54D5.8,T05C3.5,C47E8.5,F26D10.3,H21P03.1,C30C11.4,C15H9.6,C01G10.8	0.05,MI:cel-miR-40,MI:cel-miR-40	O95433,P61604,O60884,P11021,O95757,P08238,P11142,O60869,P31948,P10809,O75953	OMIM:605280,SPASTIC PARAPLEGIA 13, AUTOSOMAL DOMINANT; SPG13;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:612233,LEUKODYSTROPHY, HYPOMYELINATING, 4; HLD4	DOID:0005419,('schizophrenia',),5,0.0000	
Y34D9A.6,R05H10.5,F26E4.12,ZK430.3,F38B6.4,C15F1.7	0.0500,MI:cel-miR-253,MI:cel-miR-253;0.0437,MI:cel-miR-252,MI:cel-miR-252;0.0483,MI:cel-miR-264,MI:cel-miR-264;0.0453,MI:cel-miR-251,MI:cel-miR-251	P00441,P35754,P22102	OMIM:105400,AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1		
W07B8.5,Y105E8B.5,W04G3.5,T07C4.1,R151.2	0.05,MI:cel-miR-356,MI:cel-miR-356	O60256,P00492,P60891	OMIM:300322,LESCH-NYHAN SYNDROME; LNS;OMIM:300661,PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY;OMIM:300323,KELLEY-SEEGMILLER SYNDROME;OMIM:311070,CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 5; CMTX5;OMIM:301835,ARTS SYNDROME; ARTS;OMIM:304500,DEAFNESS, X-LINKED 1; DFNX1;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP	DOID:0001919,('Lesch-Nyhan syndrome',),4,0.0005	
Y16B4A.2,Y22D7AL.5,Y40D12A.2,F54D5.8,C37H5.8,T05C3.5,F43E2.8,C47E8.5,H21P03.1,C30C11.4,C15H9.6	0.05,GO:0098857,membrane microdomain;0.05,GO:0045121,membrane raft;0.05,MI:cel-miR-40,MI:cel-miR-40	O60869,P08238,P38646,O95757,P11021,O75953,O60884,P10809	OMIM:605280,SPASTIC PARAPLEGIA 13, AUTOSOMAL DOMINANT; SPG13;OMIM:612233,LEUKODYSTROPHY, HYPOMYELINATING, 4; HLD4		
ZK20.3,F56G4.5,C18F10.7,B0205.3,F40G9.1	0.0487,MI:cel-miR-65,MI:cel-miR-65;0.0500,MI:cel-miR-73,MI:cel-miR-73;0.0500,MI:cel-miR-64,MI:cel-miR-64	P55036,Q8IZ07,Q96IV0,P54727,Q12981	OMIM:211980,LUNG CANCER;OMIM:615273,CONGENITAL DISORDER OF DEGLYCOSYLATION; CDDG	DOID:0001324,('lung cancer',),5,0.0188	
F45E1.6,T23D8.6,C50F4.7,C50F4.5,B0035.10	0.05,MI:cel-miR-258,MI:cel-miR-258	P84243,Q99880,P68431,P62805			
ZK180.4,F57H12.1,C24H11.7,B0336.2,C04G6.3	0.0500,MI:cel-miR-246,MI:cel-miR-246;0.0486,MI:cel-miR-254,MI:cel-miR-254;0.0481,MI:cel-miR-77,MI:cel-miR-77	P84085,Q13393,P84077,Q92538,Q9Y6B6	OMIM:246700,CHYLOMICRON RETENTION DISEASE; CMRD		
Y105E8B.5,T04A8.5,W04G3.5,T07C4.1,R151.2	0.0452,MI:cel-miR-76,MI:cel-miR-76;0.0500,MI:cel-miR-356,MI:cel-miR-356	Q06203,P00492,P60891,O60256	OMIM:300322,LESCH-NYHAN SYNDROME; LNS;OMIM:300661,PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY;OMIM:300323,KELLEY-SEEGMILLER SYNDROME;OMIM:311070,CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 5; CMTX5;OMIM:211980,LUNG CANCER;OMIM:301835,ARTS SYNDROME; ARTS;OMIM:304500,DEAFNESS, X-LINKED 1; DFNX1;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP	DOID:0001919,('Lesch-Nyhan syndrome',),5,0.0001;DOID:0001324,('lung cancer',),4,0.0053	
H20J04.2,Y71F9B.7,F37A4.8,F35G12.3	0.0494,MI:cel-miR-784,MI:cel-miR-784;0.0371,MI:cel-miR-241,MI:cel-miR-241;0.0403,MI:cel-miR-48,MI:cel-miR-48;0.0500,MI:cel-miR-58,MI:cel-miR-58;0.0380,MI:cel-miR-1018,MI:cel-miR-1018;0.0427,MI:cel-miR-252,MI:cel-miR-252	Q9NSY1,Q9NRL2,P28370	OMIM:209850,AUTISM		
W06H8.2,F19B6.2,F59E12.4,C17G10.4		Q92890,Q9UNH5			
T16G1.11,C17G10.9,Y41D4B.19,F36G9.12	0.05,GO:0005852,eukaryotic translation initiation factor 3 complex;0.05,MI:cel-miR-356,MI:cel-miR-356	Q9Y262,Q9UBQ5,O75694	OMIM:615770,ATRIAL FIBRILLATION, FAMILIAL, 15; ATFB15;OMIM:115080,CARDIAC CONDUCTION DEFECT		CORUM:4392;CORUM:4389;CORUM:742;CORUM:4403
T16G1.11,C17G10.9,Y39B6A.3,F36G9.12	0.0250,GO:0097428,protein maturation by iron-sulfur cluster transfer;0.0167,GO:0005852,eukaryotic translation initiation factor 3 complex;0.0500,GO:0003743,translation initiation factor activity;0.0250,GO:0005506,iron ion binding;0.0250,GO:0008198,ferrous iron binding;0.0334,GO:0051540,metal cluster binding;0.0334,GO:0051536,iron-sulfur cluster binding;0.0334,GO:0051539,4 iron, 4 sulfur cluster binding;0.0250,GO:0051537,2 iron, 2 sulfur cluster binding;0.0434,MI:cel-miR-251,MI:cel-miR-251;0.0500,MI:cel-miR-356,MI:cel-miR-356	Q9BUE6,Q9Y262,Q9UBQ5			CORUM:4392;CORUM:4389;CORUM:742;CORUM:4403
T16G1.11,C17G10.9,K02F3.10,F36G9.12	0.0500,GO:0005852,eukaryotic translation initiation factor 3 complex;0.0500,MI:cel-miR-356,MI:cel-miR-356;0.0463,MI:cel-miR-264,MI:cel-miR-264	Q9Y262,Q9UBQ5			
F55A4.5,F26E4.10,D1037.1,F15C11.1	0.0475,MI:cel-miR-84,MI:cel-miR-84	Q9NSC2,Q9NRR4,P18583,Q9NUL3	OMIM:107480,TOWNES-BROCKS SYNDROME; TBS;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:164210,HEMIFACIAL MICROSOMIA; HFM;OMIM:141400,HEMIFACIAL MICROSOMIA WITH RADIAL DEFECTS;OMIM:128600,EAR MALFORMATION	DOID:0005419,('schizophrenia',),2,0.0000	
Y41G9A.1,Y50D7A.4,K07H8.3,F13G3.10	0.05,MI:cel-miR-74,MI:cel-miR-74	Q9BXJ9,Q13099,P41227,Q9NX55	OMIM:309800,MICROPHTHALMIA, SYNDROMIC 1; MCOPS1;OMIM:300855,OGDEN SYNDROME; OGDNS		
C02F4.1,C33H5.9,F27D9.1,C01G8.9	0.0500,MI:cel-miR-273,MI:cel-miR-273;0.0472,MI:cel-miR-786,MI:cel-miR-786	O14497,O00471,P61764,Q14185	OMIM:600669,EPILEPSY, IDIOPATHIC GENERALIZED; EIG;OMIM:614607,MENTAL RETARDATION, AUTOSOMAL DOMINANT 14; MRD14;OMIM:209850,AUTISM;OMIM:312750,RETT SYNDROME; RTT;OMIM:135900,COFFIN-SIRIS SYNDROME; CSS;OMIM:252010,MITOCHONDRIAL COMPLEX I DEFICIENCY;OMIM:607208,EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 6; EIEE6;OMIM:612164,EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 4; EIEE4	DOID:0012849,('autistic disorder',),2,0.0000	
ZK470.5,K08E3.6,C09B8.7,F52A8.2	0.05,MI:cel-miR-36,MI:cel-miR-36	O14775,Q13153,Q9H0H5,O43639	OMIM:181500,SCHIZOPHRENIA; SCZD		
Y39A1A.15,Y110A2AL.8,H06O01.1,C09H6.2	0.0500,MI:cel-miR-799,MI:cel-miR-799;0.0458,MI:cel-miR-78,MI:cel-miR-78	Q96P47,P30101			
T04A11.2,F19B6.2,F59E12.4,C17G10.4		Q92890,P30039,Q9UNH5			
F46F6.2,Y51H4A.3,C09G12.8,C27A2.6	0.05,MI:cel-miR-256,MI:cel-miR-256	Q16513,P63000,Q92997,P61586	OMIM:182940,NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO; NTD		
Y48G1A.3,Y54E5A.5,T22A3.4		Q8IV38,Q9H7B4,Q9BVG4	OMIM:209850,AUTISM		CORUM:5432;CORUM:1856;CORUM:49;CORUM:163;CORUM:64;CORUM:166;CORUM:282;CORUM:159
F35G12.8,M106.1,F28B3.7,Y47D3A.26,K08A8.3,C29A12.3	0.0500,MI:cel-miR-235,MI:cel-miR-235;0.0442,MI:cel-miR-245,MI:cel-miR-245;0.0317,MI:cel-miR-241,MI:cel-miR-241	O95347,O60216,Q9NTJ3,Q14683,Q9UQE7,P18858	OMIM:614701,CORNELIA DE LANGE SYNDROME 4; CDLS4;OMIM:122470,CORNELIA DE LANGE SYNDROME 1; CDLS1;OMIM:209850,AUTISM;OMIM:610759,CORNELIA DE LANGE SYNDROME 3; CDLS3;OMIM:615222,SMITH-MCCORT DYSPLASIA 2; SMC2;OMIM:605130,WIEDEMANN-STEINER SYNDROME; WDSTS	DOID:0012849,('autistic disorder',),3,0.0000;DOID:0060247,('Smith-McCort dysplasia',),5,0.0013	
F48E8.5,C23G10.8,F38H4.9,W08G11.4,F26E4.1	0.0423,MI:cel-miR-243,MI:cel-miR-243;0.0484,MI:cel-miR-240,MI:cel-miR-240;0.0426,MI:cel-miR-793,MI:cel-miR-793;0.0500,MI:cel-miR-356,MI:cel-miR-356;0.0424,MI:cel-miR-795,MI:cel-miR-795;0.0480,MI:cel-miR-392,MI:cel-miR-392	Q16537,P62714,P63151,P30153			
R05D3.7,T07D4.3,C28H8.12,W10G11.20,C18C4.10	0.05,MI:cel-miR-58,MI:cel-miR-58	Q13561,O60282,Q07866,Q08211	OMIM:615282,CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 2; CDCBM2		
R11A5.1,W09G10.4,K06B9.2		Q13367,O14617	OMIM:209850,AUTISM;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0012849,('autistic disorder',),3,0.0000;DOID:0005419,('schizophrenia',),2,0.0000	
F43D9.4,Y87G2A.4,F35F11.1		Q6P1J9,P51159	OMIM:607624,GRISCELLI SYNDROME, TYPE 2; GS2;OMIM:608266,PARATHYROID CARCINOMA		
F29F11.6,T27A8.1,D1022.7		Q7Z3T8,P62140			
C06E1.4,F07F6.6,B0280.12		P42261,Q05586	OMIM:614254,MENTAL RETARDATION, AUTOSOMAL DOMINANT 8; MRD8	DOID:0060307,('autosomal dominant non-syndromic intellectual disability',),2,0.0334	
F48E8.5,F38H4.9,W08G11.4,F26E4.1,C13G3.3	0.0480,MI:cel-miR-392,MI:cel-miR-392;0.0425,MI:cel-miR-793,MI:cel-miR-793;0.0424,MI:cel-miR-795,MI:cel-miR-795;0.0500,MI:cel-miR-356,MI:cel-miR-356;0.0422,MI:cel-miR-243,MI:cel-miR-243	Q16537,Q14738,P62714,P63151,P30153			
Y105E8A.2,ZK1307.8,F43H9.2		O15270,Q96DZ1,P14314	OMIM:174050,POLYCYSTIC LIVER DISEASE; PCLD;OMIM:613640,NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IC; HSAN1C		
Y47G6A.8,W02D9.1,F18A1.5,T23G5.1,F34D10.2,C09H10.8	0.0500,MI:cel-miR-41,MI:cel-miR-41;0.0497,MI:cel-miR-36,MI:cel-miR-36;0.0500,MI:cel-miR-788,MI:cel-miR-788	P27694,P23921,P39748,P49643,O75419	OMIM:114480,BREAST CANCER	DOID:0001612,('breast cancer',),6,0.0241	CORUM:1176
F32E10.4,F28B3.8,K01G5.4,ZK742.1,Y48G1A.5,C35A5.8,C53D5.6,F59A2.1,C26D10.1	0.0471,MI:cel-miR-76,MI:cel-miR-76;0.0492,MI:cel-miR-262,MI:cel-miR-262;0.0500,MI:cel-miR-253,MI:cel-miR-253	O14980,O00410,Q14974,P18754,P55060,Q9UIA9,P62826,O00629	OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),4,0.0000	
ZK858.3,H12C20.2,F33H2.5,H26D21.2,B0218.6	0.05,MI:cel-miR-50,MI:cel-miR-50	Q07864,Q9BWP8,P43246,P54278	OMIM:158320,MUIR-TORRE SYNDROME; MRTES;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:613659,GASTRIC CANCER;OMIM:400042,SPERMATOGENIC FAILURE, Y-LINKED, 1; SPGFY1;OMIM:120435,LYNCH SYNDROME I;OMIM:265050,3MC SYNDROME 2; 3MC2;OMIM:614337,COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 4; HNPCC4;OMIM:176807,PROSTATE CANCER;OMIM:276300,MISMATCH REPAIR CANCER SYNDROME; MMRCS;OMIM:167000,OVARIAN CANCER;OMIM:608089,ENDOMETRIAL CANCER;OMIM:114480,BREAST CANCER;OMIM:260350,PANCREATIC CANCER	DOID:0001520,('colon carcinoma',),4,0.0041;DOID:0009256,('colorectal cancer',),4,0.0030;DOID:0001612,('breast cancer',),2,0.0019	
F48E8.5,F38H4.9,Y65B4BR.6,W08G11.4,F26E4.1	0.0425,MI:cel-miR-793,MI:cel-miR-793;0.0422,MI:cel-miR-243,MI:cel-miR-243;0.0424,MI:cel-miR-795,MI:cel-miR-795;0.0480,MI:cel-miR-392,MI:cel-miR-392;0.0500,MI:cel-miR-356,MI:cel-miR-356	Q16537,P62714,P63151,P30153			
T24H7.1,Y47G6A.10,Y37E3.9,D2030.2,C25A1.13	0.0500,MI:cel-miR-34,MI:cel-miR-34;0.0449,MI:cel-miR-784,MI:cel-miR-784;0.0479,MI:cel-miR-270,MI:cel-miR-270;0.0500,MI:cel-miR-1020,MI:cel-miR-1020;0.0479,MI:cel-miR-1019,MI:cel-miR-1019;0.0393,MI:cel-miR-243,MI:cel-miR-243	P35232,Q9Y4W6,O76031,Q8N983,Q99623	OMIM:614487,SPASTIC ATAXIA 5, AUTOSOMAL RECESSIVE; SPAX5;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:114480,BREAST CANCER;OMIM:610246,SPINOCEREBELLAR ATAXIA 28; SCA28	DOID:0005419,('schizophrenia',),2,0.0000;DOID:0001612,('breast cancer',),3,0.0013	
F38E9.5,Y50D7A.10,K08E3.4,C38C3.5,C04F6.4	0.0453,MI:cel-miR-264,MI:cel-miR-264;0.0500,MI:cel-miR-232,MI:cel-miR-232;0.0486,MI:cel-miR-256,MI:cel-miR-256	Q6IBS0,P60983,Q9Y281,Q16643	OMIM:610687,NEMALINE MYOPATHY 7; NEM7		
M02D8.4,F19B6.1		Q9NWZ5			
K10C3.5,Y48B6A.12		Q7Z2Z2,Q16798			
F23H12.2,C18E9.6		O96008,Q15388	OMIM:104300,ALZHEIMER DISEASE; AD		
C14B1.5,C09G5.2		Q9BQC3,Q9BZG8	OMIM:220200,DANDY-WALKER SYNDROME; DWS;OMIM:123155,HYDROCEPHALUS, AUTOSOMAL DOMINANT; HDCPH1;OMIM:236600,HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 1; HYC1		
C25A1.5,T13F2.1		Q7L5A8	OMIM:209850,AUTISM;OMIM:612319,SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35	DOID:0012849,('autistic disorder',),2,0.0000;DOID:0002476,('hereditary spastic paraplegia',),2,0.0010	
C36B1.7,R12E2.13		Q99470,P00374	OMIM:613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY		
K11H3.1,F19H8.1,Y22D7AL.10,F22B7.5,C32E8.10		P61604,P21695,Q96EY1,Q13492	OMIM:601626,LEUKEMIA, ACUTE MYELOID; AML;OMIM:614480,HYPERTRIGLYCERIDEMIA, TRANSIENT INFANTILE; HTGTI		
ZK858.7,W02A11.1,Y39A1A.14,W07E6.2,ZC376.5,F33D11.10,ZK795.3,C15H11.8	5.64e-04,GO:0046483,heterocycle metabolic process;1.79e-02,GO:0043170,macromolecule metabolic process;1.30e-02,GO:0044260,cellular macromolecule metabolic process;1.98e-04,GO:0010467,gene expression;3.01e-02,GO:0044085,cellular component biogenesis;1.40e-02,GO:0022613,ribonucleoprotein complex biogenesis;1.00e-02,GO:0042254,ribosome biogenesis;4.99e-04,GO:0006725,cellular aromatic compound metabolic process;5.98e-04,GO:1901360,organic cyclic compound metabolic process;1.74e-03,GO:0006807,nitrogen compound metabolic process;1.25e-03,GO:0034641,cellular nitrogen compound metabolic process;4.89e-04,GO:0006139,nucleobase-containing compound metabolic process;2.19e-04,GO:0090304,nucleic acid metabolic process;1.27e-04,GO:0016070,RNA metabolic process;3.33e-04,GO:0034660,ncRNA metabolic process;6.72e-03,GO:0016072,rRNA metabolic process;1.16e-05,GO:0006396,RNA processing;2.82e-04,GO:0034470,ncRNA processing;6.72e-03,GO:0006364,rRNA processing;9.26e-04,GO:0009451,RNA modification;3.84e-02,GO:0006400,tRNA modification;1.72e-02,GO:0000154,rRNA modification;1.84e-03,GO:0032259,methylation;3.99e-04,GO:0043414,macromolecule methylation;1.33e-04,GO:0001510,RNA methylation;1.72e-02,GO:0030488,tRNA methylation;4.30e-03,GO:0031167,rRNA methylation;4.30e-03,GO:0070475,rRNA base methylation;3.53e-04,GO:0032991,macromolecular complex;6.24e-04,GO:1990904,ribonucleoprotein complex;6.24e-04,GO:0030529,intracellular ribonucleoprotein complex;3.78e-03,GO:0030684,preribosome;2.41e-03,GO:0032040,small-subunit processome;3.84e-02,GO:0071013,catalytic step 2 spliceosome;8.60e-03,GO:0034708,methyltransferase complex;8.60e-03,GO:0043527,tRNA methyltransferase complex;4.30e-03,GO:0031515,tRNA (m1A) methyltransferase complex;3.15e-02,GO:0031974,membrane-enclosed lumen;1.38e-02,GO:0043226,organelle;5.00e-02,GO:0043228,non-membrane-bounded organelle;8.62e-03,GO:0043227,membrane-bounded organelle;1.99e-02,GO:0044422,organelle part;2.88e-02,GO:0043233,organelle lumen;1.21e-02,GO:0043229,intracellular organelle;5.00e-02,GO:0043232,intracellular non-membrane-bounded organelle;1.11e-02,GO:0044446,intracellular organelle part;2.88e-02,GO:0070013,intracellular organelle lumen;7.54e-03,GO:0043231,intracellular membrane-bounded organelle;2.36e-04,GO:0005634,nucleus;1.53e-03,GO:0044428,nuclear part;1.80e-02,GO:0031981,nuclear lumen;8.87e-03,GO:0005730,nucleolus;1.29e-02,GO:0034457,Mpp10 complex;2.14e-02,GO:0008173,RNA methyltransferase activity;4.30e-03,GO:0008649,rRNA methyltransferase activity;4.30e-03,GO:0070037,rRNA (pseudouridine) methyltransferase activity;2.81e-02,GO:0097159,organic cyclic compound binding;2.81e-02,GO:1901363,heterocyclic compound binding;1.40e-02,GO:0003676,nucleic acid binding;9.25e-03,GO:0003723,RNA binding;4.69e-02,GO:0030515,snoRNA binding;1.87e-04,GO:0019843,rRNA binding;8.60e-03,GO:0042134,rRNA primary transcript binding;5.00e-02,MI:cel-miR-56*,MI:cel-miR-56*	Q92979,Q9NXH9,Q9P1U0,Q9NVX2,Q96FX7,Q9UJA5,Q96G21	OMIM:211180,BOWEN-CONRADI SYNDROME; BWCNS	DOID:0050684,('Bowen-Conradi syndrome',),6,0.0000	
F58D5.1,F28C6.6,F56A8.6,R10E9.1,D1007.7	0.050,MI:cel-miR-257,MI:cel-miR-257;0.038,MI:cel-miR-251,MI:cel-miR-251	O95104,Q12996,Q96DH6,O43390,Q9H0L4			
Y37E11B.5,ZK858.7,W02A11.1,Y39A1A.14,W07E6.2,W02B12.10,F57B9.5,C16A3.4	5.36e-04,GO:0006725,cellular aromatic compound metabolic process;1.92e-02,GO:0043170,macromolecule metabolic process;1.40e-02,GO:0044260,cellular macromolecule metabolic process;2.12e-04,GO:0010467,gene expression;1.41e-03,GO:0043412,macromolecule modification;6.43e-04,GO:1901360,organic cyclic compound metabolic process;6.06e-04,GO:0046483,heterocycle metabolic process;1.87e-03,GO:0006807,nitrogen compound metabolic process;1.34e-03,GO:0034641,cellular nitrogen compound metabolic process;5.25e-04,GO:0006139,nucleobase-containing compound metabolic process;2.35e-04,GO:0090304,nucleic acid metabolic process;1.37e-04,GO:0016070,RNA metabolic process;3.37e-06,GO:0034660,ncRNA metabolic process;4.80e-06,GO:0006399,tRNA metabolic process;1.25e-08,GO:0009451,RNA modification;1.85e-02,GO:0000154,rRNA modification;1.24e-05,GO:0006396,RNA processing;9.24e-03,GO:0036260,RNA capping;9.24e-03,GO:0009452,7-methylguanosine RNA capping;2.69e-06,GO:0034470,ncRNA processing;2.91e-06,GO:0008033,tRNA processing;1.11e-06,GO:0006400,tRNA modification;1.85e-02,GO:0002943,tRNA dihydrouridine synthesis;1.75e-05,GO:0032259,methylation;1.59e-06,GO:0043414,macromolecule methylation;2.65e-07,GO:0001510,RNA methylation;4.63e-03,GO:0036265,RNA (guanine-N7)-methylation;5.75e-05,GO:0030488,tRNA methylation;4.63e-03,GO:0031167,rRNA methylation;4.63e-03,GO:0070475,rRNA base methylation;1.83e-02,GO:1902494,catalytic complex;9.94e-03,GO:1990234,transferase complex;9.59e-06,GO:0034708,methyltransferase complex;5.00e-02,GO:0044444,cytoplasmic part;9.59e-06,GO:0043527,tRNA methyltransferase complex;4.63e-03,GO:0031515,tRNA (m1A) methyltransferase complex;1.13e-02,GO:0032991,macromolecular complex;1.61e-03,GO:0016741,transferase activity, transferring one-carbon groups;1.61e-03,GO:0008168,methyltransferase activity;1.29e-03,GO:0008757,S-adenosylmethionine-dependent methyltransferase activity;9.57e-05,GO:0008173,RNA methyltransferase activity;1.39e-02,GO:0008175,tRNA methyltransferase activity;4.63e-03,GO:0016423,tRNA (guanine) methyltransferase activity;4.63e-03,GO:0008176,tRNA (guanine-N7-)-methyltransferase activity;4.63e-03,GO:0008649,rRNA methyltransferase activity;4.63e-03,GO:0070037,rRNA (pseudouridine) methyltransferase activity;3.22e-02,GO:0019843,rRNA binding;1.85e-02,GO:0017150,tRNA dihydrouridine synthase activity;5.00e-02,MI:cel-miR-48,MI:cel-miR-48	Q92979,Q9NVX2,Q969S3,Q96G46,Q96FX7,Q9UBP6,Q13895,Q9UJA5	OMIM:211180,BOWEN-CONRADI SYNDROME; BWCNS	DOID:0050684,('Bowen-Conradi syndrome',),5,0.0003	
Y48A5A.1,Y48A6B.3,C25A1.6		Q6PI26,Q9NPE3,Q9NX24	OMIM:224230,DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1; DKCB1;OMIM:613987,DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 2; DKCB2		CORUM:728;CORUM:2179;CORUM:2174;CORUM:726;CORUM:727
Y39B6A.36,C56C10.3,C01F1.1		P35269,Q9H444,P13984	OMIM:605387,CATARACT 31, MULTIPLE TYPES; CTRCT31		
T27E9.1,C34E10.6,W02D3.6,F23H12.2,C03B1.12	0.05,MI:cel-miR-392,MI:cel-miR-392	P06576,Q15388			
T04C10.2,M7.1,F15C11.2,Y32G9A.4,F25B5.4	0.05,MI:cel-miR-259,MI:cel-miR-259	Q9UMX0,Q9Y6I3,P62837,P0CG48	OMIM:211530,BROWN-VIALETTO-VAN LAERE SYNDROME 1; BVVLS1	DOID:0050694,('Brown-Vialetto-Van Laere syndrome',),3,0.0277	
Y63D3A.5,C37A2.2,F58G6.1		P49418,Q92734	OMIM:604484,NEUROPATHY, HEREDITARY MOTOR AND SENSORY, OKINAWA TYPE; HMSNO;OMIM:609541,SPASTIC PARAPLEGIA, OPTIC ATROPHY, AND NEUROPATHY; SPOAN;OMIM:615658,SPASTIC PARAPLEGIA 57, AUTOSOMAL RECESSIVE; SPG57;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0002476,('hereditary spastic paraplegia',),3,0.0049;DOID:0005419,('schizophrenia',),3,0.0000	
R05D11.4,F30A10.9,F18C5.3,E02H1.1,C05C8.2	0.02980,GO:0044085,cellular component biogenesis;0.01360,GO:0022613,ribonucleoprotein complex biogenesis;0.00975,GO:0042254,ribosome biogenesis;0.01270,GO:0034660,ncRNA metabolic process;0.00649,GO:0016072,rRNA metabolic process;0.02390,GO:0006396,RNA processing;0.01140,GO:0034470,ncRNA processing;0.00649,GO:0006364,rRNA processing;0.01930,GO:1990904,ribonucleoprotein complex;0.01930,GO:0030529,intracellular ribonucleoprotein complex;0.00364,GO:0030684,preribosome;0.00231,GO:0032040,small-subunit processome;0.03120,GO:0031974,membrane-enclosed lumen;0.02840,GO:0043233,organelle lumen;0.05000,GO:0043228,non-membrane-bounded organelle;0.02840,GO:0070013,intracellular organelle lumen;0.03470,GO:0044428,nuclear part;0.01760,GO:0031981,nuclear lumen;0.05000,GO:0043232,intracellular non-membrane-bounded organelle;0.00859,GO:0005730,nucleolus;0.05000,MI:cel-miR-257,MI:cel-miR-257;0.02110,MI:cel-miR-355,MI:cel-miR-355	Q9Y2R4,Q9Y324,Q9UNQ2,O75691,Q13601			
F25B4.6,Y42G9A.4,C23F12.1,D2063.3	0.05,MI:cel-miR-48,MI:cel-miR-48	O76003,P54868,Q03426	OMIM:610377,MEVALONIC ACIDURIA; MEVA;OMIM:605911,3-HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE-2 DEFICIENCY; HMGCS2D;OMIM:175900,POROKERATOSIS 3, MULTIPLE TYPES; POROK3;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP;OMIM:260920,HYPER-IgD SYNDROME; HIDS	DOID:0050452,('mevalonic aciduria',),3,0.0079;DOID:0050572,('cone-rod dystrophy',),3,0.0004;DOID:0010584,('retinitis pigmentosa',),3,0.0000	
ZK1128.5,Y113G7B.23,R07E5.3,B0303.3	0.0500,GO:0043227,membrane-bounded organelle;0.0484,GO:0043231,intracellular membrane-bounded organelle;0.0379,GO:0044444,cytoplasmic part;0.0111,GO:0005739,mitochondrion;0.0500,MI:cel-miR-265,MI:cel-miR-265	Q12824,Q92922,P55084,Q6STE5	OMIM:609015,MITOCHONDRIAL TRIFUNCTIONAL PROTEIN DEFICIENCY; MTPD;OMIM:601358,NICOLAIDES-BARAITSER SYNDROME; NCBRS;OMIM:118200,CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B;OMIM:162091,SCHWANNOMATOSIS 1; SWNTS1;OMIM:209850,AUTISM;OMIM:135900,COFFIN-SIRIS SYNDROME; CSS;OMIM:609016,LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY;OMIM:610253,KLEEFSTRA SYNDROME;OMIM:609322,RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1;OMIM:156240,MESOTHELIOMA, MALIGNANT; MESOM;OMIM:614608,MENTAL RETARDATION, AUTOSOMAL DOMINANT 15; MRD15	DOID:0012849,('autistic disorder',),3,0.0000	
M01E5.5,K12D12.1,T01G9.6,B0205.7,Y119C1B.8	0.05,MI:cel-miR-58,MI:cel-miR-58	P68400,P67870,P11388,O60885,P11387	OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),5,0.0000	
F23F12.6,K08F4.1,C34B2.6,C18E9.11	0.00455,GO:0051131,chaperone-mediated protein complex assembly;0.02730,GO:0006515,misfolded or incompletely synthesized protein catabolic process;0.02730,GO:0001067,regulatory region nucleic acid binding;0.05000,GO:0003677,DNA binding;0.00909,GO:0003697,single-stranded DNA binding;0.02730,GO:0000975,regulatory region DNA binding;0.02730,GO:0044212,transcription regulatory region DNA binding;0.00455,GO:0070361,mitochondrial light strand promoter anti-sense binding;0.02730,GO:0004176,ATP-dependent peptidase activity;0.05000,MI:cel-miR-355,MI:cel-miR-355	P36776,Q8WVB6,P43686	OMIM:600373,CODAS SYNDROME		
C06G4.2,Y77E11A.11		O14815	OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),2,0.0000	
F57B10.1,W02H5.7					
M04B2.4,Y69A2AR.5		Q96CU9,Q99489	OMIM:252010,MITOCHONDRIAL COMPLEX I DEFICIENCY;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:256000,LEIGH SYNDROME; LS	DOID:0005419,('schizophrenia',),2,0.0000	
C31B8.8,K07C11.5		P16035,P45452	OMIM:265900,PYLE DISEASE;OMIM:100070,AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 1; AAA1;OMIM:602111,SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MISSOURI TYPE		
R02D3.3,Y97E10AR.6		Q9NW68,P32780			
R57.1,ZC506.1		Q04609,Q9BZQ6	OMIM:176807,PROSTATE CANCER	DOID:0010283,('prostate cancer',),2,0.0085	
F54G8.2,T10B11.2		Q9Y6T7,Q8TCT0	OMIM:181500,SCHIZOPHRENIA; SCZD		
F45H7.2,H14N18.1		Q9Y3M8	OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),2,0.0000	
F18E3.7,K03D3.10					
C56G2.1,Y71D11A.2		O75940			
Y57G11C.10,T25G12.4,W03C9.3,F26H9.6,T23H2.5,R05D11.3,F53G12.1,F46H6.1,F59B2.7,C27B7.8,D1037.4,C39F7.4,C15C7.2	0.0500,MI:cel-miR-250,MI:cel-miR-250;0.0361,MI:cel-miR-264,MI:cel-miR-264;0.0303,MI:cel-miR-795,MI:cel-miR-795;0.0450,MI:cel-miR-2,MI:cel-miR-2	Q92930,P62820,P51149,P61026,P20340,P61970,P20339,P50395,P52566,P61224,P62491	OMIM:600882,CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B; CMT2B		CORUM:192;CORUM:191;CORUM:194;CORUM:5209
C02F4.1,C33H5.9,C03D6.5,C01G8.9	0.0381,MI:cel-miR-794,MI:cel-miR-794;0.0500,MI:cel-miR-232,MI:cel-miR-232;0.0480,MI:cel-miR-66,MI:cel-miR-66;0.0477,MI:cel-miR-63,MI:cel-miR-63;0.0500,MI:cel-miR-792,MI:cel-miR-792;0.0438,MI:cel-miR-65,MI:cel-miR-65;0.0449,MI:cel-miR-64,MI:cel-miR-64	O14497,O00471,Q9Y294,Q14185	OMIM:135900,COFFIN-SIRIS SYNDROME; CSS;OMIM:614607,MENTAL RETARDATION, AUTOSOMAL DOMINANT 14; MRD14		
T16G12.6,F14F3.1,R02E12.4,C29F3.2	0.0500,MI:cel-miR-253,MI:cel-miR-253;0.0406,MI:cel-miR-794,MI:cel-miR-794;0.0455,MI:cel-miR-788,MI:cel-miR-788;0.0491,MI:cel-miR-787,MI:cel-miR-787	Q969V4,O94829,P26367	OMIM:165550,OPTIC NERVE HYPOPLASIA, BILATERAL;OMIM:148190,KERATITIS, HEREDITARY;OMIM:120200,COLOBOMA, OCULAR, AUTOSOMAL DOMINANT;OMIM:209850,AUTISM;OMIM:120430,COLOBOMA OF OPTIC NERVE;OMIM:109730,AORTIC VALVE DISEASE 1; AOVD1;OMIM:206700,ANIRIDIA, CEREBELLAR ATAXIA, AND MENTAL RETARDATION;OMIM:136520,FOVEAL HYPOPLASIA 1; FVH1;OMIM:106210,ANIRIDIA; AN;OMIM:604229,PETERS ANOMALY	DOID:0011975,('coloboma of optic nerve',),3,0.0325;DOID:0012849,('autistic disorder',),3,0.0000	
Y16B4A.1,ZK377.1,K02E2.2,D2030.6	0.0479,MI:cel-miR-58,MI:cel-miR-58;0.0500,MI:cel-miR-232,MI:cel-miR-232	Q96J94,Q9UH73			
Y39H10A.7,W03D2.4,M04B2.1,T04C10.1	0.0500,MI:cel-miR-82,MI:cel-miR-82;0.0479,MI:cel-miR-80,MI:cel-miR-80	Q13627,Q9Y462,P12004,O14757	OMIM:300495,AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2;OMIM:300803,MENTAL RETARDATION, X-LINKED 97; MRX97;OMIM:614104,MENTAL RETARDATION, AUTOSOMAL DOMINANT 7; MRD7;OMIM:615919,ATAXIA-TELANGIECTASIA-LIKE DISORDER 2; ATLD2	DOID:0012849,('autistic disorder',),2,0.0000	
Y77E11A.13,ZK328.5,K06A4.3,Y113G7A.3		Q15436,P55735,P52948	OMIM:209850,AUTISM;OMIM:607812,CRANIOLENTICULOSUTURAL DYSPLASIA; CLSD;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),3,0.0000	
C34G6.7,Y106G6H.12,F46G10.3,C07A12.7	0.05,MI:cel-miR-359,MI:cel-miR-359	Q6ZVM7,Q92783			CORUM:87
W07B3.2,Y105E8B.1,R09B3.5,C04C3.5		Q96A72,P06753,Q96AJ1	OMIM:255310,MYOPATHY, CONGENITAL, WITH FIBER-TYPE DISPROPORTION; CFTD;OMIM:609284,NEMALINE MYOPATHY 1; NEM1;OMIM:255300,MYOPATHY, CONGENITAL		
T24H10.1,C41D11.8,C15H11.8		Q14249,Q9P1U0,P23193			
Y54E10BL.6,F54F2.1,ZK678.5,F13B9.5	0.0410,MI:cel-miR-49,MI:cel-miR-49;0.0474,MI:cel-miR-124,MI:cel-miR-124;0.0409,MI:cel-miR-797,MI:cel-miR-797;0.0418,MI:cel-miR-2,MI:cel-miR-2;0.0394,MI:cel-miR-83,MI:cel-miR-83;0.0409,MI:cel-miR-229,MI:cel-miR-229;0.0361,MI:cel-miR-65,MI:cel-miR-65;0.0500,MI:cel-miR-54,MI:cel-miR-54;0.0371,MI:cel-miR-64,MI:cel-miR-64;0.0358,MI:cel-miR-47,MI:cel-miR-47;0.0416,MI:cel-miR-270,MI:cel-miR-270;0.0396,MI:cel-miR-66,MI:cel-miR-66;0.0346,MI:cel-miR-46,MI:cel-miR-46;0.0499,MI:cel-miR-53,MI:cel-miR-53;0.0411,MI:cel-miR-61,MI:cel-miR-61;0.0440,MI:cel-miR-44,MI:cel-miR-44;0.0479,MI:cel-miR-51,MI:cel-miR-51;0.0482,MI:cel-miR-228,MI:cel-miR-228;0.0414,MI:cel-miR-230,MI:cel-miR-230;0.0420,MI:cel-miR-247,MI:cel-miR-247;0.0394,MI:cel-miR-63,MI:cel-miR-63	P53708,P36507,Q6VAB6	OMIM:601665,OBESITY;OMIM:209850,AUTISM;OMIM:615280,CARDIOFACIOCUTANEOUS SYNDROME 4; CFC4;OMIM:191830,RENAL HYPODYSPLASIA/APLASIA 1; RHDA1;OMIM:115150,CARDIOFACIOCUTANEOUS SYNDROME 1; CFC1;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),3,0.0000	
Y46G5A.4,K03H1.2,T23H2.3,K07C5.6	0.05,GO:0000375,RNA splicing, via transesterification reactions;0.05,GO:0005681,spliceosomal complex;0.05,MI:cel-miR-248,MI:cel-miR-248	Q92620,O95391,O75643,Q9UNY4	OMIM:268000,RETINITIS PIGMENTOSA; RP;OMIM:204000,LEBER CONGENITAL AMAUROSIS 1; LCA1;OMIM:120300,COLOBOMA OF MACULA;OMIM:209850,AUTISM;OMIM:610359,RETINITIS PIGMENTOSA 33; RP33;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:241850,HYPOTHYROIDISM, THYROIDAL OR ATHYROIDAL, WITH SPIKY HAIR AND CLEFT PALATE	DOID:0010584,('retinitis pigmentosa',),4,0.0000;DOID:0012849,('autistic disorder',),2,0.0000;DOID:0050572,('cone-rod dystrophy',),4,0.0015	
Y53F4B.13,ZK1320.7,T23G7.3,R07E5.1,F58B3.7,C07E3.1,D1037.1	0.01670,GO:0036260,RNA capping;0.01670,GO:0009452,7-methylguanosine RNA capping;0.00836,GO:0006370,7-methylguanosine mRNA capping;0.01670,GO:0016556,mRNA modification;0.05000,GO:0001510,RNA methylation;0.00836,GO:0080009,mRNA methylation;0.00836,GO:0036451,cap mRNA methylation;0.00836,GO:0097309,cap1 mRNA methylation;0.00836,GO:0008171,O-methyltransferase activity;0.04170,GO:0008173,RNA methyltransferase activity;0.00836,GO:0008174,mRNA methyltransferase activity;0.00836,GO:0004483,mRNA (nucleoside-2'-O-)-methyltransferase activity;0.04920,MI:cel-miR-271,MI:cel-miR-271;0.05000,MI:cel-miR-253*,MI:cel-miR-253*	Q96I25,P18583,Q96BK5,Q9UBB9,Q9BRR8,O95872	OMIM:211980,LUNG CANCER;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0001324,('lung cancer',),6,0.0414	
F48E8.5,Y32H12A.4,F38H4.9,W08G11.4,F26E4.1	0.0422,MI:cel-miR-243,MI:cel-miR-243;0.0480,MI:cel-miR-392,MI:cel-miR-392;0.0500,MI:cel-miR-356,MI:cel-miR-356;0.0424,MI:cel-miR-795,MI:cel-miR-795;0.0425,MI:cel-miR-793,MI:cel-miR-793	Q16537,P41236,P62714,P63151,P30153			
T06E6.2,ZC168.4,T05G5.3,T20F10.1	0.0469,MI:cel-miR-64,MI:cel-miR-64;0.0491,MI:cel-miR-392,MI:cel-miR-392;0.0500,MI:cel-miR-58,MI:cel-miR-58;0.0457,MI:cel-miR-65,MI:cel-miR-65	P14635,P06493			CORUM:310;CORUM:1005;CORUM:1004
T06E6.2,ZC168.4,T05G5.3,T27E9.3	0.05,MI:cel-miR-86,MI:cel-miR-86	P14635,Q00535,P06493			
F27D9.5,F52E4.1		P05165,P05166	OMIM:606054,PROPIONIC ACIDEMIA		
T06E8.1,ZK40.1		Q99943			CORUM:310;CORUM:1005;CORUM:1004
C05E4.9,K07A3.1		P09467	OMIM:229700,FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D		
F40F4.6,T25C12.3					
R01H2.5,Y71H10A.2,C53B4.7,F01G4.2,C15H11.4	0.0470,MI:cel-miR-252,MI:cel-miR-252;0.0500,MI:cel-miR-253*,MI:cel-miR-253*;0.0472,MI:cel-miR-90,MI:cel-miR-90;0.0488,MI:cel-miR-251,MI:cel-miR-251	Q99714,O60547,Q8WVX9,Q13630,Q96NR8	OMIM:268000,RETINITIS PIGMENTOSA; RP;OMIM:612712,LEBER CONGENITAL AMAUROSIS 13; LCA13;OMIM:300438,17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;OMIM:204000,LEBER CONGENITAL AMAUROSIS 1; LCA1;OMIM:616154,PEROXISOMAL FATTY ACYL-CoA REDUCTASE 1 DISORDER; PFCRD;OMIM:300220,MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:300495,AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2	DOID:0012849,('autistic disorder',),2,0.0000	
Y55F3AM.4,M7.5,T03F1.1,F11H8.1,C26E6.8	0.0472,MI:cel-miR-238,MI:cel-miR-238;0.0448,MI:cel-miR-266,MI:cel-miR-266;0.0473,MI:cel-miR-77,MI:cel-miR-77;0.0429,MI:cel-miR-787,MI:cel-miR-787;0.0499,MI:cel-lin-4,MI:cel-lin-4;0.0493,MI:cel-miR-43,MI:cel-miR-43;0.0473,MI:cel-miR-2,MI:cel-miR-2;0.0500,MI:cel-miR-250,MI:cel-miR-250;0.0431,MI:cel-miR-262,MI:cel-miR-262	Q13564,Q9NT62,O95352,Q8TBC4,Q9GZZ9	OMIM:143100,HUNTINGTON DISEASE; HD;OMIM:114480,BREAST CANCER	DOID:0012858,("Huntington's disease",),4,0.0148;DOID:0001612,('breast cancer',),2,0.0003	
T04A11.6,Y45F10A.4,W06D4.6,F10F2.2	0.05000,GO:0019637,organophosphate metabolic process;0.03330,GO:0090407,organophosphate biosynthetic process;0.03570,GO:0055086,nucleobase-containing small molecule metabolic process;0.02860,GO:0006753,nucleoside phosphate metabolic process;0.00833,GO:0009123,nucleoside monophosphate metabolic process;0.00833,GO:0009161,ribonucleoside monophosphate metabolic process;0.01550,GO:1901293,nucleoside phosphate biosynthetic process;0.00357,GO:0009124,nucleoside monophosphate biosynthetic process;0.00357,GO:0009156,ribonucleoside monophosphate biosynthetic process;0.02860,GO:0009117,nucleotide metabolic process;0.01550,GO:0009165,nucleotide biosynthetic process;0.02380,GO:0072521,purine-containing compound metabolic process;0.01430,GO:0006163,purine nucleotide metabolic process;0.01190,GO:0072522,purine-containing compound biosynthetic process;0.00714,GO:0006164,purine nucleotide biosynthetic process;0.02140,GO:0006520,cellular amino acid metabolic process;0.01900,GO:1901605,alpha-amino acid metabolic process;0.00476,GO:0009064,glutamine family amino acid metabolic process;0.00357,GO:0006541,glutamine metabolic process;0.01550,GO:0036094,small molecule binding;0.00476,GO:0097367,carbohydrate derivative binding;0.00119,GO:0001882,nucleoside binding;0.00119,GO:0001883,purine nucleoside binding;0.00119,GO:0032549,ribonucleoside binding;0.00119,GO:0032550,purine ribonucleoside binding;0.03930,GO:0043168,anion binding;0.01430,GO:1901265,nucleoside phosphate binding;0.00119,GO:0035639,purine ribonucleoside triphosphate binding;0.01430,GO:0000166,nucleotide binding;0.00119,GO:0032553,ribonucleotide binding;0.00238,GO:0017076,purine nucleotide binding;0.00238,GO:0030554,adenyl nucleotide binding;0.00119,GO:0032555,purine ribonucleotide binding;0.00119,GO:0032559,adenyl ribonucleotide binding;0.00119,GO:0005524,ATP binding;0.00833,GO:0016874,ligase activity;0.00476,GO:0016879,ligase activity, forming carbon-nitrogen bonds;0.00357,GO:0016884,carbon-nitrogen ligase activity, with glutamine as amido-N-donor;0.00119,GO:0004642,phosphoribosylformylglycinamidine synthase activity;0.04320,MI:cel-miR-74,MI:cel-miR-74;0.03800,MI:cel-miR-50,MI:cel-miR-50;0.04730,MI:cel-miR-264,MI:cel-miR-264;0.05000,MI:cel-miR-58,MI:cel-miR-58;0.04990,MI:cel-miR-63,MI:cel-miR-63;0.04570,MI:cel-miR-65,MI:cel-miR-65;0.03730,MI:cel-miR-241,MI:cel-miR-241;0.04810,MI:cel-miR-37,MI:cel-miR-37;0.04690,MI:cel-miR-64,MI:cel-miR-64;0.04350,MI:cel-miR-793,MI:cel-miR-793;0.04570,MI:cel-miR-72,MI:cel-miR-72;0.04690,MI:cel-miR-73,MI:cel-miR-73	Q92698,P49903,O15067	OMIM:211980,LUNG CANCER;OMIM:114480,BREAST CANCER;OMIM:605027,LYMPHOMA, NON-HODGKIN, FAMILIAL	DOID:0001612,('breast cancer',),2,0.0003	
T01E8.3,T24C12.2,T21H3.3,F36D4.3	0.0485,MI:cel-miR-74,MI:cel-miR-74;0.0500,MI:cel-miR-41,MI:cel-miR-41	P62158,Q14644,Q9Y4I1,P19174	OMIM:214450,GRISCELLI SYNDROME, TYPE 1; GS1		
K01G5.7,T28D6.2,C54C6.2,F44F4.11,F40F4.5,F32H2.9,F26E4.8,C36E8.5,F16D3.1,C47B2.3,C44B11.3,ZK154.3,B0272.1	0.05000,MI:cel-miR-79,MI:cel-miR-79;0.05000,MI:cel-miR-253,MI:cel-miR-253;0.04040,MI:cel-miR-86,MI:cel-miR-86;0.04800,MI:cel-miR-73,MI:cel-miR-73;0.04590,MI:cel-miR-271,MI:cel-miR-271;0.04340,MI:cel-miR-62,MI:cel-miR-62;0.03930,MI:cel-miR-50,MI:cel-miR-50;0.00263,MI:cel-miR-1018,MI:cel-miR-1018;0.04730,MI:cel-miR-76,MI:cel-miR-76	Q71U36,P68371	OMIM:209850,AUTISM;OMIM:213000,CEREBELLAR HYPOPLASIA;OMIM:142623,HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1;OMIM:611603,LISSENCEPHALY 3; LIS3	DOID:0012849,('autistic disorder',),3,0.0000	
C01G8.5,F54F3.1,C55B7.4,B0361.5		P26038,Q9UG56,Q14112			
C01G8.5,K06A5.6,C55B7.4,B0361.5	0.0500,MI:cel-miR-1020,MI:cel-miR-1020;0.0475,MI:cel-miR-230,MI:cel-miR-230;0.0484,MI:cel-miR-70,MI:cel-miR-70	P26038,Q9UG56,P45954	OMIM:610006,2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY		
Y39A1A.5,ZK20.3,K11E4.4,F56G4.5	0.0441,MI:cel-miR-790,MI:cel-miR-790;0.0355,MI:cel-miR-261,MI:cel-miR-261;0.0500,MI:cel-miR-272,MI:cel-miR-272;0.0378,MI:cel-miR-784,MI:cel-miR-784;0.0338,MI:cel-miR-35,MI:cel-miR-35;0.0352,MI:cel-miR-38,MI:cel-miR-38;0.0367,MI:cel-miR-39,MI:cel-miR-39;0.0338,MI:cel-miR-36,MI:cel-miR-36;0.0360,MI:cel-miR-42,MI:cel-miR-42;0.0412,MI:cel-miR-791,MI:cel-miR-791;0.0400,MI:cel-miR-249,MI:cel-miR-249;0.0347,MI:cel-miR-40,MI:cel-miR-40;0.0368,MI:cel-miR-37,MI:cel-miR-37;0.0340,MI:cel-miR-41,MI:cel-miR-41;0.0341,MI:cel-miR-271,MI:cel-miR-271	Q9UJ41,Q15052,P54727,Q96IV0	OMIM:211980,LUNG CANCER;OMIM:209850,AUTISM;OMIM:300436,MENTAL RETARDATION, X-LINKED 46; MRX46;OMIM:615273,CONGENITAL DISORDER OF DEGLYCOSYLATION; CDDG	DOID:0012849,('autistic disorder',),2,0.0000;DOID:0001324,('lung cancer',),3,0.0027	
C01G8.5,ZK512.5,C55B7.4,B0361.5		P26038,Q9UG56			
K02A4.1,T11G6.1,F22D6.3,W03B1.4,T10F2.1,C47E12.1,C47D12.6	0.05,MI:cel-miR-270,MI:cel-miR-270	P54687,P49591,P26639,M0R2C6,P41250,O43776,P12081	OMIM:601472,CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2D; CMT2D;OMIM:118200,CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B;OMIM:500004,RETINITIS PIGMENTOSA-DEAFNESS SYNDROME;OMIM:600361,HEREDITARY MOTOR AND SENSORY NEUROPATHY V;OMIM:600794,NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A;OMIM:614504,USHER SYNDROME, TYPE IIIB; USH3B;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP	DOID:0050572,('cone-rod dystrophy',),6,0.0228;DOID:0010584,('retinitis pigmentosa',),6,0.0012	CORUM:49;CORUM:159
T11G6.1,F22D6.3,W03B1.4,T10F2.1,C47E12.1,C47D12.6,Y66D12A.23		P49591,P26639,M0R2C6,Q96I59,P41250,O43776,P12081	OMIM:601472,CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2D; CMT2D;OMIM:203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A;OMIM:118200,CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B;OMIM:500004,RETINITIS PIGMENTOSA-DEAFNESS SYNDROME;OMIM:256000,LEIGH SYNDROME; LS;OMIM:600361,HEREDITARY MOTOR AND SENSORY NEUROPATHY V;OMIM:616239,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 24; COXPD24;OMIM:600794,NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A;OMIM:614504,USHER SYNDROME, TYPE IIIB; USH3B;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP	DOID:0010584,('retinitis pigmentosa',),7,0.0031	
C52A11.4,F11C7.4,C25F6.2,B0034.3	0.0414,MI:cel-miR-83,MI:cel-miR-83;0.0500,MI:cel-miR-124,MI:cel-miR-124;0.0367,MI:cel-miR-251,MI:cel-miR-251;0.0471,MI:cel-miR-87,MI:cel-miR-87;0.0353,MI:cel-miR-252,MI:cel-miR-252;0.0500,MI:cel-miR-273,MI:cel-miR-273	O94985,Q8NI35,Q12959,P82279	OMIM:248200,STARGARDT DISEASE 1; STGD1;OMIM:266600,INFLAMMATORY BOWEL DISEASE 1; IBD1;OMIM:204000,LEBER CONGENITAL AMAUROSIS 1; LCA1;OMIM:600669,EPILEPSY, IDIOPATHIC GENERALIZED; EIG;OMIM:172870,PIGMENTED PARAVENOUS CHORIORETINAL ATROPHY; PPCRA;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP;OMIM:607208,EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 6; EIEE6;OMIM:613835,LEBER CONGENITAL AMAUROSIS 8; LCA8;OMIM:600105,RETINITIS PIGMENTOSA 12; RP12	DOID:0050572,('cone-rod dystrophy',),3,0.0006;DOID:0005419,('schizophrenia',),2,0.0000;DOID:0010584,('retinitis pigmentosa',),3,0.0000	
F35G12.8,ZC8.4,M106.1,F28B3.7	0.0441,MI:cel-miR-245,MI:cel-miR-245;0.0500,MI:cel-miR-235,MI:cel-miR-235	Q9NTJ3,Q5TZA2,O95347,Q14683	OMIM:122470,CORNELIA DE LANGE SYNDROME 1; CDLS1;OMIM:615222,SMITH-MCCORT DYSPLASIA 2; SMC2;OMIM:605130,WIEDEMANN-STEINER SYNDROME; WDSTS		
Y77E11A.13,ZK328.5,Y113G7A.3,ZC518.2,ZK180.4,F12F6.6	0.0479,MI:cel-miR-254,MI:cel-miR-254;0.0400,MI:cel-miR-271,MI:cel-miR-271;0.0411,MI:cel-miR-244,MI:cel-miR-244;0.0500,MI:cel-miR-250,MI:cel-miR-250	P55735,Q9Y6B6,Q15436,P53992,O95487,P52948	OMIM:246700,CHYLOMICRON RETENTION DISEASE; CMRD;OMIM:182940,NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO; NTD;OMIM:607812,CRANIOLENTICULOSUTURAL DYSPLASIA; CLSD;OMIM:181500,SCHIZOPHRENIA; SCZD;OMIM:209850,AUTISM	DOID:0005419,('schizophrenia',),5,0.0000;DOID:0012849,('autistic disorder',),4,0.0000	
Y104H12BR.1,F38E9.5,K08E3.4,C38C3.5,C04F6.4	0.0500,MI:cel-miR-232,MI:cel-miR-232;0.0486,MI:cel-miR-256,MI:cel-miR-256;0.0453,MI:cel-miR-264,MI:cel-miR-264	Q6IBS0,Q16643,Q9Y281	OMIM:610687,NEMALINE MYOPATHY 7; NEM7		CORUM:87
R06C7.5,F38B6.4,F25B4.1,C55F2.1,C05D11.11	0.0500,MI:cel-miR-786,MI:cel-miR-786;0.0403,MI:cel-miR-65,MI:cel-miR-65;0.0391,MI:cel-miR-251,MI:cel-miR-251;0.0343,MI:cel-miR-86,MI:cel-miR-86;0.0376,MI:cel-miR-252,MI:cel-miR-252;0.0413,MI:cel-miR-64,MI:cel-miR-64	P48728,P31939,P34896,P22102,P30566	OMIM:182940,NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO; NTD;OMIM:209850,AUTISM;OMIM:605899,GLYCINE ENCEPHALOPATHY; GCE;OMIM:103050,ADENYLOSUCCINASE DEFICIENCY;OMIM:608688,AICAR TRANSFORMYLASE/IMP CYCLOHYDROLASE DEFICIENCY	DOID:0012849,('autistic disorder',),5,0.0000;DOID:0009268,('glycine encephalopathy',),3,0.0374	
H20J04.2,ZC155.7,D1014.3,Y57G11C.4,F56A8.7	0.0500,MI:cel-miR-44,MI:cel-miR-44;0.0233,MI:cel-miR-1018,MI:cel-miR-1018	Q9NRL2,Q16623,O14662,P54920,Q96AJ9	OMIM:603233,PSEUDOHYPOPARATHYROIDISM, TYPE IB; PHP1B;OMIM:219700,CYSTIC FIBROSIS; CF	DOID:0004184,('pseudohypoparathyroidism',),4,0.0465	
M03A8.1,F53C11.3,F26D2.15,T05C12.3	0.0500,GO:0009605,response to external stimulus;0.0389,GO:0009607,response to biotic stimulus;0.0389,GO:0043207,response to external biotic stimulus;0.0389,GO:0051704,multi-organism process;0.0389,GO:0051707,response to other organism;0.0389,GO:0009617,response to bacterium;0.0375,GO:0098542,defense response to other organism;0.0375,GO:0042742,defense response to bacterium;0.0319,GO:0050829,defense response to Gram-negative bacterium;0.0386,MI:cel-miR-258,MI:cel-miR-258;0.0500,MI:cel-miR-79,MI:cel-miR-79	Q16698			
R31.1,T28A8.7,F53H1.1,Y43F4B.6	0.042,GO:0010501,RNA secondary structure unwinding;0.044,GO:0016071,mRNA metabolic process;0.038,GO:0006397,mRNA processing;0.036,GO:0008380,RNA splicing;0.032,GO:0000375,RNA splicing, via transesterification reactions;0.030,GO:0000377,RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;0.030,GO:0000398,mRNA splicing, via spliceosome;0.050,GO:0004386,helicase activity;0.046,GO:0070035,purine NTP-dependent helicase activity;0.046,GO:0003724,RNA helicase activity;0.046,GO:0008186,RNA-dependent ATPase activity;0.046,GO:0008026,ATP-dependent helicase activity;0.046,GO:0004004,ATP-dependent RNA helicase activity	Q9NRC6,O95239,Q7L014,P40692	OMIM:158320,MUIR-TORRE SYNDROME; MRTES;OMIM:300923,MENTAL RETARDATION, X-LINKED 100; MRX100;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:613659,GASTRIC CANCER;OMIM:609310,COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 2; HNPCC2;OMIM:209850,AUTISM;OMIM:176807,PROSTATE CANCER;OMIM:276300,MISMATCH REPAIR CANCER SYNDROME; MMRCS;OMIM:167000,OVARIAN CANCER;OMIM:608089,ENDOMETRIAL CANCER;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0009256,('colorectal cancer',),3,0.0004;DOID:0005419,('schizophrenia',),4,0.0000;DOID:0001520,('colon carcinoma',),3,0.0006;DOID:0012849,('autistic disorder',),4,0.0000	
K08D10.4,ZK1010.2,D2089.4,H20J04.8	0.0458,MI:cel-miR-77,MI:cel-miR-77;0.0500,MI:cel-miR-248,MI:cel-miR-248	P26599,Q9NWS8,P09012	OMIM:614922,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 11; COXPD11		
K12G11.3,T09F3.3,R03G5.1,ZK593.1,T21B10.2,Y87G2A.8,Y75B12B.5,Y75B12B.2,Y17G7B.7,T03F1.3,F33H1.2,K10B3.8,K10B3.7,F31E3.5,T05E11.1,Y57G11C.34	0.05,MI:cel-miR-67,MI:cel-miR-67	Q9Y2R9,Q05639,P06733,P04406,P00558,P30405,P06744,P46782,P60174	OMIM:613470,HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO GLUCOSE PHOSPHATE ISOMERASE DEFICIENCY;OMIM:300653,PHOSPHOGLYCERATE KINASE 1 DEFICIENCY;OMIM:615512,TRIOSEPHOSPHATE ISOMERASE DEFICIENCY; TPID	DOID:0002861,('congenital nonspherocytic hemolytic anemia',),11,0.0000;DOID:0050884,('triosephosphate isomerase deficiency',),8,0.0000	
M03A8.1,F53C11.3,T05C12.3,F25D1.5	0.0389,GO:0009607,response to biotic stimulus;0.0389,GO:0051704,multi-organism process;0.0500,GO:0009605,response to external stimulus;0.0389,GO:0043207,response to external biotic stimulus;0.0389,GO:0051707,response to other organism;0.0389,GO:0009617,response to bacterium;0.0375,GO:0098542,defense response to other organism;0.0375,GO:0042742,defense response to bacterium;0.0319,GO:0050829,defense response to Gram-negative bacterium;0.0500,MI:cel-miR-79,MI:cel-miR-79;0.0390,MI:cel-miR-1018,MI:cel-miR-1018	Q16698			
M03A8.1,F53C11.3,T05C12.3,R08H2.1	0.0500,GO:0009605,response to external stimulus;0.0389,GO:0009607,response to biotic stimulus;0.0389,GO:0043207,response to external biotic stimulus;0.0389,GO:0051704,multi-organism process;0.0389,GO:0051707,response to other organism;0.0389,GO:0009617,response to bacterium;0.0375,GO:0098542,defense response to other organism;0.0375,GO:0042742,defense response to bacterium;0.0319,GO:0050829,defense response to Gram-negative bacterium;0.0500,MI:cel-miR-79,MI:cel-miR-79	Q16698			
F21C3.2,Y44E3B.2,C02C2.1		P14679	OMIM:606952,ALBINISM, OCULOCUTANEOUS, TYPE IB; OCA1B;OMIM:601800,SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 3; SHEP3;OMIM:155600,MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1;OMIM:606579,VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1; VAMAS1;OMIM:103470,ALBINISM, OCULAR, WITH SENSORINEURAL DEAFNESS;OMIM:203100,ALBINISM, OCULOCUTANEOUS, TYPE IA; OCA1A		
Y43E12A.1,ZK593.5,C17H12.1		Q14203,Q13409	OMIM:168605,PERRY SYNDROME;OMIM:105400,AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1;OMIM:607641,NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB; HMN7B		
D1037.3,Y105C5B.9,C54F6.14		Q5SRE7,P02794	OMIM:615517,HEMOCHROMATOSIS, TYPE 5; HFE5		
B0511.13,ZK546.15,T21C9.4		Q8NF86,Q53F39,P84090			
C24F3.4,ZK353.7,Y56A3A.13		Q6IA69,Q86X76,Q9NTM9			
Y37A1C.1,Y59A8B.10,F26B1.2		P61978,P55011,Q9UNW9			
F32B6.2,W09B6.1,D2023.2		Q96RQ3,P11498,Q13085	OMIM:266150,PYRUVATE CARBOXYLASE DEFICIENCY;OMIM:176860,THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL DOMINANT; THPH3;OMIM:613933,ACETYL-CoA CARBOXYLASE DEFICIENCY; ACACAD;OMIM:210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D;OMIM:612304,THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL RECESSIVE; THPH4;OMIM:167000,OVARIAN CANCER	DOID:0050710,('3-Methylcrotonyl-CoA carboxylase deficiency',),3,0.0260	
T20H4.5,Y45G12B.1,ZC477.9,Y54F10AM.5	0.05000,GO:1901135,carbohydrate derivative metabolic process;0.01560,GO:1901657,glycosyl compound metabolic process;0.04370,GO:0019637,organophosphate metabolic process;0.01460,GO:0019693,ribose phosphate metabolic process;0.03120,GO:0055086,nucleobase-containing small molecule metabolic process;0.02500,GO:0006753,nucleoside phosphate metabolic process;0.00625,GO:0009141,nucleoside triphosphate metabolic process;0.00625,GO:0009144,purine nucleoside triphosphate metabolic process;0.00521,GO:0009199,ribonucleoside triphosphate metabolic process;0.00521,GO:0009205,purine ribonucleoside triphosphate metabolic process;0.00729,GO:0009123,nucleoside monophosphate metabolic process;0.00729,GO:0009161,ribonucleoside monophosphate metabolic process;0.00521,GO:0009126,purine nucleoside monophosphate metabolic process;0.00521,GO:0009167,purine ribonucleoside monophosphate metabolic process;0.02500,GO:0009117,nucleotide metabolic process;0.01350,GO:0009259,ribonucleotide metabolic process;0.01150,GO:0006091,generation of precursor metabolites and energy;0.03230,GO:0055114,oxidation-reduction process;0.01150,GO:0015980,energy derivation by oxidation of organic compounds;0.00729,GO:0045333,cellular respiration;0.02080,GO:0072521,purine-containing compound metabolic process;0.01250,GO:0006163,purine nucleotide metabolic process;0.01040,GO:0009150,purine ribonucleotide metabolic process;0.00417,GO:0022900,electron transport chain;0.00417,GO:0022904,respiratory electron transport chain;0.01560,GO:0009116,nucleoside metabolic process;0.01350,GO:0009119,ribonucleoside metabolic process;0.01250,GO:0042278,purine nucleoside metabolic process;0.01040,GO:0046128,purine ribonucleoside metabolic process;0.00521,GO:0046034,ATP metabolic process;0.00417,GO:0006119,oxidative phosphorylation;0.00417,GO:0042773,ATP synthesis coupled electron transport;0.00417,GO:0042775,mitochondrial ATP synthesis coupled electron transport;0.00313,GO:0006120,mitochondrial electron transport, NADH to ubiquinone;0.00208,GO:0042493,response to drug	P28331,O00217,P18206,P51970	OMIM:613255,CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 15; CMH15;OMIM:252010,MITOCHONDRIAL COMPLEX I DEFICIENCY;OMIM:115200,CARDIOMYOPATHY, DILATED, 1A; CMD1A;OMIM:611407,CARDIOMYOPATHY, DILATED, 1W; CMD1W;OMIM:256000,LEIGH SYNDROME; LS	DOID:0012930,('dilated cardiomyopathy',),2,0.0001	
R02E12.2,T19A5.2,C14A4.11		Q9Y376,O00506,Q9BUL8	OMIM:603285,CEREBRAL CAVERNOUS MALFORMATIONS 3; CCM3		
F31C3.5,Y113G7B.24,R53.6		Q9Y248,Q9BRT9,Q14691			
C26D10.2,Y53G8AR.6,C28H8.3		O00148,P82979,Q8IY21			
W04A8.7,Y37E11B.4		Q6P1X5,P21675	OMIM:209850,AUTISM;OMIM:615599,MENTAL RETARDATION, AUTOSOMAL RECESSIVE 40; MRT40;OMIM:314250,DYSTONIA 3, TORSION, X-LINKED; DYT3;OMIM:143465,ATTENTION DEFICIT-HYPERACTIVITY DISORDER; ADHD	DOID:0012849,('autistic disorder',),2,0.0000	
F47G9.1,W02D7.7		Q15363,P49755			
B0361.10,F55A4.1		O15498,O75396			
T27F7.1,Y46G5A.12		O43633,Q9Y3E7	OMIM:181500,SCHIZOPHRENIA; SCZD		
F25H2.4,Y57G7A.10		Q9Y3B6,Q15006			
F23B12.6,R02D3.5		P49356,P49354			
Y71G12B.24,ZC410.2		Q10713,O75439			
R07E5.8,Y47D3A.4		P13010,P12956			
C34C12.5,F14D12.2		Q15404,Q7Z4I7			
C05D11.9,C15C6.4		O95707,Q99575	OMIM:211980,LUNG CANCER;OMIM:607095,ANAUXETIC DYSPLASIA	DOID:0001324,('lung cancer',),2,0.0007	
F26D12.1,ZK1151.1		Q9UPN3	OMIM:209850,AUTISM		
B0250.5,M153.1		P32322,P31937	OMIM:219100,CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IA; ARCL1A;OMIM:614438,CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIB; ARCL3B;OMIM:219150,CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIA; ARCL3A;OMIM:612940,CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB; ARCL2B		
F57F5.5,PAR2.3		Q02156			
C26G2.1,F48E3.8		O60500	OMIM:256300,NEPHROTIC SYNDROME, TYPE 1; NPHS1		
F59F4.1,F56H11.1		Q15067,P23142	OMIM:219050,CRYPTORCHIDISM, UNILATERAL OR BILATERAL;OMIM:264470,PEROXISOMAL ACYL-CoA OXIDASE DEFICIENCY;OMIM:608180,SYNPOLYDACTYLY 2; SPD2		
K11C4.4,C54G4.1		P11926,O75582	OMIM:114500,COLORECTAL CANCER; CRC	DOID:0009256,('colorectal cancer',),2,0.0000;DOID:0001520,('colon carcinoma',),2,0.0000	
F57C9.1,F07A11.5		O00764,Q9H477			
F58H1.3,R151.10		Q9UHY7			
F10B5.5,C04A11.4		Q15645,O43184	OMIM:165720,OSTEOARTHRITIS SUSCEPTIBILITY 1; OS1		
T20B5.1,F02E8.3		O94973,P53680	OMIM:600740,HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3		
C24H11.7,Y47G6A.18,T24B1.1		Q8TBA6,Q92538,Q9H4A6	OMIM:114500,COLORECTAL CANCER; CRC;OMIM:188550,THYROID CANCER, NONMEDULLARY, 1; NMTC1		
F23H11.3,F47B10.1,C05G5.4		P53597,Q9P2R7	OMIM:245400,MITOCHONDRIAL DNA DEPLETION SYNDROME 9 (ENCEPHALOMYOPATHIC TYPE WITH METHYLMALONIC ACIDURIA); MTDPS9;OMIM:612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5;OMIM:180200,RETINOBLASTOMA; RB1;OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),2,0.0000	
C10C5.5,C34B2.5,C10C5.4,C10C5.3	0.05,MI:cel-miR-256,MI:cel-miR-256	Q03154,Q99614	OMIM:609924,AMINOACYLASE 1 DEFICIENCY; ACY1D		
Y56A3A.32,H24K24.5,C26D10.3,C17G10.8	0.050,MI:cel-miR-799,MI:cel-miR-799;0.048,MI:cel-miR-359,MI:cel-miR-359;0.050,MI:cel-miR-790,MI:cel-miR-790	Q6YN16,P49326,O95831,Q8WU10	OMIM:300816,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 6; COXPD6;OMIM:310490,COWCHOCK SYNDROME; COWCK;OMIM:236600,HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 1; HYC1		
R03G5.2,Y54E10BL.6,ZK678.5,F13B9.5	0.0467,MI:cel-miR-64,MI:cel-miR-64;0.0451,MI:cel-miR-47,MI:cel-miR-47;0.0455,MI:cel-miR-65,MI:cel-miR-65;0.0500,MI:cel-miR-66,MI:cel-miR-66;0.0497,MI:cel-miR-63,MI:cel-miR-63;0.0436,MI:cel-miR-46,MI:cel-miR-46	P52564,P36507,Q6VAB6	OMIM:209850,AUTISM;OMIM:615280,CARDIOFACIOCUTANEOUS SYNDROME 4; CFC4;OMIM:115150,CARDIOFACIOCUTANEOUS SYNDROME 1; CFC1;OMIM:601665,OBESITY		
ZC504.4,R07G3.1,C32D5.2,ZK377.2	0.0380,MI:cel-miR-1018,MI:cel-miR-1018;0.0500,MI:cel-miR-58,MI:cel-miR-58;0.0431,MI:cel-miR-243,MI:cel-miR-243;0.0445,MI:cel-miR-788,MI:cel-miR-788	Q9HCK4,P60953,Q7Z2Y5,O00238	OMIM:112600,BRACHYDACTYLY, TYPE A2; BDA2;OMIM:609441,ACROMESOMELIC DYSPLASIA, DEMIRHAN TYPE; AMDD;OMIM:113100,BRACHYDACTYLY, TYPE C; BDC;OMIM:193000,VESICOURETERAL REFLUX 1; VUR1;OMIM:610878,VESICOURETERAL REFLUX 2; VUR2;OMIM:178600,PULMONARY HYPERTENSION, PRIMARY, 1; PPH1		
C18E3.2,F09E5.1,C30F8.2		P61421,P41743			
K02F2.1,K07C5.5,B0464.9		Q86TI2,Q9Y570			
K08H10.9,ZK1098.5,Y57A10A.16		O43617,Q8IUR0,Q86SZ2			
F42F12.4,Y47D3A.21,C11D2.7		Q9BV57,O43583,Q9ULC4	OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),2,0.0000	
T12F5.4,T13H2.5					
F33E11.6,Y48G1A.6		Q8WUB8			
C47E12.5,W02A11.4		Q9UBT2,P22314	OMIM:301830,SPINAL MUSCULAR ATROPHY, X-LINKED 2; SMAX2		
D2045.6,ZK287.5		Q13616,P62877			
Y47G6A.22,C07B5.5					
F37F2.2,F21D5.7		P09132,P61011			
F43D9.2,W06A7.3		Q9H082,O95197	OMIM:615222,SMITH-MCCORT DYSPLASIA 2; SMC2;OMIM:156530,METATROPIC DYSPLASIA;OMIM:223800,DYGGVE-MELCHIOR-CLAUSEN DISEASE; DMC;OMIM:607326,SMITH-MCCORT DYSPLASIA 1; SMC1		
B0218.3,C44C8.6		Q16539			
ZK1290.12,Y16B4A.1,ZK377.1,D2030.6,F29F11.1	0.0479,MI:cel-miR-58,MI:cel-miR-58;0.0500,MI:cel-miR-232,MI:cel-miR-232	Q96J94,O60701,Q9UH73			
Y110A7A.8,Y46G5A.4,K03H1.2,K07C5.6,Y55F3AM.3	0.05,GO:0000375,RNA splicing, via transesterification reactions;0.05,GO:0005681,spliceosomal complex	Q8WWY3,Q92620,Q14498,O75643,O95391	OMIM:204000,LEBER CONGENITAL AMAUROSIS 1; LCA1;OMIM:600138,RETINITIS PIGMENTOSA 11; RP11;OMIM:120300,COLOBOMA OF MACULA;OMIM:610359,RETINITIS PIGMENTOSA 33; RP33;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP	DOID:0050572,('cone-rod dystrophy',),5,0.0062;DOID:0010584,('retinitis pigmentosa',),5,0.0002	
F54D5.12,Y106G6H.2,F58D5.1,F28C6.6,F56A8.6,R10E9.1,D1007.7	0.050,MI:cel-miR-257,MI:cel-miR-257;0.038,MI:cel-miR-251,MI:cel-miR-251	O95104,Q9H0L4,Q12996,P11940,Q96DH6,O43390,Q8N465	OMIM:600721,D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1	DOID:0050575,('D-2-hydroxyglutaric aciduria',),7,0.0000	
Y106G6H.2,F58D5.1,F44A6.1,F28C6.6,F56A8.6,R10E9.1,D1007.7	0.050,MI:cel-miR-257,MI:cel-miR-257;0.038,MI:cel-miR-251,MI:cel-miR-251	P80303,Q9H0L4,Q12996,P11940,O95104,O43390,Q96DH6	OMIM:601665,OBESITY		
F58A6.1,Y25C1A.13		Q13011			
Y50D4C.1,Y54E5B.1		Q9H2E6,Q8N8S7			
R12C12.2,Y116A8C.12		P62330			
R09E10.7,W03F8.5		A7E2V4,P07942	OMIM:615191,LISSENCEPHALY 5; LIS5;OMIM:209850,AUTISM		
F42H10.7,T26A5.4		Q9BT22,Q96DF8	OMIM:608540,CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik; CDG1K;OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),2,0.0000	
C14B9.1,T22A3.2		P02511	OMIM:613763,CATARACT 16, MULTIPLE TYPES; CTRCT16;OMIM:613869,MYOPATHY, MYOFIBRILLAR, FATAL INFANTILE HYPERTONIC, ALPHA-B CRYSTALLIN-RELATED;OMIM:115200,CARDIOMYOPATHY, DILATED, 1A; CMD1A;OMIM:615184,CARDIOMYOPATHY, DILATED, 1II; CMD1II;OMIM:116800,CATARACT 5, MULTIPLE TYPES; CTRCT5;OMIM:608810,MYOPATHY, MYOFIBRILLAR, 2; MFM2	DOID:0012930,('dilated cardiomyopathy',),2,0.0001	
C45H4.17,T10B9.10		P20815	OMIM:145500,HYPERTENSION, ESSENTIAL		
C01G6.1,F40F9.9		Q92482	OMIM:607457,GIL BLOOD GROUP		
T07D3.9,Y54G11A.3		Q9NXZ2,Q9Y305			
F32B6.3,T01B7.4		Q99633,O43447			
Y82E9BR.18,C48B4.1,F54D5.7		O60524,Q92947	OMIM:231670,GLUTARIC ACIDEMIA I		
F53G2.7,F38B7.5,W03A5.7		O75190,P51948	OMIM:603511,MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1E; LGMD1E		
K02F2.3,K08D10.4,D2089.4,H20J04.8,K08D10.3	0.0500,MI:cel-miR-77,MI:cel-miR-77;0.0494,MI:cel-miR-230,MI:cel-miR-230	P26599,Q15393,P09012			
T14D7.1,T25B9.1,T01C8.5,C32F10.8	0.017400,GO:0044283,small molecule biosynthetic process;0.050000,GO:0006082,organic acid metabolic process;0.050000,GO:0043436,oxoacid metabolic process;0.050000,GO:0019752,carboxylic acid metabolic process;0.019600,GO:0006520,cellular amino acid metabolic process;0.017400,GO:1901605,alpha-amino acid metabolic process;0.009780,GO:0009069,serine family amino acid metabolic process;0.003260,GO:0006544,glycine metabolic process;0.012000,GO:0016053,organic acid biosynthetic process;0.012000,GO:0046394,carboxylic acid biosynthetic process;0.009780,GO:0008652,cellular amino acid biosynthetic process;0.009780,GO:1901607,alpha-amino acid biosynthetic process;0.006520,GO:0009070,serine family amino acid biosynthetic process;0.002170,GO:0006545,glycine biosynthetic process;0.001090,GO:0019265,glycine biosynthetic process, by transamination of glyoxylate;0.012000,GO:0042579,microbody;0.012000,GO:0005777,peroxisome;0.004350,GO:0016769,transferase activity, transferring nitrogenous groups;0.004350,GO:0008483,transaminase activity;0.002170,GO:0008453,alanine-glyoxylate transaminase activity;0.001090,GO:0004760,serine-pyruvate transaminase activity;0.050000,MI:cel-miR-232,MI:cel-miR-232;0.000999,MI:cel-miR-54,MI:cel-miR-54;0.046000,MI:cel-miR-787,MI:cel-miR-787;0.042600,MI:cel-miR-788,MI:cel-miR-788	P17174,P21549,P24298,O75600	OMIM:259900,HYPEROXALURIA, PRIMARY, TYPE I; HP1;OMIM:614419,ASPARTATE AMINOTRANSFERASE, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1		CORUM:2920
Y60A3A.1,R07B7.11,Y108G3AL.1,C27A12.5	0.05,MI:cel-lsy-6,MI:cel-lsy-6	A6NJ46,Q13618,Q8IYT8,P06280	OMIM:301500,FABRY DISEASE;OMIM:209850,AUTISM;OMIM:614496,PSEUDOHYPOALDOSTERONISM, TYPE IIE; PHA2E;OMIM:601367,STROKE, ISCHEMIC;OMIM:145260,PSEUDOHYPOALDOSTERONISM, TYPE IIA; PHA2A;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0012849,('autistic disorder',),2,0.0000;DOID:0014499,('Fabry disease',),3,0.0056;DOID:0005419,('schizophrenia',),2,0.0000	
F21H12.6,F54E4.1,C51E3.7		P29144,P16519,Q9Y485	OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),2,0.0000	
T25B9.1,T01C8.5,T04F3.1,C32F10.8	0.0500,MI:cel-miR-54,MI:cel-miR-54;0.0435,MI:cel-miR-359,MI:cel-miR-359;0.0349,MI:cel-miR-251,MI:cel-miR-251;0.0394,MI:cel-miR-1,MI:cel-miR-1;0.0452,MI:cel-miR-790,MI:cel-miR-790;0.0336,MI:cel-miR-252,MI:cel-miR-252;0.0378,MI:cel-miR-787,MI:cel-miR-787;0.0350,MI:cel-miR-788,MI:cel-miR-788;0.0456,MI:cel-miR-248,MI:cel-miR-248	P17174,P24298,O75600	OMIM:614419,ASPARTATE AMINOTRANSFERASE, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1		
T13C2.4,T23F11.1,F48E3.3,F10G8.9	0.0463,MI:cel-miR-264,MI:cel-miR-264;0.0500,MI:cel-miR-356,MI:cel-miR-356;0.0480,MI:cel-miR-392,MI:cel-miR-392;0.0496,MI:cel-miR-256,MI:cel-miR-256;0.0422,MI:cel-miR-243,MI:cel-miR-243;0.0477,MI:cel-miR-59,MI:cel-miR-59;0.0425,MI:cel-miR-793,MI:cel-miR-793	Q9NWU1,Q9NYU2,Q9NP77			
K09A9.5,T10E9.7,F22D6.4,T26A5.3	0.0431,MI:cel-miR-797,MI:cel-miR-797;0.0430,MI:cel-miR-245,MI:cel-miR-245;0.0500,MI:cel-miR-273,MI:cel-miR-273	O75489,O75306,O75380	OMIM:252010,MITOCHONDRIAL COMPLEX I DEFICIENCY;OMIM:256000,LEIGH SYNDROME; LS		CORUM:1737
Y54F10BM.14,T08A11.2,W03F9.10,C08B11.5	0.0500,GO:0005488,binding;0.0329,GO:0005515,protein binding;0.0500,MI:cel-miR-72,MI:cel-miR-72;0.0220,MI:cel-miR-265,MI:cel-miR-265	Q7RTV0,Q13435,O75533,Q15427	OMIM:614286,MYELODYSPLASTIC SYNDROME; MDS;OMIM:154400,ACROFACIAL DYSOSTOSIS 1, NAGER TYPE; AFD1		
F36H1.1,Y18D10A.19,C56C10.10,B0261.2	0.035,MI:cel-miR-796,MI:cel-miR-796;0.050,MI:cel-miR-1,MI:cel-miR-1	O00170,P26885,P42345,P62942	OMIM:219090,PITUITARY ADENOMA, ACTH-SECRETING;OMIM:155350,MEGALENCEPHALY, AUTOSOMAL DOMINANT;OMIM:102200,PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 1; PAGH1;OMIM:600634,PITUITARY ADENOMA, PROLACTIN-SECRETING;OMIM:248000,MACROCEPHALY/MEGALENCEPHALY SYNDROME, AUTOSOMAL RECESSIVE; MGCPH		
F07H5.8,K04F10.7,F59F3.1,C50F7.10	0.01550,GO:0070646,protein modification by small protein removal;0.00517,GO:0000338,protein deneddylation;0.01210,GO:0019783,ubiquitin-like protein-specific protease activity;0.00172,GO:0019784,NEDD8-specific protease activity;0.05000,MI:cel-miR-79,MI:cel-miR-79;0.05000,MI:cel-miR-253,MI:cel-miR-253;0.04860,MI:cel-miR-354,MI:cel-miR-354	Q9H227,Q5HYJ3			CORUM:2901;CORUM:2903;CORUM:2905;CORUM:2904;CORUM:2920;CORUM:2948
ZK1127.5,R13A5.12,K12H4.3,Y46E12BL.2,T22H9.1,K09H9.6,ZK945.3,ZK430.7,Y105E8B.3,F58B3.4,Y54H5A.1,T19A6.2,T07A9.9,K01G5.5,Y45F10D.7,Y71G12B.8,W07E6.1,Y54E10A.10,Y75B8A.7,Y94H6A.5,Y23H5B.5,H20J04.4,Y73E7A.2,Y61A9LA.10,Y52B11A.10,Y48G1A.4,Y48B6A.1,F54C9.9,Y39B6A.33,F57B9.5,F55F8.5,H06I04.3,F32E10.1,F13H8.2,K01C8.9,F10E7.5,ZK512.2,K07C5.4,JC8.2,F55F8.2,C05C8.2,F55F8.3,F11A10.7,C24H12.4,C16A3.3,C15H11.9,C07E3.2,C06E1.10,F10G7.1,Y53C12B.1,F28D1.1,C48B6.2,C18A3.3,C43E11.9,C37H5.5,B0491.7,F44G4.1,B0511.6	2.98e-02,GO:0006356,regulation of transcription from RNA polymerase I promoter;2.98e-02,GO:0045943,positive regulation of transcription from RNA polymerase I promoter;2.98e-02,GO:1990481,mRNA pseudouridine synthesis;2.98e-02,GO:0018202,peptidyl-histidine modification;2.98e-02,GO:0017182,peptidyl-diphthamide metabolic process;2.98e-02,GO:0017183,peptidyl-diphthamide biosynthetic process from peptidyl-histidine;2.98e-02,GO:0043467,regulation of generation of precursor metabolites and energy;2.98e-02,GO:0043457,regulation of cellular respiration;2.98e-02,GO:1901857,positive regulation of cellular respiration;1.06e-06,GO:0043170,macromolecule metabolic process;2.21e-07,GO:0044260,cellular macromolecule metabolic process;2.15e-09,GO:0010467,gene expression;1.51e-13,GO:0006725,cellular aromatic compound metabolic process;2.85e-13,GO:0046483,heterocycle metabolic process;3.90e-13,GO:1901360,organic cyclic compound metabolic process;9.77e-08,GO:0071840,cellular component organization or biogenesis;5.70e-15,GO:0044085,cellular component biogenesis;3.49e-18,GO:0022613,ribonucleoprotein complex biogenesis;1.23e-19,GO:0042254,ribosome biogenesis;1.20e-08,GO:0042274,ribosomal small subunit biogenesis;5.82e-06,GO:0042273,ribosomal large subunit biogenesis;2.63e-02,GO:0043933,macromolecular complex subunit organization;6.77e-04,GO:0071826,ribonucleoprotein complex subunit organization;1.61e-02,GO:0022607,cellular component assembly;3.35e-05,GO:0070925,organelle assembly;5.37e-03,GO:0065003,macromolecular complex assembly;4.81e-03,GO:0034622,cellular macromolecular complex assembly;4.39e-04,GO:0022618,ribonucleoprotein complex assembly;1.15e-05,GO:0042255,ribosome assembly;3.95e-05,GO:0000027,ribosomal large subunit assembly;9.43e-11,GO:0006807,nitrogen compound metabolic process;1.75e-11,GO:0034641,cellular nitrogen compound metabolic process;1.35e-13,GO:0006139,nucleobase-containing compound metabolic process;1.92e-15,GO:0090304,nucleic acid metabolic process;1.02e-16,GO:0016070,RNA metabolic process;2.04e-06,GO:0010501,RNA secondary structure unwinding;8.63e-17,GO:0034660,ncRNA metabolic process;2.98e-02,GO:0016073,snRNA metabolic process;1.48e-19,GO:0016072,rRNA metabolic process;2.98e-02,GO:0016074,snoRNA metabolic process;2.98e-02,GO:0033979,box H/ACA snoRNA metabolic process;5.00e-02,GO:0009451,RNA modification;2.98e-02,GO:0040031,snRNA modification;2.98e-02,GO:0031120,snRNA pseudouridine synthesis;2.39e-14,GO:0006396,RNA processing;3.15e-17,GO:0034470,ncRNA processing;2.98e-02,GO:0043144,snoRNA processing;2.98e-02,GO:0034964,box H/ACA snoRNA processing;2.98e-02,GO:0031126,snoRNA 3'-end processing;2.98e-02,GO:0000495,box H/ACA snoRNA 3'-end processing;1.48e-19,GO:0006364,rRNA processing;7.13e-09,GO:0030490,maturation of SSU-rRNA;3.92e-08,GO:0000462,maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);1.00e-05,GO:0000470,maturation of LSU-rRNA;5.56e-04,GO:0000463,maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);3.26e-03,GO:0000154,rRNA modification;1.87e-07,GO:0032991,macromolecular complex;1.12e-13,GO:1990904,ribonucleoprotein complex;1.12e-13,GO:0030529,intracellular ribonucleoprotein complex;4.05e-18,GO:0030684,preribosome;6.60e-13,GO:0030686,90S preribosome;1.65e-03,GO:0030687,preribosome, large subunit precursor;5.07e-14,GO:0032040,small-subunit processome;5.37e-03,GO:0005732,small nucleolar ribonucleoprotein complex;1.68e-04,GO:0043234,protein complex;1.40e-05,GO:0043226,organelle;1.02e-15,GO:0043228,non-membrane-bounded organelle;1.83e-06,GO:0043227,membrane-bounded organelle;5.36e-10,GO:0044422,organelle part;7.51e-18,GO:0031974,membrane-enclosed lumen;2.85e-18,GO:0043233,organelle lumen;8.05e-06,GO:0043229,intracellular organelle;1.02e-15,GO:0043232,intracellular non-membrane-bounded organelle;1.24e-11,GO:0044446,intracellular organelle part;2.85e-18,GO:0070013,intracellular organelle lumen;1.01e-06,GO:0043231,intracellular membrane-bounded organelle;6.85e-14,GO:0005634,nucleus;2.35e-17,GO:0044428,nuclear part;2.98e-02,GO:0005697,telomerase holoenzyme complex;1.67e-20,GO:0031981,nuclear lumen;2.98e-02,GO:0072588,box H/ACA RNP complex;4.54e-24,GO:0005730,nucleolus;1.40e-14,GO:0044452,nucleolar part;2.98e-02,GO:0031428,box C/D snoRNP complex;1.65e-03,GO:0034457,Mpp10 complex;8.54e-07,GO:0034388,Pwp2p-containing subcomplex of 90S preribosome;2.98e-02,GO:0070545,PeBoW complex;2.98e-02,GO:0031429,box H/ACA snoRNP complex;2.98e-02,GO:0080008,Cul4-RING E3 ubiquitin ligase complex;1.40e-02,GO:0005488,binding;1.94e-06,GO:0097159,organic cyclic compound binding;2.75e-02,GO:0044877,macromolecular complex binding;1.94e-06,GO:1901363,heterocyclic compound binding;5.59e-08,GO:0003676,nucleic acid binding;6.31e-09,GO:0003723,RNA binding;1.98e-08,GO:0030515,snoRNA binding;1.10e-02,GO:0019843,rRNA binding;2.98e-02,GO:0004164,diphthine synthase activity;6.94e-04,GO:0016817,hydrolase activity, acting on acid anhydrides;6.94e-04,GO:0016818,hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides;6.94e-04,GO:0016462,pyrophosphatase activity;6.94e-04,GO:0017111,nucleoside-triphosphatase activity;6.32e-06,GO:0004386,helicase activity;3.70e-06,GO:0070035,purine NTP-dependent helicase activity;3.70e-06,GO:0003724,RNA helicase activity;5.07e-05,GO:0016887,ATPase activity;3.55e-05,GO:0042623,ATPase activity, coupled;3.70e-06,GO:0008186,RNA-dependent ATPase activity;3.70e-06,GO:0008026,ATP-dependent helicase activity;3.70e-06,GO:0004004,ATP-dependent RNA helicase activity;4.75e-02,MI:cel-miR-57,MI:cel-miR-57;3.08e-02,MI:cel-miR-268,MI:cel-miR-268;5.00e-02,MI:cel-miR-360,MI:cel-miR-360;3.83e-02,MI:cel-miR-243,MI:cel-miR-243;4.99e-02,MI:cel-miR-239b,MI:cel-miR-239b;4.08e-02,MI:cel-miR-71,MI:cel-miR-71;4.55e-02,MI:cel-miR-270,MI:cel-miR-270;4.44e-02,MI:cel-miR-85,MI:cel-miR-85;4.18e-02,MI:cel-miR-354,MI:cel-miR-354;4.15e-02,MI:cel-miR-264,MI:cel-miR-264;4.75e-02,MI:cel-miR-60,MI:cel-miR-60;5.12e-03,MI:cel-miR-56*,MI:cel-miR-56*;4.70e-02,MI:cel-miR-255,MI:cel-miR-255;4.09e-02,MI:cel-miR-261,MI:cel-miR-261;4.12e-02,MI:cel-miR-73,MI:cel-miR-73;4.61e-02,MI:cel-miR-239a,MI:cel-miR-239a;4.48e-02,MI:cel-miR-245,MI:cel-miR-245	Q12788,Q13823,Q96EU6,Q9H9Y2,Q9Y3T9,Q5C9Z4,Q8NHQ9,Q15269,Q8N9T8,Q9GZL7,P42696,Q9UNX4,Q9NY93,Q9BVS4,Q9H2P9,Q8WTT2,Q9NV06,Q8IY37,Q9NZM5,P78316,O15213,Q13610,P46087,O00541,O00566,Q9NVP1,Q9Y221,Q99848,Q5JTH9,Q9H501,Q13601,Q9BQ67,Q13895,Q9H7B2,Q14690,Q8TDD1,Q14137,Q15397,Q9BZE4,Q9NVN8,Q9BSC4,Q9NQ55,Q9Y6V7,Q8NI36,Q9NV31,Q9UKD2,Q15050,Q8TED0,Q2NL82,Q9NY61,Q9GZR7,O60832,Q8TDN6,O00567,Q8IY81	OMIM:614153,SPINOCEREBELLAR ATAXIA 36; SCA36;OMIM:137760,GLAUCOMA, PRIMARY OPEN ANGLE; POAG;OMIM:609887,GLAUCOMA 1, OPEN ANGLE, G; GLC1G;OMIM:209850,AUTISM;OMIM:305000,DYSKERATOSIS CONGENITA, X-LINKED; DKCX;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0002729,('dyskeratosis congenita',),45,0.0000;DOID:0005419,('schizophrenia',),14,0.0000;DOID:0001441,('spinocerebellar ataxia',),21,0.0000;DOID:0001070,('primary open angle glaucoma',),44,0.0000;DOID:0001067,('open-angle glaucoma',),44,0.0000	
F31D4.5,ZK546.14,Y23H5B.6,F54C9.9	0.042,GO:0010501,RNA secondary structure unwinding;0.050,GO:0004386,helicase activity;0.046,GO:0070035,purine NTP-dependent helicase activity;0.046,GO:0008026,ATP-dependent helicase activity;0.046,GO:0003724,RNA helicase activity;0.046,GO:0008186,RNA-dependent ATPase activity;0.046,GO:0004004,ATP-dependent RNA helicase activity;0.050,MI:cel-miR-261,MI:cel-miR-261	A6NEE1,Q13206,Q8N9T8,O75683			
Y71G12B.10,F17A9.4,F17A9.5,Y73C8C.10	0.0383,MI:cel-miR-62,MI:cel-miR-62;0.0483,MI:cel-miR-67,MI:cel-miR-67;0.0480,MI:cel-miR-238,MI:cel-miR-238;0.0333,MI:cel-miR-785,MI:cel-miR-785;0.0500,MI:cel-miR-246,MI:cel-miR-246	P35914	OMIM:246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD		
T09A5.9,Y38C1AA.3,F56C9.1,C07H6.2	0.03220,GO:0065009,regulation of molecular function;0.01440,GO:0044092,negative regulation of molecular function;0.03110,GO:0050790,regulation of catalytic activity;0.01560,GO:0051336,regulation of hydrolase activity;0.04000,GO:0048519,negative regulation of biological process;0.03440,GO:0048523,negative regulation of cellular process;0.01890,GO:0051174,regulation of phosphorus metabolic process;0.01890,GO:0019220,regulation of phosphate metabolic process;0.05000,GO:0051246,regulation of protein metabolic process;0.03000,GO:0009892,negative regulation of metabolic process;0.01440,GO:0043086,negative regulation of catalytic activity;0.00667,GO:0051346,negative regulation of hydrolase activity;0.02560,GO:0010605,negative regulation of macromolecule metabolic process;0.01780,GO:0051248,negative regulation of protein metabolic process;0.05000,GO:0032268,regulation of cellular protein metabolic process;0.02330,GO:0031399,regulation of protein modification process;0.02780,GO:0031324,negative regulation of cellular metabolic process;0.01110,GO:0010563,negative regulation of phosphorus metabolic process;0.01110,GO:0045936,negative regulation of phosphate metabolic process;0.01780,GO:0032269,negative regulation of cellular protein metabolic process;0.01110,GO:0031400,negative regulation of protein modification process;0.02110,GO:0016311,dephosphorylation;0.00556,GO:0035303,regulation of dephosphorylation;0.00444,GO:0035305,negative regulation of dephosphorylation;0.02000,GO:0006470,protein dephosphorylation;0.00556,GO:0035304,regulation of protein dephosphorylation;0.00556,GO:0010921,regulation of phosphatase activity;0.00556,GO:0043666,regulation of phosphoprotein phosphatase activity;0.00444,GO:0035308,negative regulation of protein dephosphorylation;0.00444,GO:0010923,negative regulation of phosphatase activity;0.00444,GO:0032515,negative regulation of phosphoprotein phosphatase activity;0.00444,GO:1903293,phosphatase complex;0.00444,GO:0008287,protein serine/threonine phosphatase complex;0.00333,GO:0000164,protein phosphatase type 1 complex;0.02330,GO:0098772,molecular function regulator;0.01780,GO:0030234,enzyme regulator activity;0.00444,GO:0019208,phosphatase regulator activity;0.00444,GO:0019888,protein phosphatase regulator activity;0.01220,GO:0004857,enzyme inhibitor activity;0.00333,GO:0019212,phosphatase inhibitor activity;0.00333,GO:0004864,protein phosphatase inhibitor activity;0.00333,GO:0004865,protein serine/threonine phosphatase inhibitor activity;0.01670,GO:0019899,enzyme binding;0.00444,GO:0019902,phosphatase binding;0.00444,GO:0019903,protein phosphatase binding;0.00333,GO:0008157,protein phosphatase 1 binding	Q15435,P62136			
T10B9.5,ZK1127.5,ZK430.7,Y105E8B.3,Y41C4A.9,T23F6.4,Y17G7B.12,H20J04.4,Y61A9LA.10,Y52B11A.10,F57B9.5,C06E1.10,F10G7.1,M01B12.5,C03C10.1	0.023300,GO:0071840,cellular component organization or biogenesis;0.001290,GO:0044085,cellular component biogenesis;0.000395,GO:0022613,ribonucleoprotein complex biogenesis;0.000237,GO:0042254,ribosome biogenesis;0.001280,GO:0042274,ribosomal small subunit biogenesis;0.019100,GO:0043170,macromolecule metabolic process;0.007380,GO:0010467,gene expression;0.000602,GO:0046483,heterocycle metabolic process;0.000532,GO:0006725,cellular aromatic compound metabolic process;0.000639,GO:1901360,organic cyclic compound metabolic process;0.013900,GO:0044260,cellular macromolecule metabolic process;0.001860,GO:0006807,nitrogen compound metabolic process;0.001340,GO:0034641,cellular nitrogen compound metabolic process;0.000521,GO:0006139,nucleobase-containing compound metabolic process;0.000234,GO:0090304,nucleic acid metabolic process;0.000136,GO:0016070,RNA metabolic process;0.000355,GO:0034660,ncRNA metabolic process;0.000128,GO:0016072,rRNA metabolic process;0.000926,GO:0006396,RNA processing;0.000301,GO:0034470,ncRNA processing;0.000128,GO:0006364,rRNA processing;0.001130,GO:0030490,maturation of SSU-rRNA;0.000623,GO:0000462,maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);0.050000,GO:0090501,RNA phosphodiester bond hydrolysis;0.018300,GO:0000469,cleavage involved in rRNA processing;0.036500,GO:0090502,RNA phosphodiester bond hydrolysis, endonucleolytic;0.009180,GO:0000478,endonucleolytic cleavage involved in rRNA processing;0.009180,GO:0000479,endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);0.021000,GO:1990904,ribonucleoprotein complex;0.021000,GO:0030529,intracellular ribonucleoprotein complex;0.004040,GO:0030684,preribosome;0.002580,GO:0032040,small-subunit processome;0.001380,GO:0031974,membrane-enclosed lumen;0.002830,GO:0043228,non-membrane-bounded organelle;0.002830,GO:0043232,intracellular non-membrane-bounded organelle;0.021300,GO:0044422,organelle part;0.001200,GO:0043233,organelle lumen;0.011800,GO:0044446,intracellular organelle part;0.001200,GO:0070013,intracellular organelle lumen;0.008400,GO:0005634,nucleus;0.001630,GO:0044428,nuclear part;0.000583,GO:0031981,nuclear lumen;0.000195,GO:0005730,nucleolus;0.004590,GO:0080008,Cul4-RING E3 ubiquitin ligase complex;0.018300,GO:0004519,endonuclease activity;0.032000,GO:0004540,ribonuclease activity;0.018300,GO:0004521,endoribonuclease activity;0.030000,GO:0097159,organic cyclic compound binding;0.030000,GO:1901363,heterocyclic compound binding;0.014900,GO:0003676,nucleic acid binding;0.009870,GO:0003723,RNA binding;0.032000,GO:0019843,rRNA binding;0.050000,GO:0030515,snoRNA binding;0.004590,GO:0034511,U3 snoRNA binding;0.050000,MI:cel-miR-56*,MI:cel-miR-56*	Q68CQ4,Q9NV06,Q8IY37,Q13895,Q9H9L3,Q9Y4C8,Q5C9Z4,Q2NL82,Q9BRS2,P48729,Q9Y6V7,Q9BVS4	OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),13,0.0000	
R12H7.2,Y16B4A.2,M106.5,C06A6.4,K05G3.3	0.05,GO:0098857,membrane microdomain;0.05,GO:0045121,membrane raft;0.05,MI:cel-miR-267,MI:cel-miR-267	P47756,P07339	OMIM:271900,CANAVAN DISEASE;OMIM:104300,ALZHEIMER DISEASE; AD;OMIM:256730,CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1;OMIM:610127,CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10;OMIM:123400,CREUTZFELDT-JAKOB DISEASE; CJD;OMIM:204500,CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2	DOID:0011949,('Creutzfeldt-Jakob disease',),5,0.0121;DOID:0003613,('Canavan disease',),5,0.0087	
Y48B6A.13,F09E5.15,E04A4.7,F26E4.12,C31E10.7	0.012300,GO:0051186,cofactor metabolic process;0.012300,GO:0006732,coenzyme metabolic process;0.036800,GO:0019637,organophosphate metabolic process;0.024600,GO:0090407,organophosphate biosynthetic process;0.011400,GO:0006790,sulfur compound metabolic process;0.001750,GO:0035383,thioester metabolic process;0.001750,GO:0006637,acyl-CoA metabolic process;0.001750,GO:0006084,acetyl-CoA metabolic process;0.041200,GO:0006629,lipid metabolic process;0.010500,GO:0008610,lipid biosynthetic process;0.027200,GO:0044255,cellular lipid metabolic process;0.002630,GO:0006720,isoprenoid metabolic process;0.009650,GO:0006644,phospholipid metabolic process;0.000877,GO:0046490,isopentenyl diphosphate metabolic process;0.007890,GO:0008654,phospholipid biosynthetic process;0.000877,GO:0008299,isoprenoid biosynthetic process;0.000877,GO:0009240,isopentenyl diphosphate biosynthetic process;0.000877,GO:0019287,isopentenyl diphosphate biosynthetic process, mevalonate pathway;0.037700,GO:0005829,cytosol;0.007020,GO:0016829,lyase activity;0.003510,GO:0016830,carbon-carbon lyase activity;0.001750,GO:0016831,carboxy-lyase activity;0.000877,GO:0004163,diphosphomevalonate decarboxylase activity;0.041800,MI:cel-miR-264,MI:cel-miR-264;0.040400,MI:cel-miR-65,MI:cel-miR-65;0.045700,MI:cel-miR-229,MI:cel-miR-229;0.044000,MI:cel-miR-63,MI:cel-miR-63;0.039200,MI:cel-miR-251,MI:cel-miR-251;0.041400,MI:cel-miR-64,MI:cel-miR-64;0.044300,MI:cel-miR-66,MI:cel-miR-66;0.050000,MI:cel-miR-786,MI:cel-miR-786;0.037800,MI:cel-miR-252,MI:cel-miR-252	P00167,P99999,P53602,P32119	OMIM:202110,ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY;OMIM:612004,THROMBOCYTOPENIA 4; THC4;OMIM:250790,METHEMOGLOBINEMIA TYPE IV		
T04H1.2,Y39G10AR.8,ZK1098.4,Y37E3.10,Y54E2A.11,T27F7.3,Y74C10AR.1,C37C3.2,K04G2.1,F22B5.2	3.58e-02,GO:0043087,regulation of GTPase activity;5.00e-02,GO:0051345,positive regulation of hydrolase activity;3.58e-02,GO:0043547,positive regulation of GTPase activity;9.97e-03,GO:0006807,nitrogen compound metabolic process;2.58e-04,GO:1901564,organonitrogen compound metabolic process;7.26e-03,GO:0034641,cellular nitrogen compound metabolic process;1.89e-05,GO:0043603,cellular amide metabolic process;1.39e-05,GO:0006518,peptide metabolic process;1.44e-03,GO:0009058,biosynthetic process;1.15e-03,GO:1901576,organic substance biosynthetic process;2.35e-05,GO:1901566,organonitrogen compound biosynthetic process;1.21e-03,GO:0010467,gene expression;2.22e-02,GO:0019538,protein metabolic process;1.50e-02,GO:0044267,cellular protein metabolic process;6.61e-04,GO:0044249,cellular biosynthetic process;1.45e-04,GO:0044271,cellular nitrogen compound biosynthetic process;2.02e-06,GO:0043604,amide biosynthetic process;1.34e-06,GO:0043043,peptide biosynthetic process;1.52e-04,GO:0009059,macromolecule biosynthetic process;1.52e-04,GO:0034645,cellular macromolecule biosynthetic process;1.16e-06,GO:0006412,translation;1.88e-08,GO:0006413,translational initiation;7.20e-03,GO:0001731,formation of translation preinitiation complex;2.15e-02,GO:0006446,regulation of translational initiation;7.20e-03,GO:0005850,eukaryotic translation initiation factor 2 complex;7.20e-03,GO:0043614,multi-eIF complex;7.20e-03,GO:0070993,translation preinitiation complex;7.20e-03,GO:0033290,eukaryotic 48S preinitiation complex;1.19e-04,GO:0005851,eukaryotic translation initiation factor 2B complex;5.00e-02,GO:0043021,ribonucleoprotein complex binding;2.87e-02,GO:0043022,ribosome binding;3.03e-02,GO:0005488,binding;3.49e-03,GO:1901363,heterocyclic compound binding;3.49e-03,GO:0097159,organic cyclic compound binding;1.20e-03,GO:0003676,nucleic acid binding;6.40e-04,GO:0003723,RNA binding;4.92e-06,GO:0008135,translation factor activity, RNA binding;8.24e-07,GO:0003743,translation initiation factor activity;3.58e-02,GO:0005085,guanyl-nucleotide exchange factor activity;2.05e-03,GO:0042802,identical protein binding;2.75e-02,GO:0016817,hydrolase activity, acting on acid anhydrides;2.75e-02,GO:0016818,hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides;2.75e-02,GO:0016462,pyrophosphatase activity;2.75e-02,GO:0017111,nucleoside-triphosphatase activity;2.98e-03,GO:0003924,GTPase activity;4.72e-02,MI:cel-miR-87,MI:cel-miR-87;4.18e-02,MI:cel-miR-266,MI:cel-miR-266;4.59e-02,MI:cel-miR-34,MI:cel-miR-34;3.18e-02,MI:cel-miR-1018,MI:cel-miR-1018;5.00e-02,MI:cel-miR-124,MI:cel-miR-124;5.00e-02,MI:cel-miR-273,MI:cel-miR-273;4.07e-02,MI:cel-miR-59,MI:cel-miR-59;4.82e-02,MI:cel-miR-248,MI:cel-miR-248	P20042,P55010,Q9BX10,Q13347,P55884,P05198,O60739,O75821,P41091,Q14232	OMIM:209850,AUTISM;OMIM:300495,AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2;OMIM:603896,LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM	DOID:0012849,('autistic disorder',),9,0.0000	
T25G3.4,T20H4.3,F54A3.4,C49F5.1,C36A4.9,C06E7.1,C06E7.3	0.0374,MI:cel-miR-86,MI:cel-miR-86;0.0497,MI:cel-miR-49,MI:cel-miR-49;0.0453,MI:cel-let-7,MI:cel-let-7;0.0486,MI:cel-miR-256,MI:cel-miR-256;0.0500,MI:cel-miR-249,MI:cel-miR-249;0.0351,MI:cel-miR-785,MI:cel-miR-785	P31153,Q9NR19,P43304	OMIM:125853,DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM		CORUM:5183
Y39G8B.1,R05F9.6,F20H11.3,F19H8.1,T25B9.9,Y24D9A.8,F01G10.1,F08F8.7,R08D7.7	4.17e-02,GO:0009056,catabolic process;3.81e-02,GO:1901575,organic substance catabolic process;5.00e-02,GO:0051186,cofactor metabolic process;5.00e-02,GO:0006732,coenzyme metabolic process;1.80e-02,GO:0006733,oxidoreduction coenzyme metabolic process;3.08e-03,GO:0044710,single-organism metabolic process;3.09e-03,GO:0044712,single-organism catabolic process;4.18e-04,GO:0044281,small molecule metabolic process;7.56e-04,GO:0044282,small molecule catabolic process;3.95e-05,GO:0005975,carbohydrate metabolic process;2.91e-05,GO:0044723,single-organism carbohydrate metabolic process;4.58e-06,GO:0005996,monosaccharide metabolic process;4.98e-06,GO:0019321,pentose metabolic process;3.60e-03,GO:0005997,xylulose metabolic process;7.20e-03,GO:0019318,hexose metabolic process;7.20e-03,GO:0006012,galactose metabolic process;7.20e-03,GO:0006006,glucose metabolic process;4.97e-05,GO:0016052,carbohydrate catabolic process;2.99e-05,GO:0044724,single-organism carbohydrate catabolic process;1.49e-05,GO:0046365,monosaccharide catabolic process;7.20e-03,GO:0019320,hexose catabolic process;7.20e-03,GO:0019388,galactose catabolic process;3.60e-03,GO:0019323,pentose catabolic process;3.94e-02,GO:0006091,generation of precursor metabolites and energy;3.94e-02,GO:0015980,energy derivation by oxidation of organic compounds;1.44e-02,GO:0006112,energy reserve metabolic process;1.80e-02,GO:0072524,pyridine-containing compound metabolic process;1.08e-02,GO:0019362,pyridine nucleotide metabolic process;1.08e-02,GO:0046496,nicotinamide nucleotide metabolic process;7.20e-03,GO:0006739,NADP metabolic process;1.44e-02,GO:0005976,polysaccharide metabolic process;1.44e-02,GO:0044042,glucan metabolic process;5.68e-07,GO:0044262,cellular carbohydrate metabolic process;1.44e-02,GO:0044264,cellular polysaccharide metabolic process;1.44e-02,GO:0006073,cellular glucan metabolic process;1.44e-02,GO:0005977,glycogen metabolic process;7.20e-03,GO:0046835,carbohydrate phosphorylation;7.20e-03,GO:0006081,cellular aldehyde metabolic process;3.60e-03,GO:0019682,glyceraldehyde-3-phosphate metabolic process;3.60e-03,GO:0051156,glucose 6-phosphate metabolic process;5.00e-02,GO:0019693,ribose phosphate metabolic process;3.60e-03,GO:0006098,pentose-phosphate shunt;3.60e-03,GO:0009052,pentose-phosphate shunt, non-oxidative branch;7.20e-03,GO:0016051,carbohydrate biosynthetic process;7.20e-03,GO:0000271,polysaccharide biosynthetic process;7.20e-03,GO:0034637,cellular carbohydrate biosynthetic process;7.20e-03,GO:0033692,cellular polysaccharide biosynthetic process;7.20e-03,GO:0009250,glucan biosynthetic process;7.20e-03,GO:0005978,glycogen biosynthetic process;4.41e-03,GO:0005829,cytosol;1.60e-03,GO:0016853,isomerase activity;1.08e-02,GO:0016854,racemase and epimerase activity;3.60e-03,GO:0016857,racemase and epimerase activity, acting on carbohydrates and derivatives;3.60e-03,GO:0004750,ribulose-phosphate 3-epimerase activity;1.80e-02,GO:0016866,intramolecular transferase activity;1.08e-02,GO:0016868,intramolecular transferase activity, phosphotransferases;7.20e-03,GO:0004614,phosphoglucomutase activity;3.60e-03,GO:0019200,carbohydrate kinase activity;3.60e-03,GO:0004856,xylulokinase activity;5.00e-02,MI:cel-miR-67,MI:cel-miR-67	P36871,P40926,P15121,Q96AT9,P52209,O75191,P37837,P29401	OMIM:614921,CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T;OMIM:114500,COLORECTAL CANCER; CRC;OMIM:271665,SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE;OMIM:115080,CARDIAC CONDUCTION DEFECT;OMIM:606003,TRANSALDOLASE DEFICIENCY;OMIM:601144,BRUGADA SYNDROME 1; BRGDA1	DOID:0005212,('congenital disorder of glycosylation',),8,0.0000;DOID:0009256,('colorectal cancer',),3,0.0002;DOID:0001520,('colon carcinoma',),3,0.0003	
Y80D3A.1,T28A11.11,Y87G2A.5,T11G6.1,F58B3.5	0.0500,MI:cel-miR-228,MI:cel-miR-228;0.0487,MI:cel-miR-800,MI:cel-miR-800;0.0428,MI:cel-miR-230,MI:cel-miR-230	P12081,P23381,P56192,P26640	OMIM:500004,RETINITIS PIGMENTOSA-DEAFNESS SYNDROME;OMIM:615486,INTERSTITIAL LUNG AND LIVER DISEASE; ILLD;OMIM:614504,USHER SYNDROME, TYPE IIIB; USH3B;OMIM:616280,CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2U; CMT2U;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0050572,('cone-rod dystrophy',),2,0.0001;DOID:0010584,('retinitis pigmentosa',),2,0.0000;DOID:0005419,('schizophrenia',),5,0.0000	
Y54E2A.11,T23D8.4,K08F11.3,T27F7.3,Y74C10AR.1,C37C3.2,Y54F10BM.2,D2085.3,F22B5.2,C27D11.1,B0511.10,B0025.2	0.0379,MI:cel-let-7,MI:cel-let-7;0.0366,MI:cel-miR-65,MI:cel-miR-65;0.0465,MI:cel-miR-269,MI:cel-miR-269;0.0479,MI:cel-miR-236,MI:cel-miR-236;0.0395,MI:cel-miR-784,MI:cel-miR-784;0.0392,MI:cel-miR-231,MI:cel-miR-231;0.0441,MI:cel-miR-234,MI:cel-miR-234;0.0414,MI:cel-miR-49,MI:cel-miR-49;0.0370,MI:cel-miR-76,MI:cel-miR-76;0.0375,MI:cel-miR-64,MI:cel-miR-64;0.0465,MI:cel-miR-239b,MI:cel-miR-239b;0.0384,MI:cel-miR-787,MI:cel-miR-787;0.0307,MI:cel-miR-1018,MI:cel-miR-1018;0.0398,MI:cel-miR-83,MI:cel-miR-83;0.0420,MI:cel-miR-238,MI:cel-miR-238	Q13347,P55884,P55010,Q99613,Q13144,Q7L2H7,O75821,O60739,O60841,P61201,P60228,Q14152	OMIM:209850,AUTISM;OMIM:245570,EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT MENTAL RETARDATION; FESD;OMIM:603896,LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM	DOID:0012849,('autistic disorder',),4,0.0000	
K07C5.8,ZK632.7,W10G6.2,E02H4.3	0.05,MI:cel-miR-353,MI:cel-miR-353	Q13033,O00141,Q58A45			
Y55F3AM.15,Y38C1AA.2,Y59A8A.1,Y67H2A.6,B0547.1,B0025.2	0.0500,MI:cel-miR-260,MI:cel-miR-260;0.0407,MI:cel-miR-1,MI:cel-miR-1;0.0376,MI:cel-miR-76,MI:cel-miR-76	Q9BT78,Q92905,Q13098,P61201,Q9UNS2,Q7L5N1	OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),4,0.0000	
Y80D3A.1,T11G6.1,F58B3.5,T05H4.6,R11A8.6,R74.6	0.05,MI:cel-miR-1,MI:cel-miR-1	P41252,P56192,P62495,Q9BRX2,P23381,P12081	OMIM:500004,RETINITIS PIGMENTOSA-DEAFNESS SYNDROME;OMIM:615486,INTERSTITIAL LUNG AND LIVER DISEASE; ILLD;OMIM:614504,USHER SYNDROME, TYPE IIIB; USH3B;OMIM:616280,CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2U; CMT2U;OMIM:120970,CONE-ROD DYSTROPHY 2; CORD2;OMIM:268000,RETINITIS PIGMENTOSA; RP;OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0050572,('cone-rod dystrophy',),5,0.0041;DOID:0010584,('retinitis pigmentosa',),5,0.0001;DOID:0005419,('schizophrenia',),6,0.0000	CORUM:4392;CORUM:4389;CORUM:742;CORUM:4403
F39G3.7,H15N14.2,D1014.3,C41C4.8	0.05,MI:cel-miR-786,MI:cel-miR-786	Q13608,P54920,P55072,P46459	OMIM:614862,PEROXISOME BIOGENESIS DISORDER 4A (ZELLWEGER); PBD4A;OMIM:614863,PEROXISOME BIOGENESIS DISORDER 4B; PBD4B;OMIM:167320,INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA 1; IBMPFD1;OMIM:214100,PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER); PBD1A;OMIM:160750,MYOSITIS;OMIM:600361,HEREDITARY MOTOR AND SENSORY NEUROPATHY V;OMIM:104300,ALZHEIMER DISEASE; AD;OMIM:613954,AMYOTROPHIC LATERAL SCLEROSIS 14 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS14;OMIM:147421,INCLUSION BODY MYOSITIS;OMIM:181430,SCAPULOPERONEAL MYOPATHY, MYH7-RELATED; SPMM;OMIM:310300,EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1;OMIM:187500,TETRALOGY OF FALLOT; TOF		
F46E10.10,F13D12.2,F20H11.3,ZK1320.9		P40926,P07195	OMIM:614128,LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD		
Y34D9A.10,M03C11.5,D2030.2,C37C3.3	0.0489,MI:cel-miR-787,MI:cel-miR-787;0.0500,MI:cel-miR-231,MI:cel-miR-231	Q96TA2,O75351,O76031	OMIM:181500,SCHIZOPHRENIA; SCZD	DOID:0005419,('schizophrenia',),2,0.0000	
K08F4.1,F55F10.1,C34B2.6,T02C1.1	0.02730,GO:0006515,misfolded or incompletely synthesized protein catabolic process;0.00455,GO:0051131,chaperone-mediated protein complex assembly;0.02730,GO:0004176,ATP-dependent peptidase activity;0.02730,GO:0001067,regulatory region nucleic acid binding;0.05000,GO:0003677,DNA binding;0.00909,GO:0003697,single-stranded DNA binding;0.02730,GO:0000975,regulatory region DNA binding;0.02730,GO:0044212,transcription regulatory region DNA binding;0.00455,GO:0070361,mitochondrial light strand promoter anti-sense binding;0.04650,MI:cel-miR-255,MI:cel-miR-255;0.02130,MI:cel-miR-355,MI:cel-miR-355;0.04990,MI:cel-miR-233,MI:cel-miR-233;0.03950,MI:cel-miR-261,MI:cel-miR-261;0.04790,MI:cel-miR-80,MI:cel-miR-80;0.05000,MI:cel-miR-82,MI:cel-miR-82;0.04500,MI:cel-miR-77,MI:cel-miR-77;0.04800,MI:cel-miR-87,MI:cel-miR-87	P36776,Q8WVB6,Q9NU22	OMIM:600373,CODAS SYNDROME;OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),3,0.0000	
Y39G8B.1,R166.3,Y48G10A.1,R06C7.5,K11H3.1,C37H5.6	0.05,MI:cel-miR-392,MI:cel-miR-392	P10768,P15121,Q9Y4X0,P21695,P30520,P30566	OMIM:209850,AUTISM;OMIM:614480,HYPERTRIGLYCERIDEMIA, TRANSIENT INFANTILE; HTGTI;OMIM:103050,ADENYLOSUCCINASE DEFICIENCY	DOID:0012849,('autistic disorder',),3,0.0000	
M01E5.5,K12D12.1,C53B4.5,T01G9.6,B0205.7	0.05,MI:cel-miR-58,MI:cel-miR-58	P68400,P67870,P11388,P11387	OMIM:209850,AUTISM	DOID:0012849,('autistic disorder',),5,0.0000	
